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The spread of falsified drugs is increasing worldwide. Currently, 10%-30% of drugs 
in the world are falsified. Unfortunately, the supply chain system of developing countries 
(from manufacturers to customers) is not well monitored and suffers the highest rates of 
fraudulent activities. Also, the rise of product procurement from the internet increases the 
chance of American consumers' exposure to poor quality drugs. To combat this horrendous 
activity, surveillance of pharmaceutical materials is required in the supply chain system. 
Spectroscopic techniques (e.g., Near-Infrared and Raman spectroscopies) can be a potential 
solution to authenticate samples in different locations; they are non-destructive, safe, rapid, 
portable, and affordable. However, before deploying these techniques in the field, rigorous 
method development is required with the help of chemometrics. The chemometric tools to 




target class (alternate class or falsified samples). One challenge of method development is 
the sensitivity of spectrometers toward unwanted variabilities including moisture, batch to 
batch variabilities, raw material variabilities, etc. Initial research for this dissertation 
observed that the traditional chemometric methods, which are based on distribution 
assumptions, provided a high number of false negatives due to violation of distribution 
assumptions in the presence of unwanted variations. It was demonstrated that adding 
samples from different seasons in the calibration set created binominal or multimodal 
distributions due to moisture variations - which violated the assumptions of the principal 
component analysis based soft independent modeling of class analogy (SIMCA) method. 
Hence, the support vector data description (SVDD) method—which has no distribution 
assumption—is proposed for use as a class modeling approach for authentication purposes. 
Implementing the SVDD algorithm improved model performance by reducing false 
negatives relative to the traditional multivariate class modeling approach (i.e., SIMCA).  In 
addition, while developing the SVDD method, this dissertation suggested using different 
non-target class samples produced by competitor manufacturers or synthetic samples 
generated in the laboratory using design of experiment (DOE) as test or validation set to 
decrease false positives. This work also evaluated several commercially available products 
in two local pharmacies using portable spectrometers to validate the practical usefulness of 
the proposed methods. To summarize, the research performed for this dissertation has 
demonstrated the value of critical prior knowledge regarding pharmaceutical products, 
pharmaceutical manufacturing/processing, analytical methodology, and advanced 
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1 Chapter 1: Introduction 
1.1 Background, Statement of Problem 
A sound authentication process is vital to protect pharmaceutical materials from 
falsification or any fraudulent activities.  According to the World Health Organization (WHO), the 
term “falsified medicines” can be defined as “Medical products that deliberately/fraudulently 
misrepresent their identity, composition or source. Such deliberate/fraudulent misrepresentation 
refers to any substitution, adulteration, or reproduction of an authorized medical product or the 
manufacture of a medical product that is not an authorized product” [1].  Specifically, composition 
refers to the raw material or final dosage form in accordance with applicable specifications 
authorized/recognized by national or regional regulatory bodies. In May 2017, the WHO published 
this definition of falsified products to bring harmony among the member countries and replaced 
the word “counterfeit medicine” which was widely used [1]. 
Protection of pharmaceutical materials from fraudulent activities is becoming increasingly 
critical as falsified products are more widely distributed. Currently, 10%-30% of drugs in the world 
are falsified [2]. Unfortunately, the supply chain system of developing countries (from 
manufacturers to customers) is not well monitored, and suffers the highest rates of fraudulent 
activities [3, 4]. Also, the rise of product procurement from the internet increases the chance of 
American consumers' exposure to poor quality drugs [2].   
A variety of techniques have developed to eliminate such fraudulent activities. Among 





process. However, many counterfeiters and producers of falsified products can evade sophisticated 
visual tests [5]. Therefore, a variety of analytical tools have been used to reveal the different 
chemical compositions of falsified products from authentic samples. Among these analytical 
methods, several rapid screening tools provide an effective way to increase the number of products 
that can be subjected to chemical testing before reaching patients or consumers [6].  Handheld and 
portable instrument platforms provide an opportunity to implement the screening process in more 
locations (e.g., in different locations of the supply chain including rural hospitals, clinics, 
drugstores, etc.). Spectroscopic techniques offer a number of advantages for screening 
pharmaceutical products, including  rapidity, portability, etc. In particular, Near-Infrared (NIR) 
and Raman spectroscopies have been demonstrated to be valuable tools [7]. These spectroscopic 
techniques are fast and easily deployable to different inspection sites, facilitating detection of 
falsified drug products in developing countries to reduce the life-threatening prevalence of this 
scourge [8-10]. Also, these spectroscopic techniques can be applied in the developed world to 
advance internet-of-things (IoT) based smart applications. 
However, the use of such spectroscopic techniques is not straightforward due to the 
multivariate nature of the data and the significant variety of potential factors influencing the 
analytical measurements. Therefore, rigorous method development is required, usually involving 
advanced chemometric methods, before deploying such analytical techniques in the field. These 
analytical systems should declare the test sample as either target class (authentic samples) or non-
target class (an alternate class, or falsified samples). All practical methods should offer good 





when, in fact, they are authentic samples), and false positives (identification of samples as 
belonging to the target class when they are actually false samples). 
Two types of chemometric techniques have been well described in the literature for 
authentication methods, including spectral matching (SM) and class modeling (CM) techniques 
[11]. Most of the current portable spectrometers come with some variety of SM algorithm. These 
algorithms facilitate the comparison of two spectra, including a reference spectrum collected from 
a genuine or authentic material and a spectrum of the unknown material under study [12, 13]. 
These two spectra are used to calculate spectral correlation or spectral distance.  If these correlation 
or distance values match with a target threshold value, the unknown samples are declared as 
genuine or authentic samples. Research showed that the SM method was successful when samples 
included chemical differences, providing sufficient spectral uniqueness to allow detection [14, 15]. 
For example, the SM method was used to identify placebo samples and samples containing the 
wrong API.  However, this method struggled to differentiate samples containing identical APIs 
and similar excipient compositions, resulting in high false positives [16]. 
A variety of class-modeling techniques can also be applied for authentication. Multivariate 
methods such as SIMCA and its extended version, data driven SIMCA, etc. have been used for 
spectroscopic identification of pharmaceutical samples. The primary premise of these methods is 
to develop a target class using representative samples from an authentic source. A calibration 
model is developed from the target class, which is comprised of spectral data containing API and 
excipient information. Class-modeling (CM) estimates a decision boundary which is formed 





assumptions regarding the data (e.g., normal distribution, 𝜒2 distribution, etc.) [17-19]. The 
pharmaceutical literature reveals several studies proposing that CM techniques are  more powerful 
than the SM method in separating samples containing similar compositions using portable 
spectrometers [15, 20]. Critical considerations for the analytical method developer include 
identifying an appropriate sample of target class product, adequately defining boundary conditions 
for the target class, and selecting suitable non-target samples. CM methods will not be successful 
without suitable training samples. 
To achieve desirable performance, CM methods must account for the anticipated chemical 
and physical variations to be encountered in the target class of product; NIR and Raman 
spectroscopies are sensitive to different physical and chemical factors such as moisture variation, 
tablet hardness, component particle size, instrument drift, etc. This is particularly important for the 
implementation of spectroscopic methods in the field, as samples will be collected in various 
locations. Therefore, models must include this variability at the outset, or must be updated with 
new authentic samples over time to include new sources of variation. To limit the demands of 
calibration updates that might be required due to such new target class variability, different spectral 
preprocessing techniques are applied to remove or limit the spectral effect of this variability. While 
different data processing techniques reduce the unwanted effect of these variabilities, adding new 
samples over time to update the model by including such target class variability is sometimes 
considered the most effective approach. 
Defining appropriate boundary conditions for the target class is a critical aspect of defining 





target group if the computed distances of tested samples to model is shorter than a predefined 
threshold value based on a mathematical boundary. However, several challenges arise during this 
boundary formation. As analysts may be required to update the model by adding samples 
containing recently evolved variations into the calibration sample set, these newly added samples 
are often considered as extreme objects or outliers. Moreover, this may violate the assumptions of 
the model by forming clusters or binomial distribution in the model space. Therefore, the caveat 
of defining boundary condition is—without prior knowledge of the shape of the underlying 
distribution of samples, satisfactory boundary formations may not be achieved.  
A CM method can also be developed without relying on distribution assumptions. Unlike 
the traditional CM methods used for the authentication, forming a decision boundary based on 
boundary samples of the calibration set includes all of the samples produced during the model 
update or after the risk-assessment. Support vector machine (SVM) based methods are a viable 
approach for establishing a boundary through the identification of boundary samples. Here, an 
algorithm developed by Tax et al. is proposed as a method for development of a spectroscopic 
authentication system for pharmaceutical products [21]. This method is often identified as a 
support vector data description (SVDD), which has shown similar performance to the one-class 
support vector machine (OC-SVM) developed by Schölkopf et al [22]. The proposed SVDD 
method has been applied for detection of machine faults, outlier detection, etc., but has not yet 






After developing a calibration model using an appropriate decision boundary, an analyst 
should use a complex sample set to test or validate the model performance.  Particularly, to validate 
the model’s capability of rejecting falsified samples, it is critical to evaluate samples from alternate 
classes. These samples are used to test the specificity of the method, which is the portion of 
alternate class samples that are correctly identified as negative or outlier samples with respect to 
the target class. In practice, alternate class samples may be very similar to the target class; 
therefore, alternate class test samples must include samples that are ‘highly similar’ to the target 
class. Usually, these ‘highly similar’ samples are those which contain the same API and similar 
excipient composition and are manufactured using similar techniques. Therefore, the choice of the 
alternate class test samples is essential for assessing false positives (FP). Legitimate generic 
versions of the target class drugs that are manufactured by various producers can be used to test 
the FPs as such drugs should contain identical API and may contain similar excipient 
compositions. These non-target class samples should be used to optimize the boundary condition 
of the proposed SVDD model. This avoids the unnecessary acceptance of non-target class samples 
during boundary optimization and decreases FPs. 
Because the analyst will not always have access to the competitors’ products during method 
development, selecting an alternative strategy such as preparing samples using statistical design 
of experiment (DOE) may be a suitable approach to overcoming the limitations associated with 
inaccessible samples. Various challenging samples can be generated by altering the chemical 
composition of target class samples using DOE. Moreover, depending on the analytical technique 
to be used, the chemical compositions of non-target class samples may be unique based on the 





techniques could prove the value of using different non-target class samples for different 
techniques.  
1.2 Hypothesis and Specific Aims 
The proposed hypothesis is: 
Development of a support vector machine based algorithm with pertinent calibration and 
validation sets enables a multivariate spectroscopic authentication method that provides a 
superior system for both NIR and Raman spectroscopy compared to traditional multivariate 
methods of classification (e.g., SIMCA). 
Given the central hypothesis, the objectives of this dissertation are to: 
1. Demonstrate the development of a robust authentication system using NIRS and a SVM 
based algorithm in the presence of moisture variations. 
2. Demonstrate the use of Raman spectroscopy and the SVDD algorithm for authentication 
in the presence of moisture variations. 
3. Demonstrate model development for the detection of ‘highly similar’ non-target class 
samples collected from different developing countries (produced by various 
manufacturers).  
4. Demonstrate the application of DOE concepts to generate ‘highly similar’ samples for 
testing of NIR and Raman spectroscopic systems. 






In summary, the objectives of this dissertation were achieved by obtaining two figures of 
merit as described in Figure 1-1: 
 Figure 1-1: Two primary goals of an authentication method, associated 
challenges of each goal and steps taken to address the challenges.  
The first two objectives addressed opportunities to improve the sensitivity of models 
(decreasing false negatives) used for pharmaceutical authentication by addressing the critical 
quality attributes and material attributes relevant to a robust authentication of pharmaceutical 
samples. These parameters are crucial for both NIR and Raman techniques. In Chapters 2 and 3, 
respectively, the work defines how a machine learning based algorithm can be used to improve 
model performance of NIR and Raman spectroscopy and compared with an existing multivariate 
method. 
The next two chapters, Chapters 4 and 5, asses the model's ability to reject non-target class 
samples by decreasing false positives (objectives 3 and 4). In Chapter 4, the document discusses 
the analysis of a variety of highly similar samples, collected from across the globe and 
manufactured by different companies.  These were used to assess the performance of spectrometers 





always be available, the work of Chapter 5 demonstrated the use of laboratory generated tablets as 
non-target class samples. Since the spectral response of different analytical techniques is unique 
for any composition, unique non-target class samples are likely to be required in model 
development for each different analytical technique. Finally, Chapter 6 describes the use of 
portable spectrometers for sample analysis in the field. Two spectrometers were used to scan 
pharmaceutical samples in local pharmacies.  
The novelty of the work should be apparent due to 1) the requirement of applying critical 
prior knowledge regarding pharmaceutical products, pharmaceutical manufacturing methods, 
analytical methodology, and chemometric techniques, and 2) the application of a specific modern 






1.3 Literature Review of Falsified Drug Detection
Different chemometric methods have been used for the qualitative and quantitative 
analyses of NIR and Raman spectral data to detect various types of falsified products. This 
literature review compiles the details of such previously described work. Critical evaluation of 
these chemometric methods is provided to define the inherent limitations. Finally, directions are 
provided to develop an accurate and robust spectroscopic method for the authentication of 
pharmaceutical products.
1.3.1 Analytical Method Development to Detect Falsified Drugs  
 
Figure 1-2: Method development strategies for a pharmaceutical product 
authentication system 
Analyical method development starts with setting the goals of the analysis. This guides the 
subsequent method development steps (see Figure 1-2). In this case, to protect pharmaceutical 
products from any falsification activities, the analytical system should have the capabilities to 
separate genuine products from falsified products. This target will be effectively achieved if 
analysts are aware of the many potential falsified products. The pharmaceutical literature has 
reported many approaches to falsifying both pure components and finished dosage forms [2]. Such 




not limited to, intentional adulteration of pharmaceutical ingredients, tablets prepared without 
active pharmaceutical ingredient (API) (e.g., using only excipients), tablets manufactured using 
the wrong API, and tablets generated with the correct API, but different compositions of excipients 
(see Figure 1-3). Different types of falsified products are also compiled in Table 1-1.  
 
Figure 1-3: Types of falsified products 
NIR or Raman spectroscopy have been used successfully to detect different approaches to 
falsification; examples of  these counterfeiting activities are discussed in Section 1.3.2 (Step 2 in 
Figure 1-2). Selection of analytical techniques to detect such falsification activities also depend on 
the fundamental capability of the analytical techniques itself, which is further discussed in this 
section [23, 24]. Both NIR and Raman spectroscopy will typically require multivariate modeling 
approaches for the development of a suitable calibration model, discussed in Section 1.3.3 (Steps 
3-4 in Figure 1-2). Development of a robust model will reduce the need to update a calibration 
over time (discussed in Section 1.3.4). Finally, the chemometric approaches proposed in this 





Table 1-1: Overview of  representative pharmaceutical authentication studies using NIR and Raman spectroscopy, 
including model development details regarding preprocessing, number of samples, cross-validation, robustness studies.  
Category of falsified 
products* 
Analyzed medicine, brand 
name in parenthesis. 
Analytical techniques 
and types (L- Lab 
based, P- Portable) 
Product origin(s)/ Source 
Reported chemometric approaches and 
relevant comments - preprocessing, 
internal validation (type, split ratio), 
external validation, model validation, 
robustness testing, performance & 
validation parameter. 
Ref. 
Pure material 309 different USP materials Raman L USP material 
peak match, correlation, and PP: first 
derivative 
[25] 
Adulterants in the 
raw material 
DEG in glycerin, melamine 
in lactose 
Raman P Lab based experiment 
Spectral correlation method, PLS. PP: 
Savgol 1st Derv, SNV, MNCN, CV: 









SIMCA, PLS-DA, UPLS-DA; WS:GA, 
SPA; Type I, Type II error. 
[26] 







sample, simulated counterfeit 
Spectral correlation, PP: SavGol (first 
derivative, 2nd order, W-31-point), 
wavelength selection to the API specific 
regions 
[27] 
Tablet without API. artesunate - 






Category of falsified 
products* 
Analyzed medicine, brand 
name in parenthesis. 
Analytical techniques 
and types (L- Lab 
based, P- Portable) 
Product origin(s)/ Source 
Reported chemometric approaches and 
relevant comments - preprocessing, 
internal validation (type, split ratio), 
external validation, model validation, 
robustness testing, performance & 
validation parameter. 
Ref. 
Capsule without API miltefosine NIR-L, LC-MS/MS 
Bangladesh 
Spectral investigation [29] 
Tablet without API, 
Tablet with wrong 
API 
artesunate Raman L. 
Vietnam, Laos PDR, Burma, 
China, Ghana, Thailand-Burma 
border 
Spectral peak identification- assigned to 
the corresponding functional groups, PCA, 
K-mean clustering, Ncal- 50. PP: SavGol, 
SNV (to remove fluorescence).  
Robustness issue: API has strong 
fluorescence background. 
[30] 
Tablet with wrong 
API 
atorvastatin 
NIR L and Raman L, 
LC-MS 
Dutch Health Care 
Inspectorate 
PCA, PLS-DA, Robustness issue: Effect of 
storage condition was tested 
[31] 







counterfeit product was lab 
based (simulated). 
Raman barcode, PP: SavGol to remove 
fluorescence. 
[32] 
Tablet without API, 





NIR L, Raman L, LC-
MS 
Internet, Korea, Egypt, Libya, 
Turkey, Syria, Philippines, 
Thailand 
Spectral analysis, PCA analysis. [33] 
Tablet without API, 




aspirin, ampicillin, KCL, 
ampicillin, enalapril, (wide 
variety of falsified drug) 
NIR L Brazil 
PCA/SIMCA, N=50, CV: LOOV, PP: 
SavGol (5 w, 2nd polynomial). 
Robustness: effect of humidity alteration, 
sample position and sample face (for 
tablets) on model performance was tested. 
[34] 
Tablet without API, 




sildenafil citrate (Viagra) 
NIR L, TLC, UV, 
HPLC-DAD, HPLC-
DAD-MS 




Category of falsified 
products* 
Analyzed medicine, brand 
name in parenthesis. 
Analytical techniques 
and types (L- Lab 
based, P- Portable) 
Product origin(s)/ Source 
Reported chemometric approaches and 
relevant comments - preprocessing, 
internal validation (type, split ratio), 
external validation, model validation, 
robustness testing, performance & 
validation parameter. 
Ref. 
Tablet without API, 




sildenafil (Cialis) Raman L, HPLC 
Medsafe, intercepted at New 
Zealand's International Mail 
Centre 
SIMCA, PLS-DA, SVM. PP= LBC, MSC. 
N=250. Split: Cal-67%. Test-33%.  CV, 
Quantitative modeling: PCR, PLS 
[36] 
Tablet without API, 




sildenafil Raman L China, Mexico. 
PCA-HCA, PP: SavGol (13W), NCal=19, 
NTest=9, Robustness: Baseline-corrected 
before presentation, to eliminate the 
influence of broad fluorescence 
background 
[37] 




sildenafil Raman L 
Federal Agency for Medicines 
and Health Products in 
Belgium (AFMPS/FAG) 
PCA (different wavelength range), LDA, 
K-NN, SIMCA. CV:  LOOCV. Ncal= 26, 
Ntest= 12. 
[38] 




not specified NIR P Not specified 
SC, PCA, PP: SNV, SavGol (2nd, W-5, 
2nd order), unit vector normalization.  
Robustness: lamp change, lot-to-lot 
variabilities 
[13] 





Raman P, PXRD, X-Ray 
tomography 
India, Thailand, Pakistan, 
Germany 
Characteristic peaks around 1600 cm-1 was 
used to determine whether Atorvastatin 
was present or not. 
[39] 




trimethoprim, metronidazole NIR Not specified PCA, SIMCA [40] 





coated, film coated, crushed - 
wide varieties of counterfeit 
product 




Category of falsified 
products* 
Analyzed medicine, brand 
name in parenthesis. 
Analytical techniques 
and types (L- Lab 
based, P- Portable) 
Product origin(s)/ Source 
Reported chemometric approaches and 
relevant comments - preprocessing, 
internal validation (type, split ratio), 
external validation, model validation, 
robustness testing, performance & 
validation parameter. 
Ref. 




calcium channel blocker NIR P Not specified Correlation coefficient, SIMCA [15] 
Liquid ampoule with 









Raman P China 
SC, CLS models., N(Dox)= 60, 
N(Lev)=60. 
[43] 
Expired tablets paracetamol Raman P China 
Spectral Correlation; PP: max–min 
normalization (MN), SavGol (1st and 2nd 
deriv), N=120, CV: 7-round cross-
validation, SIMCA, PLS-DA, SVM, k-NN. 
(SVM proved robust compared other 
methods.) 
[44] 
Seized products Not specified NIR L, Raman L Not specified 
PCA, HCA, k-NN, PLSD-DA, SVM, 
ANN, CV: venetian blinds, 9 splits. 
[45] 
Note: USP: United Sates of Pharmacopeia; DEG: Diethylene glycol; PP: Preprocessing; Savgol: Savitzky–Golay; Ncal: Number of calibration sample; SIMCA: Soft independent 
modelling by class analogy; PLS-DA: Partial Least Squares Discriminant Analysis; UPLS-DA: Unfolded Partial Least Squares with Discriminant Analysis; WS: Wavelength 
selection; GA: Genetic algorithm; SPA: successive projections algorithm; Ncounter: Number of counterfeit samples; CV:Cross validation; LC-MS/MS: Liquid chromatography- 
mass spectroscopy; LOOV: Leave one out of validation; TLC: Thin layer chromatography; HPLC-DAD: High-performance liquid chromatography with diode-array detection; 
SC: Spectral correlation; SVM: Support vector machine; LBC: linear baseline correction;  MSC: multiplicative scatter correction; PCR: principal component regression; PLS: 
Partial least squares; regression; HCA: hierarchical cluster analysis; LDA: Linear discriminant analysis; K-NN: k-nearest neighbors; PXRD: Powder X-Ray Diffraction; CE: 




1.3.2 Analytical Tools 
1.3.2.1 Near Infrared Spectroscopy 
Near-infrared spectroscopy (NIRS) is based on the absorption of electromagnetic radiation 
in the range of 700 nm to 2500 nm, which includes overtone and combination bands of the 
fundamental vibrations observed in the mid-infrared region [46]. NIRS is a useful analytical tool 
due to its non-destructive nature and flexible sample interface. These properties provide extensive 
opportunities for qualitative and quantitative prediction of critical components of pharmaceutical 
products, managing critical process parameters and for assuring that products meet real-time 
release criteria [47].   
Detecting falsified pharmaceutical materials is one of the potential applications of NIRS. 
Typically, this application is based on the comparison of the presence or absence of spectral 
features of genuine products. A significant number of studies have been undertaken by NIRS for 
the authentication of medicines. Significantly, medicines which are critical for treating diseases 
prevalent in low and middle income countries, including antimalarial, antimicrobial, and 
antispasmodic [28, 41] medicines, were successfully authenticated using NIRS [48]. While NIR 
applications for detecting falsified drugs began in the laboratory, successful results led regulatory 
bodies to use NIRS directly in the field. Initiatives using mobile van laboratories in rural areas of 
China and India have set examples for other regions [49]. Advances in instrumentation technology 
has led to dramatic reductions in the size of NIR spectrometers, with  handheld devices now 
available [50]. These spectrometers are light-weight and do not need any dedicated vehicle to 




or smaller, and weights of just 1 kg (~2 lbs) or less. A good review of different hand-held 
spectrometers will be found in Crocombe et al. [51] 
In addition to the single point NIR spectrometer, another important spectral collection 
mode of NIRS is hyperspectral chemical imaging (NIR-CI). This enables the collection of 
additional information from pharmaceutical products such as the surface distribution of APIs, 
excipients, powders and granules [52].  NIR-CI was shown to be superior to single-point NIRS in 
some cases because it combines the capability of spectroscopy with the potential of visualization 
of API and excipients in the falsified products [52]. Furthermore, NIR-CI can be useful to measure 
both potency and the quality of the formulation, even without knowing the exact composition of 
the drug, which is critical when falsified products are collected without prior information [53]. 
1.3.2.2 Raman Spectroscopy 
Raman spectroscopy, a molecular spectroscopy, generates a polarization in the molecule 
resulting in in-elastically scattered photons [54]. The spectrum observed from a Raman 
spectrometer is a measure of the amount of energy a photon has lost (Stokes Raman scattering) or 
gained (anti-Stokes Raman scattering) which is frequently expressed as wavenumber shift. Stokes 
Raman scattering is most commonly measured because this is of higher intensity than anti-Stokes 
scattering (due to the lower probability of the molecule being in an excited vibrational state). 
Raman spectroscopy has demonstrated value as a method in the array of techniques for 
pharmaceutical analysis [47, 55]. The advent of several configuration of Raman spectrometers 
(backscattering, transmission, surface enhanced Raman (SER), and imaging systems) have opened 




primary advantage of Raman spectroscopy is the significant selectivity, which allows 
identification of different APIs, excipients and impurities present in the pharmaceutical materials 
[25, 59].  Packaging materials, including dyes, markers, etc., can also be authenticated with Raman 
spectroscopy, adding to the list of advantages for this method in the fraud detection process [60, 
61]. However, there are other possible ways to authenticate pharmaceutical packaging materials, 
which are out of the scope of this review.  
Like NIRS, application of Raman spectroscopy has also spread from benchtop to field-
based use at the point of sample collection [62, 63]. Although the portable Raman spectrometer is 
relatively new, it shows promise for detecting falsified and unapproved drugs [64]. Moreover, 
similar to NIRS, the imaging configuration of Raman spectroscopy was also successfully used to 
gain an understanding of the spatial distribution of formulation components of tablets [38, 65, 66].  
Although both Raman and NIR spectroscopy have been proven effective for the detection 
of falsified medicine, they are not without limitations. NIRS suffers from a lack of specificity issue 
due to the absence of sharp peak features (due to broad overtones and combination bands) which 
necessitates the careful use of multivariate chemometric methods. On the other hand, Raman 
spectroscopy for chemical analysis suffers from relatively low sensitivity and interference from 
fluorescence [59].  In spite of their relative advantages and limitations, both techniques have been 
used successfully to detect falsified products (Table 1-1). Understanding these the potential of each 
method facilitates selection of the appropriate analytical tool for development of suitable product 





Table 1-2: Some features and shortcomings of NIR and Raman spectroscopy. Italics 




• Sensitive to the Physical factors 
including particle size and 
compression force 
• Pharmaceutical excipients have strong 
NIR signal 
• Penetration is higher for NIR light 
Disadvantages 
• Wide bandwidth 





• Sharper peak features 
• Less sensitive to the physical factors 
• Typically, API has strong 
Raman signal. 
Disadvantages 
• Fluorescence interferences 
• Pharmaceutical excipients exhibit less 
Raman signal relative to the API 
Penetration depth is lower (and often 
insignificant for coated dosage forms) 
1.3.3 Chemometric Techniques for Model Development and Relevant Applications 
Numerous chemometric techniques have been used to extract the relevant chemical and 
physical information from the collected NIR and Raman spectra of falsified samples. These 
chemometric techniques can be divided into three categories:  
i) spectral matching methods 
ii) exploratory analysis, and 
 iii) supervised techniques  
As mentioned, various types of fraudulent activities (formulation approaches to 
counterfeiting) will generate unique spectral characteristics. The chemometric techniques to be 




these chemometric techniques are discussed below, with a description of theory and relevant 
applications. Criticisms of each method will be provided to give the reader an understanding of 
their limitations for the application of authentication. 
1.3.3.1 Spectral Matching Method 
1.3.3.1.1 Theory 
Historically, spectral features of known components have been used to accomplish 
qualitative identification of pharmaceutical samples.  This would involve assigning absorbance 
bands to corresponding functional groups of the expected component. Then, the presence or 
absence of these spectral bands in the sample spectra could be used to distinguish between genuine 
and falsified products [12]. However, this method requires recognition of the distinct peaks and 
may not be suitable for automatic detection by non-specialist analysts in the field. To simplify a 
field analyst’s work, spectral matching (SM) algorithms have been used to compare spectra of 
unknown test samples to a reference spectrum collected from genuine material. SM algorithm 
compare the proximity between vectors of a reference (or genuine) sample and an unknown sample 
to determine sample identity [67]. 
Proximity is computed by calculating distance and spectral correlation. Distance is also 
often described as SD, a spectral dissimilarity (i.e., the greater the distance, the less similar the 
objects are), which is measured based on following relations: the sum of least squares (Equation l 













) ∑ |𝐿𝑖𝑏𝑚 − 𝑈𝑛𝑘𝑛𝑚| 
2 
Here N is the number of data points, and 𝐿𝑖𝑏𝑚 and 𝑈𝑛𝑘𝑛𝑚  is the 𝑚
𝑡ℎ absorption value in 
the library spectrum and the unknown spectrum, respectively. As 𝑆𝐷1 and 𝑆𝐷2 calculate 
dissimilarity between the spectra, their minimum value is 0 for identical spectra. On the other hand, 
spectral correlation (𝑆𝐶), which is often mentioned as a similarity, is the equivalent of measuring 
the cosine of the angle between two spectra.   
𝑆𝐶 = 100 ∗ √[(𝐿𝑖𝑏𝑚 ∙ 𝑈𝑛𝑘𝑛𝑚)2]/[(𝐿𝑖𝑏𝑚 ∙ 𝐿𝑖𝑏𝑚)(𝑈𝑛𝑘𝑛𝑚 ∙ 𝑈𝑛𝑘𝑛𝑚)]             3 
Here, 𝑆𝐶 measures the similarity between the spectra; and 𝑆𝐶 values range from 0 (poorest 
match possible) to 1 (perfect match).  
Generally, the SM method can be employed for identification and verification. Before 
applying the SM method for identification, a reference library is developed using authentic 
samples. An unknown sample is systematically compared with spectra in the reference library by 
using equations 1-3. The corresponding reference spectrum, which has minimum distance or 
maximum correlation with the unknown sample, is declared as the potential target sample (e.g., 
target product or target manufacturer). This approach is often referred to as a library search. For 
verification purposes (e.g., to verify whether the claimed component is present in the sample or 




target reference spectra. A verification test uses empirically defined target threshold values, 
usually 0.95, to assign a “Pass” or “Fail” determination to the sample under study [69, 70]. 
1.3.3.1.2 Applications of Spectral Matching Method 
The application of a spectral matching methods to the chemical analysis was reviewed 
nearly two decades ago by Penchev [67]. The author evaluated the performance of SM methods 
using infrared spectroscopy. Since 1996, the use of this chemometric technique in the 
pharmaceutical industry has continued, with increased interest in its application using other 
analytical tools, such as Raman and NIR spectroscopic methods [14, 71, 72]. 
McCreery [25] in 1998, was one of the first to use Raman spectroscopy with a SM method. 
His work involved testing the identity of pure pharmaceutical materials. First, a reference library 
was prepared using 309 United State Pharmacopeia (USP) standard compounds. Then, a total of 
26 unlabeled vials were scanned blindly and used as a test set. After that, the developed reference 
library was used to calculate SM values for each of the test samples. The highest matching value 
obtained from the reference library was declared the identity of the test sample, and around 96% 
of the test samples were accurately identified. Authors noted that the use of the right preprocessing 
method was critical for getting a successful result, as it affected matching values significantly  [25]. 
Although the components were successfully identified in the McCreery study, it is important to 
understand that the library search method relies on the listed components already presented in 
library and provided the best probable compound as the possible target sample.  
While detecting pure components using spectroscopy, it is also required to study whether 




whether the contaminant is present in the sample, the matching value of the test sample to the 
claimed compound is calculated directly using SM algorithm. This accurate detection of 
contaminants is of particular importance when dealing with pharmaceutical excipients because 
they are susceptible to economically motivated adulteration with substances having comparable 
physical, chemical, and/or spectroscopic properties. The result is not only financial loss for the 
patient, but these adulterants can also cause severe health risks. For example, several adverse 
events have been reported due to adulteration of glycerin with diethylene glycol (DEG) [73] and 
melamine in baby formula [74]. Therefore, when an analyst uses a spectral matching method to 
identify the presence of active components, the method should also be sensitive to the presence of 
contaminants.  
Several studies using Raman spectroscopy have been conducted to address the SM method 
sensitivity for distinguishing adulterants while detecting the presence of anticipated raw materials. 
[72, 75, 76]. Various adulterants (e.g., DEG in glycerin, melamine in lactose, and DEG in 
polyethylene glycol) were successfully identified using a spectral matching method [11]. However, 
the limit of detection by the SM method depends on the intrinsic spectral properties of the 
materials. For example, glycerin and DEG are spectrally very close and the SC value of glycerin 
gradually changes as the amount of DEG in the test set increases (see Figure 1-4A). Rodriguez and 
colleagues published a method to measure the detection limit of impurities while using SM method 
[72]. Experiments were conducted for a range of DEG in glycerin compositions; 𝑆𝐶 was calculated 
for each of the compositions, and a polynomial line was drawn using 𝑆𝐶 values. From this line, 
the authors estimated the exact DEG compositions that would be expected to cause the 𝑆𝐶 test to 
deliver a failed result. In Figure 1-4B, it can be observed that while changing DEG composition, 




drop noticeably, crossing the 0.95 threshold when DEG is around 18%. Therefore, the authors note 
that if glycerin contains DEG below a content of 18%, contaminated samples will be misidentified 
as the pure sample. Additional studies are required to justify this detection limit, as the threshold 
value of 0.95 used by this study is an arbitrary value; there is no probabilistic interpretation 
associated with this. While setting the detection limit, other validation criteria such as sample 
repositioning analyst to analyst variability, etc., should also be considered. Other factors which 
may also affect the method quality include intra- and inter-day variability.  Setting threshold values 
based on probability statistics would enhance confidence in the limit of detection.  
Another potential solution to detect DEG might be to use unique spectrometric methods. 
For example, DEG and glycerin may have different spectral features in the NIRS, which will be 
more effective for detecting DEG in glycerin. Of course, thorough investigations would be 









Figure 1-4: (A) The Raman spectra for a series of glycerin-DEG samples. From 
bottom to top, the spectral correlation value diminishes as the DEG amount 
increases. (Glyc- glycerin; DEG- diethylene glycol). (B) Quantifying the effect of 
increasing DEG on Raman spectra for the glycerin–DEG system. The red dotted 
line is the threshold value (0.95) to pass the test. The spectral correlation value is 
expected to drop below the threshold when glycerin samples contain 18% DEG or 
more. Figures obtained from Rodriguez et al [77], Copyright (2014) with 
permission from  American Chemical Society.  
The SM method has also been applied to detect falsified tablets. One potential approach is 
to detect API in tablets using a pure component spectral library. Since 50% of tested falsified 
products do not have the claimed API, or contain the wrong API [27], such a method can screen 
this type of falsified product. Loethen et al. [27] attempted to detect falsification in antimicrobial 
and antimalarial tablets acquired from multiple manufacturers. The spectral library was prepared 
using the antimicrobial and antimalarial pure components. Results showed that all the samples 
acquired from different manufacturers had a correlation value higher than 0.95 with the claimed 
API while lab-based products, which did not contain any API, had low SC values (see Figure 1-
5). According to this method, samples manufactured by any company can be authenticated using 




while developing a reference library. Therefore, this method would appear promising for detecting 
the presence of the declared API.  
 
Figure 1-5: SC values were calculated for drug product spectra compared to the 
API library spectra. The numbers in parenthesis ( ) are the number of 
manufacturers in the sample set. Adapted from Loethen et al [27], Copyright 
(2015) with permission from Society of Public Analysts (Great Britain), 
Chemical Society (Great Britain), Society for Analytical Chemistry, Society of 
Public Analysts (Great Britain), Royal Society of Chemistry (Great Britain). 
Though detecting API in the finished dosage form is an efficient process, this approach has 
more potential for Raman spectroscopy due to the presence of sharp API features relative to that 
for excipients. While Raman offers sharper absorbance bands, NIRS has an advantage of more 
significant excipient signals compared to Raman, due to the presence of C-H and C=O bonds in 
the excipients. Ultimately, it is assumed that excipient signal will be overlapping with API peaks, 
making Loethen’s method impractical for NIRS. Additionally, samples evaluated by the Loethen 
group were relatively high-dose formulations. Low-dose drugs with overlapping API and excipient 




Rather than using the SM method with pure component libraries, some researchers have 
used the method to compare authentic samples with test samples allowing both NIR and Raman 
spectroscopy to be used for authentication of various finished dosage forms [14, 35, 78-80]. 
Because samples spectra would contain the data from each component, this method can be used to 
authenticate whether a solid dosage form contains the correct formulation. However, using sample 
spectra also has barriers. One limitation is the sensitivity of the analytical method. Studies have 
shown that, since different generic samples of a specific therapeutic group will often contain 
similar formulations (i.e., excipient compositions are often very similar to each other), both NIRS 
and Raman were unable to differentiate generic products from different manufacturers using the 
SM method [14, 15]. Therefore, cautions application of this method is recommended for 
authentication purposes. 
1.3.3.1.3 Limitations of Spectral Matching Method 
While the SM method has been useful for authentication of pure materials and finished 
products, the method has many limitations. The biggest drawback is that there is no specific 
direction established for setting a threshold value while using spectral correlation algorithms. 
Many studies used a threshold of 0.95 to determine whether two spectra are matched [13, 15, 35, 
79, 80]. However, this value does not imply any probability or assurance statistics. Moreover, in 
different studies, this threshold was determined on a system-by-system basis to suit the desired 
application and the pass/fail decision was taken based on that unique threshold. Several examples 
are provided in Table 1-3, where different applications demonstrated the unique threshold values. 
For example, to differentiate the products produced from different manufacturers, threshold values 




Table 1-3: Variation of spectral correlation method in different scenarios 



























Additionally, the threshold can be affected by many external factors such as spectral noise, 
environmental temperature, operator variability, etc. Unfortunately,  most of the studies which 
applied the SM method did not validate that the developed method would perform consistently 
over time, since they did not consider the fluctuation of these external factors [72]. While 
developing a spectral library, spectra should be collected more rigorously to avoid the effect of 
this external variability. If an effect is observed, the relative standard deviation of the measurement 
should be reported.  
Another limitation of this method is illustrated when it is used to test high quality falsified 
medicines. High quality falsified medicines are commonly produced with a recipe that is similar 
to the genuine product and manufactured with modern equipment [15, 16, 40]. Most often, one or 
two excipients vary in the high quality fake products, compared to the genuine products. This 
causes minimal spectral differences between samples, which is insufficient to separate falsified 




Moreover, the effect of excipient variation on the correlation value will vary for different 
analytical techniques. As Raman spectroscopy offers lower spectral absorbance for excipients 
compared to NIR spectroscopy, small changes in formulation may be more difficult to detect using 
Raman spectroscopy [31, 45]. However, a comprehensive comparative study between Raman and 
NIR spectroscopy has not been conducted to fully understand the effect of formulation changes on 
the SM method. Therefore, further studies are required to understand the effect of different spectral 
features of the commonly used excipients on the SM method. 
 
1.3.3.2 Exploratory Methods of Data Analysis 
Exploratory methods of data analysis have been used to measure similarity or dissimilarity 
of samples without any prior information regarding their identity. These types of analyses are often 
called as unsupervised methods, as the analysis procedure does not have affiliation with the group 
or the source of the data. Principal component analysis (PCA) and clustering analysis (CA) are 
two of the most often applied methods for exploratory data analysis.  
1.3.3.2.1 Theory 
Principal component analysis (PCA): The PCA method projects multivariate spectra into 
low-dimensional space, highlighting the variabilities present in spectral data, although not 
specifically identifying the cause of such variability [81, 82]. Spectral variability arising from 
unique sample characteristics (physical or chemical) can often be visualized by this technique. 
PCA decomposes the multivariate response arranged in an X matrix into a product of two new 
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Where 𝑇𝑘 is the matrix of scores which represent how samples relate to each other, 𝑃𝑘  is 
the matrix of loadings which contain information about how variables relate to each other, k is the 
number of factors included in the model and E is the matrix of residuals, which contains the 
information not retained by the model. Falsified products often have different chemical profiles or 
are produced by different manufacturing conditions which are discernable by this data 
decomposition mechanism [41]. Additionally, PCA is convenient to use for other chemometric 
methods, such as clustering analysis, SIMCA, support vector machines etc., which will be 
discussed in subsequent sections. The reader is referred to the works of Wold et al. [81] and 
Martens & Naes [82] for a more detailed discussion of PCA. 
Clustering method (CA): Clustering involves the partitioning of a dataset of ‘n’ objects in 
such a way that objects in the same group (cluster) are more homogeneous to each other than to 
those in other groups. Clustering analysis is accomplished using the entire spectra or using scores 
of the principal components computed with the previously described PCA models. Grouping of 
multivariate data is based on a similarity criterion. Many concepts and definitions of how to score 
the chemical or physical similarity between two samples or variables have been proposed in the 
literature [83, 84]. Among these, Euclidian distance, Mahalanobis distance, and correlation 
coefficient are commonly used to calculate similarity indices [84, 85].  These similarity indices 
are used to cluster the data in two ways: i) partition clustering and ii) hierarchical clustering. The 
partitioning method uses similarity indices to separate the dataset into user defined groups, 




methods may identify patterns in the data, but a conclusion about sample identity (whether falsified 
or genuine) should not be drawn from such method.  
1.3.3.2.2 Applications of Exploratory Methods 
PCA:  PCA has been successfully applied to visualize the difference of genuine and 
falsified samples. Dégardin et al. [86] presented a large and complicated NIR data set which 
included 29 different pharmaceutical product families. Some of the product families have similar 
spectral signatures as they used similar excipients. Moreover, low dosage forms resembled the 
spectral signatures of placebo samples. However, while PCA was applied to this dataset, the first 
two PC scores enabled visualization of only two groups, while PC 3 and PC 4 helped to observe 
at least eight other groups. Consequently, after considering additional PCs, most product families 
were discernable (See Figure 1-6). Therefore, transforming raw spectra to a lower dimension made 
these samples statistically different. This is advantageous for falsified drug detection, as falsified 




Figure 1-6:  Results of the PCA applied to the calibration spectra pretreated with 
SNV. Each color represents one of the 29 product families. Figure obtained from 
Dégardin et al. [86], Copyright (2016) with permission from Elsevier. 
Since falsified drugs are typically manufactured without the benefit of Current Good 
Manufacturing Practice (cGMP), the poor quality of these products is typically reflected in higher 
inter- and intra-tablet variabilities of components. Inter-batch variability will also be more 
significant than is typical for genuine products [41, 80, 87, 88]. These variabilities can usually be 
distinguished by NIRS or Raman spectroscopy using the PCA method. Rodionova et al. [41] 
showed that the spread of scores (generated from spectral data) in falsified products was higher 
relative to that of the genuine samples (see Figure 1-7A). Here, single point spectrometers were 
used to visualize these inter-tablet variabilities.  







To demonstrate intra-tablet variabilities, a NIR-CI imaging system was used in other 
studies. Statistical parameters of score distributions (mean, standard deviations, skewness) showed 
significant differences between genuine and falsified medicines [89, 90]. Figure 1-7B shows a PC 
image of the falsified (left) and genuine samples(right). 
 
Figure 1-7: (A) PCA scores plot of genuine tablets (dots) and falsified tablet 
(squares). Tablets were also cut and the internal surface scanned; genuine and 
falsified samples are displayed in open dots and squares B)  NIR Hyperspectral 
imaging of counterfeit (left) and original tablet (right). Figures obtained from A) 
Rodionova et al. [41], Copyright (2005) and B) Wilczyński et al. [90], Copyright 
(2016),  with permission from Elsivier. 
Compared to NIRS, Raman spectroscopy may demonstrate greater sensitivity towards the 
variation of API between genuine and falsified products. Neuberger et al. [91] systematically 
investigated the capability of Raman to differentiate chemically dissimilar samples. Raman 
spectroscopy distinguished samples with different coating levels, varying amount of drug loading, 
and different excipients using PCA. Also, Raman spectroscopy successfully detected the 
degradation of aspirin  over time due to changes in storage conditions [91]. 
Additionally, by analyzing the loadings plot of PCA analysis, it is possible to discern 




with narcotic components, which might have been attributed to the API variation. The character 
of a loadings plot may provide information related to the presence of a certain molecule, which is 
especially critical when samples are seized by law enforcement without any packaging or details 
regarding sample origin [92].  
Along with chemical content, the physical structure of the samples often provides useful 
information to detect falsified products, since it is difficult for fraudulent manufacturers to follow 
exact manufacturing steps such as blending, granulation, compression, etc. NIR spectra are 
sensitive towards the physical characteristics of the sample, and this can make NIR measurement 
information-rich. For example, samples manufactured at two different sites can be distinguished 
using NIRS [35]. Vrendenbregt et al [35] demonstrated that similar tablets from two manufacturing 
sites (Europe and the USA) were statistically separated by PCA. In another study, acetaminophen 
tablets prepared in the United Kingdom and Malaysia were also identified accurately using PCA 
[80]. Neuberger et al. [95] aimed that Raman is not adequately sensitive to detect physical 
differences (e.g., density variability associated with compression force, mixing quality), which 
ultimately created minimum PCA variations among these samples (see Figure 1-8). However, this 
study did not consider other physical factors such as particle size variations, tablet size, etc., which 
might have effects on Raman spectra. Therefore, further studies are required to investigate whether 







Figure 1-8: Score plot of PC1 and the PC2 of the samples which were prepared 
using different compression force. (very low = black, low = red, optimal = blue 
and high = green). Figure obtained from Nuremberg et al. [91], Copyright (2015) 
with permission from Elsevier. 
Cluster Analysis (CA): It is known that the global spread of falsified drugs is most likely 
funded by organized criminal activity involving manufacturers, wholesalers, distributors and local 
sellers. Hence, there is significant possibility that some falsified products are manufactured from 
common sources [33]. Investigating the source of such falsified drugs will be helpful in finding 
the origin of criminal activities. Various types of cluster analysis facilitate the development of 
dendrograms, which may provide an opportunity to visualize the clusters of the seized samples 





Figure 1-9: Dendrogram computed using Euclidean distance and average linkage 
method. NIR spectra were collected from capsules and SNV preprocessed. Figure 
obtained from Been et al. [45], Copyright (2011) with permission from Elsevier. 
Been et al. [45] used a large database of samples which were seized from 27 different 
regions and a hierarchical clustering method was applied to form a dendrogram by computing 
Euclidean distances to separate the underlying groups (see Figure 1-9). Authors found that 12 types 
of chemical profiles existed among these seized samples; the unique profiles were later confirmed 
by the reference method. This cluster formation was beneficial for profiling newly acquired 
samples. New samples were projected to these 12 groups and the distances between the test sample 
and different clusters were calculated. The cluster which provided the minimum distance was the 
suspected source of the seized sample.  Therefore, cluster analysis helps to efficiently investigate 
the sources of different falsified products [42, 45, 53, 56]. 
1.3.3.2.3 Limitations of Exploratory Methods  
Though PCA is one potential approach to identifying falsified samples, certain challenges 




are required to build an effective model. Preparation of a sufficiently large reference library can 
be difficult for the PCA method. Unfortunately,  there is no clear direction as to how many samples 
should be used for method development and the number of samples needed for PCA analysis varies 
across studies [88, 93]. Additionally, the boundary design, which is often 95% equal frequency 
ellipses, varies depending on the nature and quality of samples used in calibration development 
[31, 40, 89, 91]. As PCA explains the variation between groups, it is challenging to separate sample 
groups when intra-group variation is higher than inter-group variability. Therefore, representative 
samples should be collected from the pool of genuine samples for the development of the PCA 
method.  
Cluster analysis is useful to understand the types of seized samples. However, the most 
significant challenge for the analyst is setting an appropriate threshold value, as the actual number 
of potential sample groups is unknown to the analyst. Arbitrarily setting a threshold value often 
results in an over-classification or under-classification problem. This becomes more critical when 
the same source of sample has high batch-to-batch variability. Therefore, samples from the same 
source may be classified into two different clusters. Even genuine samples can be clustered into 
two groups if they are stored under unique conditions [94].  
As there is generally no reference information used for the unsupervised method, careful 
interpretation of PCA or CA results is required. While in typical pharmaceutical applications of 
NIRS or Raman spectroscopy, it is comparatively straightforward to gain an understanding of the 
score variability because samples are relatively well characterized, for falsified sample detection 
the samples are obtained without much detail about the source. To ensure the correct interpretation 




samples. For example, if repositioning error dominates in the spectral pattern, it is difficult for the 
analyst to make conclusions about the source of variation in the scores.  
1.3.3.3 Supervised Techniques 
1.3.3.3.1 Theory 
Supervised techniques are the most applicable methods for false product identification 
since they provide direct decisions about the test samples (whether it is falsified/genuine). 
Supervised techniques are mainly classified into two categories: class-modeling and 
discrimination. Class-modeling (also known as the soft classification approach) allows samples to 
be assigned to one or multiple groups. However, discrimination methods (also known as hard 
classification methods) always allow a sample to be considered as a member of only one group 
from the pool of groups being considered. This is illustrated in Figure 1-10, where examples of 
both the class-modeling and discrimination approaches are shown for a data set where objects are 
described by two variables and grouped into three classes (blue, green and brown). When a class-
modeling technique is applied, each class space is separated by a specific boundary from the rest 
of the data space (Figure 1-10A). Considering three unknown subjects (T1, T2, T3), T2 is considered 
as class 2, whereas here T3 is considered as an unclassified object, and T1 falls outside the model 





 Figure 1-10: Example of both class-modeling (A) and discrimination (B) on a data 
set including 52 objects described by two variables and grouped into three classes 
(blue, green, and brown circle). Figures adapted from Ballabio et al. [83], Copyright 
(2009) with permission from Elsevier.  
In the case of discrimination, T1, T2 and T3 must be classified into three classes (see Figure 
1-10B). These objects are projected into data space and assigned to the category corresponding to 
the hyperspace where they are placed. T1 and T2 are assigned to class green, even if T1 is far from 
the green samples, while T3 are recognized as blue  [83, 95]. 
The outcome of these two supervised classification methods is assessed by two important 
figures of merit: sensitivity and specificity [83, 96-98]. Sensitivity is defined as the percentage of 
samples correctly classified to the class of interest. Authentication methods should be able to 
identify the genuine samples correctly, reflecting the sensitivity of the model. Specificity is defined 
as the percentage of samples correctly rejected, since it is also important to recognize different 
types of falsified products, and reject them [99]. These two parameters are calculated by the 
following formulas: 
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where  TP,  TN, FP and FN are true positive, true negative, false positive and false negative, 
respectively [99]. A visual tool that compares sensitivity with (1-specificity), is the so-called 
receiver operating characteristic (ROC) curve, which has been applied in spectroscopic 
classification methods [96, 100]. By calculating the area under the ROC curve, it is possible to 
derive a summary performance parameter for sensitivity and specificity that may serve as adequate 
figures of merit for model comparisons. 
An assortment of multivariate modeling approaches has been developed to be used both as 
class-modeling and discriminant methods. Here, some of the most commonly applied techniques 
are briefly discussed. More detailed information on the considered techniques can be found in the 




1.3.3.3.1.1 Class-Modeling Approach: SIMCA 
SIMCA is a PCA based approach where calibration samples are used to develop a PCA 
model. After decomposing the data and reducing it to lower dimension, a decision boundary is 
formed. Over the years, different versions of SIMCA models have been developed based on unique 
approaches to boundary formation around the training set. These different versions are based on 
two distances: 1) score distance (SD): determined by computing the distance in PC space between 
an unknown sample and a target group, referred to as Hotelling’s 𝑇2, and 2) orthogonal distance 
(OD): determined by calculating the unknown sample’s squared residual distance to the model 
space, known as the 𝑄 residual [17, 18, 82, 101-104].  
The 𝑄𝑖  statistic is defined as the sum of squares of the residuals and can be calculated 
according to Equation 2, where 𝑒𝑖 is the residual of sample i after applying the SIMCA model.  
The Hotelling’s 𝑇2 measures the information of each sample within the PCA or SIMCA 
model and is calculated by means of Equation 1, where 𝑡𝑖 is the 𝑖-th row of the 𝑇𝑘, the 𝑛 by 𝑘 
matrix of 𝑘 score vectors from the PCA model, and  matrix of 𝑘 scores vectors from the PCA 
model of 𝑛 number of target class samples and 𝛬−1 is a diagonal matrix containing the inverse of 
the eigenvalues associated with the 𝑘 eigenvectors (principal components) retained in the model. 
The 𝑄𝑖statistic is defined as the sum of squares of the residuals and can be calculated 
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Figure 1-11:  Graphical representation of Hotelling’s 𝑇2 and 𝑄 residual. Threshold 
boundary based on 𝑇2 versus 𝑄 residual. The acceptance area is the squared space 
in the graph, where samples plotted at any point outside of this area are rejected. 
According to this threshold, nearly every sample will be accepted, with only the 
green sample being rejected. A more flexible boundary could be applied as shown 
by the semi-circular area. Then, both green and red samples will be accepted. Figure 
is adapted from López et al.[100], Copyright (2014) with permission from Elsevier. 
 
A sample is assigned to a target class if the computed distances are shorter than a predefined 
threshold value. These threshold values are based on 𝑇𝑙𝑖𝑚
2  and 𝑄𝑙𝑖𝑚, which are the confidence 
interval for the model under consideration. Confidence limits for SD (that is referred to as 𝑇2 in 
the PLS_Toolbox and related literature) are given from Hotelling’s 𝑇2 to obtain  𝑇𝑙𝑖𝑚
2 , i.e. (𝑇𝑙𝑖𝑚
2 =
𝐹𝑘,𝑛−𝑘𝑘(𝑛
2 − 1)/(𝑛 − 𝑘))  considering 𝑘 and  𝑛 –𝑘 degrees of freedom, where 𝑘  is the number 
of PCs and 𝑛  is the number of calibration samples for the target class. The χ2 distribution is used 
for the squared residuals and confidence limits for the orthogonal distance (OD, that is also referred 




(JM) approximation. Wolf et al. developed SIMCA model based on 𝑄 residual. Candolfi et al. 
proposed a SIMCA model which is based on the Mahalanobis distance; details will be found in 
the relevant literature [68, 105]. 
A more recent approach is to consider both Hotelling’s 𝑇2 and 𝑄 residual. According to 
this approach, boundaries are defined considering the reduced statistics. The reduced Hotelling’s 
𝑇2(𝑇𝑟
2) and the reduced 𝑄 statistic (𝑄𝑟) values can be calculated from the ratio between the 
corresponding statistic of the sample 𝑖 and the corresponding limit at α = 0.05. Here, samples must 
have values under 1 for both statistics to be considered ‘‘within the model’’ which was defined by 
the square boundary in the Figure 1-11. A newer version used by PLS toolbox takes the distance 
defined by Equation  9 [17, 18]. In this case, the boundary considered as ‘‘within the model’’ forms 
a semi-circle with a radius of √2, which is mentioned as d in the Equation 9.  
A variety of methods are proposed to develop an acceptance area are based on different 
distribution assumptions of OD and SD.  Pomerantsev proposed to use the χ2 distribution for both 
















1.3.3.3.1.2 Discrimination Analysis: PLS-DA 
Figure 1-12: Partial least squares discriminant analysis (PLS-DA) model for two 
classes, where X is a matrix containing spectral data, Y are dummy variables 
categorized as genuine (Group A) and falsified samples (Group B). Adapted from 
Brereton et al. [107], Copyright (2014) with permission from John Wiley and Sons. 
Partial least-squares discriminant analysis (PLS-DA) is derived from PLS regression to 
develop a model that predicts the class number for each sample. While developing a PLS-DA 
calibration model, the number of groups and the samples that belong to each group are defined 
with dummy variables. For example, if a data set contains just two classes, Y can be set up easily 
by assigning samples in one of the classes as 1 if the samples are in the class, and 0 if it is not. This 
membership is paired with a training set (X block), and PLS is implemented in the usual way 
(Figure 1-12). During the calibration process, the PLS-DA method is trained to compute 
membership values and assigned a class membership. It is reasonable that the model does not 
predict perfectly, so a limit must be set, for example, 0.5, above which the sample is estimated as 
1 and below which the sample is estimated as 0. For spectroscopic product authentication system 
development, PLS-DA can give good insight to the underlying reason for discrimination via 
weight and loadings. Also, it is a popular technique due to the advantages of wavelength selection 
and noise reduction associated with the PLS algorithm. A more detailed discussion of the PLS-DA 




1.3.3.3.2 Applications of Supervised Classifications: 
SIMCA: PCA analysis utilizing both Raman and NIR spectroscopy can separate diverse 
samples based on physico-chemical differences (e.g., composition differences, API amount 
differences, etc.). SIMCA, using PCA, is an effective method for detecting falsified drugs. Scafi 
and colleagues [34] demonstrated the use of SIMCA to  detect 12 types of falsified products of 
different compositions. Scafi used PCA, constructed from NIR spectral data generated from the 
genuine samples. Then, falsified products were projected onto these PCA models, and distances 
were calculated for each falsified sample showing clear separation. Here, it is important to mention 
that this method only rejected samples declared as falsified products. Further reference analysis 
could provide better understanding of the specific nature of these falsified samples relative to the 
genuine samples.  
In another study, Storme-Paris and co-authors [20] used SIMCA, noting that the SIMCA 
method distinguished tablets with small differences of composition Raman spectral data. In their 
study, falsified and genuine products varied by 1.0 - 2.5% API (%w/w), and the SIMCA method 
was successfully able to identify the falsified products.  
SIMCA was used in a later study with NIR and Raman to overcome some of the limitations 
of the spectral matching method, detecting a small amount of impurities in the raw materials. This 
study detected a contaminant (DEG) in glycerin up to 5% w/w; three times lower concentration 
range than using the spectral matching method [11]. It is important to note that although SIMCA 
provides certain advantages, this method is only providing information about whether the sample 
is pure or has some adulterants. Additional investigation may provide information about the types 





Figure 1-13: (A) Score plots for PCA analysis: (a) PC1 vs. PC2. (Different color 
and shape represent different groups of samples, (B) Result of the Test sets is 
displayed. Here, SIMCA model is developed from the target class (yellow-round). 
Figure adapted from Zontov [15], Copyright (2016) with permission from Elsevier. 
Liquid dosage forms have also been authenticated using SIMCA. One example is the 
authentication of dexamethasone ampules [40]. This study used two genuine batches (G1 and G2) 
of 4% dexamethasone 21-phosphate, and a batch of falsified product (F2) in 1 mL closed 
transparent glass ampoules. NIR spectra were collected through the vials. The performance of this 
approach was evaluated with reference testing by CE-UV, GC-MS, and HPLC-DAD. SIMCA 
analysis of NIRS data demonstrated comparable performance to the reference techniques. 
SIMCA has also been used to detect high quality falsified products. However, to detect this 
type of product, adjustment of the decision boundary improved the model performance, 
demonstrated using DD-SIMCA. Figure 1-13A shows, when products contained the same API but 




grouped. This tight representation of scores also reflects the similarity of the formulation of the 
scanned samples. In Figure 1-13B it was observed that, if method developed using one group 
(yellow-round), and all the other groups (green- triangle, red-triangle, brown-square, blue-
diamond) projected onto the developed model, then initially developed model rejected two of its 
test samples (yellow-round). This decreases the sensitivity of the model by tuning the confidence 
interval. The authors moved the boundary from 1 to 2, which changed the acceptance area of the 
model. This change avoided rejection of two genuine samples and improved the sensitivity of the 
model [15, 16, 110-113]. Despite this successful result, risks of changing boundaries may be high 
without using an independent validation set to test the consistency of the result. Without an 
independent validation, it is difficult to predict if the model will be adequately sensitive to accept 
other batches of genuine samples consistently. Also, enhancing the model with representative 
genuine samples from different batches would reduce this concern. Above all, this study 
emphasized the importance of considering a change in the decision boundary to enable detecting 
high quality falsified products [17, 111]. 
Though there are advantages of using SIMCA, it is also highly sensitive towards small 
variation of external factors which can decrease the performance of the method. For example, 
operator and instrument variabilities caused spectral perturbation, which often projected genuine 
test samples outside the PCA space,  causing degradation of model performance [114, 115]. This 
introduces new challenges, especially when the analyst needs to transfer the model from one 
instrument to another instrument [116]. Some of these issues can be resolved by removing 
unwanted variables, which have small discriminant power [117].  Selection of appropriate 
preprocessing methods may help to reduce some of this variability. For example, offset or baseline 




correction (MSC) algorithms [18]. Calibration transfer and method algorithms are useful when 
analysts are required to use multiple instruments. The following studies provide direction for 
analysts who must transfer spectroscopic methods [116, 118, 119]. 
Another essential model parameter is selection of the appropriate number of PCs to use for 
calibration development. Rodionova et al [16] developed two SIMCA models by selecting a 
different number of PCs. Here, a model developed using three PCs successfully separated samples 
prepared in the different seasons, whereas the model developed including only two PCs did not 
[15, 105]. Proper statistical approaches should be followed in selecting PCs. One way to select the 
appropriate number of PCs is via cross-validation (CV) [82]. Finally, selecting the proper number 
of PCs avoids unnecessary rejection of genuine samples (false negative) or incorrect authentication 
of falsified products (false positive).  Analysts should be careful about both factors, as rejecting 
falsified samples are important from a patient’s perspective, but, similarly, accepting genuine 
samples is critical from a manufacturer’s perspective. Further discussion about selecting principal 
components can be found in Bro el al. [120]  
PLS-DA: PLS-DA successfully identified falsified tablets containing the wrong API in an 
example by Piender et al [31].  Lovastatin is occasionally used in falsified products instead of 
atorvastatin. For discriminating lovastatin from atorvastatin, Piender et al [31] demonstrated PLS-
DA as a useful technique for discriminating the two active components. Moreover, investigations 
of the regression vector of PLS-DA analysis demonstrated the important features which helped to 
distinguish the differences (Figure 1-14) [31, 45, 121]. Similarly, tadalafil and sildenafil were 
separated using the PLS-DA method. Another potential application for the PLS-DA method is to 




calibration method, samples containing the expected amount of impurities should be added into 
the model as an alternate class of the pure sample. Otherwise, impure samples may be accepted as 
pure samples, which will give false positive result.  
 
PLS-DA is also useful for identifying expired products which are often repackaged and 
resold, resulting in a major public health risk. Qun et al.[44] used both expired and non-expired 
products to develop the PLS-DA calibration model, where expired products and non-expired 
products are used as two classes. Then expired products were detected by using an independent 
test set [20, 36, 44]. The success rate of detecting the expired product in this study was possible 
due to a change in the expired tablet’s matrix. Raman spectroscopy was sensitive to the change of 
the tablet matrix. However, this might not be true in other cases. Therefore, before implementing 
the PLS-DA method to detect expired products, analysts should carefully investigate whether the 
expiration of the product creates any change in the sample spectra. PCA can also be an important 
tool to understand the variabilities among the expired and non-expired products before developing 
PLS-DA method. It is also suggested that manufacturers store their expired products and develop 
Figure 1-14: Class prediction plot (A) and regression vector(B) of the PLS-DA 
model of NIR spectra based on three LV’s to discriminate counterfeits (•) from 
genuine tablets (▼). Figure obtained from Peinder  [31]. Copyright (2008) with 




a reference library. This will be helpful to develop an authentication system to detect expired 
products in the future.   
Similar to SIMCA, proper wavelength selection and preprocessing methods also help to 
improve PLS-DA classification model performance [36]. For example, baseline removal by a 
derivative method minimizes spectral changes associated with the tablet geometry, physical 
differences in tablet faces, and sample position relative to the probe beam [34]. Theoretical and 
experimental evidence showed that elimination of useless predictors (wavelengths which are not 
carrying important information) increases the anticipated performance of PLS-DA [121, 122]. Li 
et al [121] showed that classification of five different manufacturers of anisomide tablets was 
successfully accomplished by appropriate variable selection method. Here, iterative PCA (iPCA) 
was successfully applied to find the superior spectral regions to predict and classify falsified 
products. However, wavelength selection is not always necessary. In fact, Fernandes et al [26] 
demonstrated cases where false sample identification was less effective with wavelength reduction 
as there is a risk of inadvertently removing an essential wavelength region [44, 121]. 
1.3.3.3.3 Limitations of Supervised Techniques 
It is evident from the literature that SIMCA and PLS-DA are often used for the same 
application, and their performance has been compared [20, 45]. However, this comparison is not 
necessarily reasonable, since different models use varying amounts of information. In the case of 
PLS-DA, the algorithm uses information regarding several classes and develops a decision 
boundary based on the existing classes; whereas SIMCA develops a decision boundary based on 




Depending on the different scenarios, PLS-DA and SIMCA should be used carefully. For 
example, SIMCA is one of the best choices when the variabilities of falsified samples are not 
possible to be sampled sufficiently. By using genuine samples, a target class can be developed, 
and any new unknown sample which is dissimilar from the genuine samples is projected outside. 
However, when an analyst develops a PLS-DA model, the model assigns class membership based 
on the variability modeled from available samples. Then, predicted unknown samples are assigned 
to any of the classes, even if they have very different compositions. This leads to an incorrect 
recognition of new samples [123]. 
On the other hand, when the potential variability of falsified samples has a limit, PLS-DA 
is applicable. For instance, when the types of impurities found in falsified samples are expected, 
then the discriminant techniques may perform better than class-modeling. Since data from genuine 
and impure samples have different directions in the score space, effective boundaries around 
different groups’ scores form easily. For the above reasons, PLS-DA and SIMCA should be 
selected depending on the target sample.  
Supervised classification methods provide only diagnostic results (in class or out of class), 
but other specific information, such as types of impurities, whether a sample contains any harmful 
content, or whether a tablet contains any API or not, is not typically identified using this method. 
Therefore, while developing authentication systems, the analyst should consider a variety of 






















• Prescreening of raw material identification 
• Impurities/adulterant detection 
• Detection of API or excipients in the 
finished dosage form. 
• Must determine a useful threshold. 
• For NIRS broad overtones and combination 








data in a 
low- dimensional 
space 
• Physico-chemical differences of the 
genuine and falsified products captured by 
spectroscopic techniques.  
• PCA forms data clusters, which are related 
to the sample variance. Examples: 
composition differences between genuine 
and falsified products, variance observation 





• Link developed between seized samples 













on its distance 
to the class 
The class-modeling approach is useful for detecting 
unknown falsified samples: 
• Finished falsified dosage forms which are 
highly similar to genuine products, and 
difficult to separate by spectral matching 
method, are easily identifiable.  
• Drugs containing the wrong active 
substance and or the correct active 
substance with wrong dose are detectable. 
Adulterated raw materials (API and 
excipients) may be detectable.  











• Classification methods are developed from 
two or more classes, for example, a) the 
original drugs with expired date and  b) 
drug developed from different APIs.   
• Directions in the data space that 
discriminates the two or more medicine 





1.3.3.4 Other Methods 
Raman Barcode: Lawson and colleagues developed an interesting method to screen 
whether seized finished products contain API or not, which they stated as “Raman barcode” 
method [32, 64]. A barcode is developed from API spectra and finished products by replacing zero 
intensity to every wavelength shift except the wavelength shift that represented Raman peaks. The 
identity of API was ensured by comparing the percentage of nonzero overlap between the target 
API barcode and finished drug product barcode (Figure 1-15). This method was successfully 
applied to test 18 different original products acquired from the market and nine simulated falsified 
products. A Raman barcode was applied only for high dose drug products with the assumption that 
excipients are Raman inactive. However, this conjecture restricted the use of this method only for 
Raman spectroscopy, as NIRS demonstrates high excipients signal. Additionally, this method was 
only applied for samples containing a single API and was not tested for the tablets which contained 





Figure 1-15: Generation of Raman Barcode. All peaks denoted with a green circle 
are included in the barcode spectrum. Figure obtained from Lawson et al. [32],  
Copyright (2016) with permission from American Chemical Society. 
Machine Learning Method (Support Vector Machine):  A Support Vector Machine 
(SVM) is developed by constructing the best separation hyperplane to maximize the margin 
between different groups. The widest margin between the two groups is identified using several 
samples residing in the boundary, which are called support vectors. This margin can be linear or 
nonlinear depending on the type of kernel function that is applied. Finding the optimal hyperplane 
requires optimization of the model parameters. Details of the methods are discussed elsewhere 
[124, 125].  
SVM can handle some of the challenges usually related to a) large datasets [86],  b) samples 
which are collected using a limited spectroscopic wavelength range[63], and c) calibration transfer 




compared to full size spectrometers, creating sensitivity challenges in terms of detecting product 
identity. However, falsified products can be successfully separated from genuine products using 
SVM even with limited wavelength range. SVM is also less affected by small spectral perturbation 
when compared to SIMCA, which makes it a better algorithm for calibration transfer [116, 126]. 
However, careful optimization of SVM parameters are required before implementation.  
Though classical SVM has been applied for falsified drug detection, other forms of the 
SVM algorithm, such as the support vector data description (SVDD) method, can also be useful 
for class-modeling.   The advantage of SVDD is that it does not require two classes of samples 
during method development. Therefore, it is more suitable to use class-modeling techniques for 
analysis of pharmaceutical samples. In this dissertation project, SVDD was explored as a potential 
class-modeling technique for falsified drug detection. 
Multivariate Quantitative Analysis: Hyperspectral chemical imaging systems use different 
multivariate regression methods to quantify the composition of falsified products. In most cases, 
compositions of the seized samples are generated without knowing actual formulations. Different 
algorithms, for example, classical least-squares (CLS) and multivariate curve resolution (MCR) 







Figure 1-16: PLS predicted images of (a) genuine tablet; (b) falsified tablet– red 
pixels indicate higher concentration and blue pixels indicate lower concentration of 
the target component [89], Copyright (2010) with permission from Elsevier.  
Lopes and co-authors [89] implemented Classical Least Squares to quantify pure 
components of  falsified and genuine samples. Concentration maps of each pure material, including 
the API (lamivudine) and the excipients microcrystalline cellulose, sodium starch glycollate, rice 
starch and talc, were estimated using CLS [89]. Imaging of predicted concentration of the 
components showed apparent differences in the sample (see Figure 1-16) [127].  
1.3.4 Challenges and Considerations of Routine Spectroscopic Authentication Methods 
Many sources of variability impacting the spectra of pharmaceutical samples occur during 
the life-cycle of a spectroscopic technique. Some examples include manufacturing process 
variability, analytical instrument variability, and environmental fluctuations. Sample variability is 




on material variability. Lot-to-lot variations of incoming raw materials introduce new physical and 
chemical variations to which both Raman and NIR spectra have been shown to be sensitive [128, 
129]. However, the significance of variabilities on spectral quality depends on the sampling 
configuration, collection modalities, etc. [130-132]. For Raman spectroscopy, the effect of particle 
size variation in tablets between backscatter and transmission mode were compared. As the Raman 
backscatter mode generates most of the signal from the tablet surface, it was relatively less 
impacted by the variation in particle size relative to the transmission mode [133]. Tablet surface 
roughness also affected the impact of particle size on the spectra for the backscatter mode. 
However, in transmission mode, photon propagation characteristics were more influenced by 
particle size variations due to the scattering coefficient and optical path length [1, 133-135]. A 
change of size, shape or density of tablets due to the changes in the manufacturing process also 
generate spectral variabilities [134, 136, 137]. Physical factors are very critical for NIRS, as this 
method is highly sensitive to physical variations of the samples mentioned above [138-144]. These 
sources of variability are well known, but their effect on the model is not always well characterized. 
One way to test the effect of such physical variation is to develop calibration models with and 
without these variations in the model, and then determine whether including the variabilities 
improves the model performance.  
Another challenging source of variability that analysts often encounter with the 
spectroscopic method development and deployment is environmental variability; for example, 
relative humidity often varies from the warehouse, where materials are stored, to the 
manufacturing facilities where samples are analyzed. The impact of relative humidity and extreme 
temperatures on model performance is critical to product quality and must be considered during 




using NIRS over the duration of a one year period .The variability was due to moisture variations 
of the testing period.  This highlights the importance of including moisture variability in a NIRS 
model development [71, 91, 145-147].    
Figure 1-17: PCA plots (PC1/PC2) and the related 95% confidence intervals of two 
lubricant spectra recorded five times over a 1-year period. Figures obtained from 
Vredenbregt [148], Copyright (2003) with permission from Elsevier.  
For Raman spectroscopy, although water has a weak Raman scattering, it was found that 
for tablets exposed to high humidity and temperature, the spectral baseline demonstrated variation. 
As chloroquine has broad fluorescence background, moisture variability caused spectral artifacts 
in the form of baseline variations, which is associated with fluorescence quenching  [146]. This 
caused failure of the detection method. Fluorescence quenching also happens due to long laser 
exposure to samples. It was reported that due to the fluorescence background, obtaining reliable 
Raman spectra was an issue [147]. Using a 1064 nm laser can decrease fluorescence background, 
but requires longer exposure time to acquire similar S/N compared to 785 nm [149, 150]. 
McCreery showed that among 308 reference samples, around 8% of compounds showed a 
fluorescence background, and 3% of compounds were misidentified using the SM method  [25]. 




rigorously for Raman Spectroscopy. Also, the suitability of baseline removal algorithms for 
removing this unwanted effect should be carefully evaluated.  
Two recommendations are proposed to fill the gap in current literature regarding 
authentication method development. First, before developing a multivariate calibration model, a 
thorough investigation should be conducted to identify and understand the possible risks that may 
occur throughout the life-cycle of the method [151, 152]. Introducing systematic risk assessment 
based on previous experiences can be helpful to achieve this goal. For example, using Ishikawa 
diagrams and Failure Mode and Effects Analysis (FMEA) can be beneficial for developing a robust 
authentication model. Such risk assessment techniques were used to develop robust quantitative 
modeling in past studies [153, 154]. It is recommended that even for qualitative modeling to detect 
falsified drugs, risk assessment approaches may be quite practical. In  Figure 1-18, an Ishikawa 
diagram showed critical factors for NIR and Raman spectroscopic techniques to detect falsified 
samples.  
 









































Second, using an independent validation set over time to validate model performance will 
be helpful.  This will also ensure long-term model performance [109, 151, 155]. 
1.3.5 Project Description  
In this dissertation project, detailed investigations were conducted to demonstrate an 
optimized spectroscopic authentication method using class-modeling techniques for the detection 
of falsified pharmaceutical samples.  
Appropriate prior knowledge of the pharmaceutical product, the manufacturing process, 
the spectroscopic technique, and the mathematical algorithm for calibration were required to 
develop and validate a sensitive, selective, and robust method. For a proper spectroscopic 
authentication system, the method was validated using independent sample sets, and the developed 
method met two validation criteria: 1) acceptance of genuine products and 2) rejection of falsified 
products.  
The first validation parameter was that the model must accept authentic samples. To ensure long 
term model performance, proper risk assessment was investigated during method development. 
This risk assessment explored a variety of critical factors, including the effect of variability in 
materials, environmental conditions, manufacturing variability, and analytical instrument 
parameters. To understand the effect of these factors on the multivariate model performance, 
further studies were conducted. When it was found that certain factors were a risk for the model 
performance, inclusion of these factors improved the long-term model performance and decreased 




method, e.g., SIMCA, had certain limitations that may be resolved with more modern algorithms, 
in particular, a SMV based algorithm. 
The research project generated simulated falsified samples to test the capability of the 
analytical technique and to test the second validation criteria, i.e., rejection of falsified product. A 
variety of falsified sample characteristics were simulated in the lab. Specifically, the models were 
tested against falsified samples which contained the appropriate API but different excipient 
compositions. This was the most difficult condition of falsified samples to detect.  To evaluate the 
ability of the analytical techniques and the developed chemometric model, a systematic variation 
of excipients was required in the formulations. Statistical method such as design of experiment 
(DOE) is a valuable tool to explore the spectroscopic capability to identify different falsified 
products. DOE is also helpful to understand which falsified samples are spectrally similar in 
comparison to genuine samples, and which pose a risk on the developed method. Carefully 
developed DOE, accomplished with appropriate prior knowledge, minimized the risk of model 
failure. Using samples created at small scale, in the laboratory, reduced the burden of sample 
preparation and made the model development efficient.   






2 Chapter 2: Evaluation of SVDD and SIMCA methods as 
Class-Modeling Techniques using Near-Infrared 
Calibration Sets of Pharmaceutical Tablets Containing 
Moisture Variation 
2.1 Introduction 
Protection of pharmaceutical materials from fraudulent activities is becoming increasingly 
critical due to the growing distribution of falsified products. The rise of procurement of internet 
products by American consumers increases the chance of exposure to these falsified products [6]. 
Currently, 10%-30% of drugs in the world are falsified [156, 157] and pharmaceutical tablets are 
the most common type of falsified products.  
The primary method of pharmaceutical tablet falsification is to vary the chemical 
composition. This includes, but is not limited to, tablets prepared without active pharmaceutical 
ingredient (API), tablets manufactured using the wrong API and tablets generated using the correct 
API but different excipient compositions. Implementation of tools to monitor the chemical 
composition of pharmaceutical products during distribution from manufacturers to customers can 
reduce fraudulent activities [3, 4].     
Near infrared spectroscopy (NIRS) offers the ability to rapidly determine the chemical 
content of pharmaceutical tablets. In studies utilizing NIRS, antimalarial, antimicrobial, 




medications were collected from around the world and tested in the laboratory. Further progress 
in instrumentation technology has led to opportunities for NIRS to be implemented as portable, 
even handheld spectrometers, for the detection of falsified products in the field. These 
spectrometers allow screening for the quality of medicines in multiple locations (e.g., in different 
locations of the supply chain including rural hospitals, clinics, drugstores, etc.) [51].  
However, developing authentication methods using NIRS is challenging due to sample 
constraints and the multivariate nature of the collected data. Only authentic samples are available 
during method development, as it is impracticable to produce or collect all types of falsified 
samples.  Additionally, rigorous chemometric methods are required to statistically compare an 
authentic sample’s NIR spectrum with an unknown sample’s spectrum  to determine  whether the 
unknown sample is genuine or falsified.   
Two types of chemometric techniques are highlighted in the literature for authentication of 
pharmaceutical tablets: 1) spectral matching (SM) and 2) class-modeling (CM) techniques [11]. 
SM compares two spectra, including a reference NIR spectrum from an authentic tablet and an 
unknown spectrum from a sample. The spectral correlation or spectral distance is calculated 
between these two spectra and, if these values fall within a target threshold, the unknown sample 
is declared to be genuine [158]. Research has shown that the SM method is successful when 
samples have large chemical differences providing sufficient spectral uniqueness [14]. For 
example, the SM method was used to identify placebo samples and samples containing the wrong 
API.  However, this method struggled to separate samples containing identical APIs and similar 
excipient compositions or what would be considered high quality falsified products [15].  




to research instruments, and insufficient spectral resolution to distinguish the differences between 
authentic and falsified samples. Regardless, SM is a popular technique included in most of the 
current portable spectrometers due to its rapid and relatively simple assessment of authenticity. 
Class-modeling (CM) is another chemometric technique that can be applied for the purpose 
of authentication. Multivariate methods such as SIMCA and its extended versions have been used 
for spectroscopic class-modeling techniques for authentication. The primary premise of these 
methods is to develop a target class using representative samples from an authentic source. A 
calibration model is developed from the target class, comprised of NIR spectral data containing 
API and excipient information. CM estimates a decision boundary which is formed around the 
calibration data at a specific significance level. For example, the boundary of different versions of 
SIMCA is developed based on the distribution assumptions such as normal, 𝜒2, etc. [17-19]. 
Several studies have compared the performance of SM and CM, and proposed that CM techniques 
are more effective than the SM method. In these studies, portable spectrometers successfully 
separated pharmaceutical tablets containing similar compositions [15, 20]. 
The CM methods require two critical considerations: suitable target class samples and the 
establishment of appropriate boundary conditions. A typical target class includes authentic 
samples; however, it does not necessarily include the variabilities that have a critical impact on 
NIR spectra. For example, a CM method using NIRS data based on a target class including 
authentic samples from one batch may consider an authentic sample from a different batch to be 
falsified because batch-to-batch variability is not considered in the original calibration. Batch-to-
batch variability can have a severe impact on the performance of NIR prediction models, 




Specific sources of small chemical and physical changes between authentic samples include raw 
material variability and environmental (i.e., temperature, relative humidity) fluctuations. 
Specifically, environmental variability is of high concern because authentic samples are often 
produced in different manufacturing sites around the world with varying relative humidity 
conditions. NIR spectra are highly sensitive to moisture; thus, the relative humidity variation needs 
to be considered during method development, especially if the NIRS method is to be directly 
applied at these different sites. To reduce the impact of these potentially important variabilities, 
several spectral preprocessing techniques are available. However, these pre-processing techniques 
are not always sufficient; an additional, valuable option is to update the calibration model using 
new samples comprising these variabilities. 
The addition of samples to the target class to create a robust model can be accomplished in 
two ways. First, the empirical approach where the model is updated over time by adding samples 
to include newly evolved variabilities. This empirical approach depends on stepwise addition of 
newly available samples to the calibration set and rebuilding the model over time  [159]. Another 
approach can be taken by implementing risk-assessment concepts during method development. 
According to ICH-Q9 guidelines, a risk-assessment can be conducted while developing the 
calibration method, and factors which can be risks for spectroscopic method performance are 
added into the target class during model development [154]. 
In addition to sample considerations for development of a suitable target class, the 
boundary conditions are also important.  The boundary around the target class decides if an 
unknown sample is authentic or falsified. The CM method assumes that the target class forms one 




samples (e.g., samples with different moisture levels) may introduce multiple clusters within the 
target class. This violates the assumption of the model by forming a binomial or multimodal 
distribution in the model space. In addition, the boundary formed around the multiple clusters may 
not include all potential calibrations samples, and the model will be more prone to rejecting 
authentic samples. Therefore, the caveat of this approach is that without prior knowledge of the 
shape of the underlying distribution of samples, satisfactory results may not be achieved.  
 This chapter explores the use of a support vector machine based method to resolve 
boundary condition issues of a traditional CM method. Support vector machine methods create a 
spherically shaped boundary around the samples. The boundary is typically described by a few 
training objects which are mentioned as support vectors. It is possible to replace normal inner 
products by kernel functions to obtain more flexible data descriptions. This method is often 
referred to as a support vector data description (SVDD) approach, proposed by Tax et al [21]. This 
method has been used for the detection of machine faults, outlier detection, etc., and has shown 
similar results to the one-class support vector machine (OC-SVM) developed by Schölkopf et al 
[22]. However, the SVDD method has not yet been evaluated for analyzing pharmaceutical 
samples using spectroscopic data, particularly for authentication purposes. 
The objective of this paper is to explore the performance of SVDD as a class-modeling 
technique relative to that of the widely used SIMCA method in order to authenticate 
pharmaceutical products. This study emphasized the suitability of these chemometric techniques 
in the presence of seasonal variations. To demonstrate the capabilities of these methods, tablets 
were prepared in-house (in the laboratories of the Duquesne University Center for Pharmaceutical 




generated in the laboratory, this study provides direction for further development of an 
authentication method using spectroscopic data.  
2.2 Materials and Methods 
2.2.1 Theory 
2.2.1.1 SIMCA based Approach  
SIMCA is extensively used as a class-modeling technique for authentication purposes. The 
procedure for SIMCA first involves decomposing calibration samples using a PCA model with the 
optimal number of principal components.  Classification rules are then constructed to create a 
decision boundary. Different versions of classification rules have been developed over time; this 
is discussed extensively in existing literature [17, 103, 160]. However, in this study, one of the 
most immediate and commonly used versions was applied for the SIMCA analysis. In this method, 
the boundary around a training set of SIMCA is based on two distances: 1) score distance (SD) 
and 2) orthogonal distance (OD). The SD is determined by computing the distance, in the space of 
the PCs, between an unknown sample and a target group, commonly referred to as the Hotelling’s 
𝑇2. The OD is determined by calculating the unknown sample’s squared residual distance from 
the model space, referred as the 𝑄 residual [17, 82]. Hotelling’s 𝑇2 measures the information of 
each sample within the PCA, or SIMCA model, and is calculated by Equation 1, where 𝑡𝑖 is the 𝑖-
th row of the 𝑇𝑘, the 𝑛 by 𝑘 matrix of 𝑘 score vectors from the PCA model, and  matrix of 𝑘  scores 
vectors from the PCA model of 𝑛 number of target class samples and Λ- 1 is a diagonal matrix 
containing the inverse of the eigenvalues associated with the 𝑘 eigenvectors (principal 




The 𝑄𝑖  statistic is defined as the sum of squares of the residuals and can be calculated 









A sample is assigned to a target class if the computed distances are shorter than a predefined 
threshold value. These threshold values are based on 𝑇𝑙𝑖𝑚
2  and 𝑄𝑙𝑖𝑚, which are the confidence 
intervals for the model under consideration. Confidence limits for SD (referred to as 𝑇2 in the 
PLS_Toolbox and related literature) are given from Hotelling’s 𝑇2 to obtain 𝑇𝑙𝑖𝑚
2 , i.e. (𝑇𝑙𝑖𝑚
2 =
𝐹𝑘,𝑛−𝑘𝑘(𝑛
2 − 1)/(𝑛 − 𝑘)  considering 𝑘 and  (𝑛 – 𝑘) degrees of freedom, where 𝑘  is the number 
of PCs and 𝑛  is the number of calibration samples for the target class. 
The χ2 distribution is used for the squared residuals and confidence limits for the 
orthogonal distance (OD, also referred to as Q in the PLS_Toolbox and related literature) are 
computed by the Jackson and Mudholkar (JM) approximation. 
The limit of Hotelling’s 𝑇2(𝑇𝑙𝑖𝑚
2 ) and the limit of 𝑄 statistic (𝑄𝑙𝑖𝑚) values can be 
calculated from the ratio between the corresponding statistic of the sample 𝑖 and the corresponding 
limit at α = 0.05 [𝑒. 𝑔. , (𝑇𝑙𝑖𝑚
2 =  𝑇95%
2  and 𝑄𝑙𝑖𝑚 = 𝑄95%] [17]. A more flexible boundary is 
developed by a semi-circle with a radius of √2, which is mentioned as d; this d is calculated 


















 This distance measure gives equal weighting to distance in the model space, i.e. scores 
distance (SD or 𝑇2) and residual space, i.e. orthogonal distance (OD or 𝑄).  The outcome of this 
boundary was depicted in Figure 2-1. 
2.2.1.2 SVDD based Approach 
The theory of SVDD has been extensively described in the literature [21, 161].  Therefore, 
only a brief description of the concept of SVM in the framework of classification is given here.  
Figure 2-1: Threshold boundary based on the confidence interval of Hotelling’s 
𝑇2 versus  𝑄  residual. The squared acceptance area is the green space in the graph, 
where samples plotted at any point outside of this area are rejected. According to 
this threshold, nearly every sample will be accepted, with only the green sample 
being rejected. A more flexible boundary could be applied as shown by the semi-
circular area. Then, both green and red will be accepted. Figure is adapted from 




Figure 2-2: The hypersphere containing the target data (blue), described by the 
center a and radius R. Five objects (red) are on the boundary. Three object (red) 
xi is outside and has ξi > 0. 
The SVDD algorithm avoids the estimation of a complete probability density; it obtains a 
data boundary by forming a circle or hyperplane around the data where  𝜇 is the data center and  𝑅 
is the distance from the center to the hyperplane that forms the boundary around the samples 
(Figure 2-2). However, it is not always possible to include all data within the boundary.  Therefore, 





∅(𝑅, 𝑎, 𝜉) = 𝑅2 + 𝐶 ∑ 𝜉 
||𝑥𝑖 − 𝑎||




Usually, slack variables 𝜉, allow a probability that some of the training samples will be placed 
outside the boundary. Samples which reside on the boundary (𝜉 = 0), or outside of the hypersphere 
(𝜉 > 0), are referred to as support vectors. Development of the hypersphere is based on the 
optimization of these support vectors, where the distance of each of the samples should be less 
than or equal to 𝑅2 + 𝜉 . Therefore, mathematically, it is possible to define a structure error 
function (∅) for an SVDD model with a constraint.  
In Equation 4, 𝐶 shows the trade-off between the volume of the hypersphere (calculated by 𝑅2 ) 
and the number of errors (𝜉) and therefore controls the fraction of samples lying outside the 
boundary. The higher the 𝐶  value, the more samples are included in the model space. This 𝐶  can 











The C and D are related by 𝑛 which is defined as the number of samples in the calibration 
set. 𝐷 has some analogy to confidence levels in distance-based classifiers. When 𝐷 = 0, no target 
samples are misclassified, whereas 𝐷 = 0.05 means 5% of samples will be outside the boundary. 
However, this number is an approximation. This optimization problem was further modified using 
the Lagrangian method which simplified the calculation [21]. 
It is also possible to incorporate kernel functions into the model to create a non-linear 
boundary (Figure 2-3) [21]. It provides additional dimensions which transform the shape of the 
data. The shape of the boundary can be optimized using different kernel function, but most popular 
is the Gaussian radial basis function (RBF),  







σ =5 σ =25 
Figure 2-3: Data description trained on a banana-shaped data set. The kernel is a 
Gaussian kernel with different width sizes σ. Support vectors are indicated by the solid 
circles; the dashed line is the description boundary (adapted from Tax et al. [160]).  





The broader the Gaussian, the smoother is the surface; hence, the radius of the RBF (or σ) 
relates to how ‘bumpy’ the surface is, and varying this parameter can change the appearance of 
boundaries between points.   Using a small σ results in a sharp Gaussian that effectively forms a 
boundary around each point (or occasionally neighboring points). Therefore, a small σ value may 
overfit the model, whereas as σ increases, the model becomes smoother and more circular, 
resembling a PCA or SIMCA models.  It is essential to understand that the number of samples on 
the boundary decreases as σ increases—this is because fewer points are required to model a smooth 
boundary and so fewer SVs are required. 
2.2.2 Figures of Merit 
In the class-modeling approach, two validation parameters are used for performance 
analysis. The goal of the method is to accept target class samples. This is referred to as the 
sensitivity of the model. It describes the ability of the model to declare genuine samples. The 
following formula calculates the sensitivity of the method (accepting genuine samples): 
Sensitivity=TP/(TP+FN)                                                                                   7                                   
where TP and FN are true positive and false negative, respectively.  If the model accepts 
falsified samples, it needs further optimization.   
The second measure of model performance is rejection of the non-target class samples. 
This is called specificity.  The specificity of the method (rejecting falsified samples) is used as a 
validation parameter. The following formula calculates this parameter: 




where TN and FP are true negative and false positive, respectively.   
To consider both factors simultaneously, the geometric average of these two parameters 
were calculated. The average of sensitivity (Equation 7) and specificity (Equation 8) will be 
indicated as average performance (see Equation 9).  
Average performance= (Sensitivity + Specificity)/2                                          9 
2.2.3 Sample Set 
2.2.3.1 Sample Preparation 
For this study, acetaminophen (APAP) was used as a model drug.  The target formulation 
was APAP (27.30%w/w), microcrystalline cellulose (MCC 200; 34.15% w/w), lactose (34.15% 
w/w), hydroxypropyl methyl cellulose (HPMC; 3.90% w/w), and magnesium stearate (0.5% w/w).   
Tablets were generated with a wet-granulation approach. First, granules containing APAP, HPMC, 
and lactose were manufactured using a fluid bed granulator (model WSG 5, Glatt, Binzen, 
Germany).  Then, granules and extra-granular excipients (MCC 200, lactose, magnesium stearate) 
were mixed in a 3.5 quartz V-blender for a total blend mass of 1 kg for 45 min. Target blending 
time for homogeneity was tested using NIRS. The blends were subsequently compacted on a 38-
station rotary tablet press (Elizabeth-Hata International, Inc., North Huntingdon, PA, USA).  The 
target tablet weight was 350 mg.   
To consider non-target class test samples during model development, another set of 
samples containing low concentration of API (19% w/w) was manufactured. The shape and size 




2.2.4 NIR Scanning 
NIR reflectance measurements were acquired for both sides of each tablet over the 
wavelength range of 925 to 1700 nm at a 6.38 nm increment, averaging 5000 scans (JDSU 
MicroNIR). Before scanning, the tablets were precisely centered using the positioning iris, 
standard on this instrument.  A period of two weeks elapsed between compression and spectral 
collection to allow the tablets to undergo viscoelastic relaxation. 
All spectral data were analyzed in  Matlab  (version 8.6, MathWorks, Natick, MA) using 
PLS_Toolbox (version 8.8, Eigenvector Research, Inc, Manson, WA) [162], and software 
developed by the Duquesne University Center for Pharmaceutical Technology. 
2.2.5 Reference Testing 
Acetaminophen reference values for all compacts were determined using high-pressure 
liquid chromatography (HPLC; Waters Alliance 2790, Milford, MA, USA), followed by 
ultraviolet detection (Waters 2487). A method, modified from USP29-NF24 (“Acetaminophen 
Tablets’’), was employed [41]. The mobile phase was water: methanol: acetic acid (80: 17: 3), and 
the stationary phase was a 15 cm by 4.6 mm C18 column with 3μm packing. The detection 
wavelength was 243 nm. The error of the reference measurement was estimated at 0. 83%. 
2.2.6 Sample Considerations for Calibration, Test and Validation 
During the study, a total of six granulations and fourteen tablet batches of the target 
formulation were manufactured.  There was significant variability in the particle-size distribution 




observed because the environment of the laboratory in which the experiments were performed was 
not controlled for humidity; during winter the air was dry (20–30% relative humidity (RH)). 
During the summer months, typical RH was between 60 and 70%.   
Samples prepared in the lab were used to investigate these seasonal spectral variabilities 
and the subsequent effect on the model performance during spectroscopic analysis. Samples were 
prepared using six different granules (containing different particle size distribution) and in 
different seasons of the year (in the presence of different relative humidity). 
The target class samples were developed from the target concentration, and the non-target 
class product was prepared using a lower concentration of API, as mentioned previously. 
Calibration, test, and validation sets were the sample sets used for the model development 
process. The model was optimized using the test set which contained both target and non-target 
class samples, whereas the calibration set contained only target class samples. Non-target class 





Figure 2-4: Method development flow chart and considered samples. 
Three calibration scenarios were created to demonstrate three conditions of calibration sets: 
1) Basic: Samples prepared in the summer (lab humidity ~ RH65%) were added to the 
calibration set. This set will be further mentioned as the “basic calibration set”.  
2) Updated: The updated data includes the basic calibration set and additional samples 
created during the winter, representing a real-life scenario in terms of the likely scenario for the 
model update. This data set will hereafter be called the “updated calibration set.”  
3) Risk-based: In this approach, samples prepared during the summer were stored in lower 




sample set along with the samples of the basic calibration set. This will be henceforth described as 
the “risk-based calibration set.” 
Calibration sets for model development: Samples were considered for calibration set from 
three scenarios mentioned above. Each of these calibration sets were used to generate SIMCA and 
SVDD  model.  Test sets were used to optimize calibration model and validation sets were used to 
measure the final performance. (Table 2-1).  
 Test sets for model optimization: Cross-validation was conducted using calibration sample 
sets of target class samples. Samples of similar composition containing a low level of API 
(19%w/w) were used as non-target class samples to optimize the model parameters. 
 Validation sets for performance evaluation: The model was challenged with the validation 
set to test whether it could accommodate seasonal variabilities present in the independent target 
class samples. Three batches of target class validation sample sets were generated from new 
granules (that had not been present   in the calibration set) and manufactured under summer, spring, 
and winter conditions.  
Table 2-1: Details of the modeling scenarios 
 Scenarios 
 Basic Updated Risk-Based 
Calibration Set    
Moisture variations High High+Low High+Low 
API Concentration Target Target Target 
Test Set    
Moisture variations High+Low High+Low High+Low 
API Concentration Target+Low Target+Low Target+Low 
Validation Set    
Moisture Variation High+Low High+Low High+Low 





2.3.1 Spectral Investigation and Exploratory Analysis 
Samples were prepared using granules containing different particle size distributions and 
created in different seasons of the year (containing different relative humidity conditions).  Figure 
2-5 shows the second derivative treated spectra of tablets. Figure 2-5A used the same granules 
manufactured in two different seasons. Different spectral regions of the samples generated in the 
summer (~60% RH) and in the winter (~25%RH) demonstrated intensity differences [164, 165]. 
The preprocessing method removed the effects of physical variation by eliminating the baseline 
differences. However, the water bands around 1470 nm exhibited significant variability compared 
to other regions of the spectra. This 1470 nm region represents primarily the combination bands 
of water. This spectral change depicts the influence of moisture on the spectra [164, 165]. Figure 
2-5B showed the spectral difference in the 1167 nm region due to APAP concentration differences; 
here, the target concentration and low concentration tablets represented target class and non-target 




Figure 2-5: A) NIR spectra of different moisture conditions B) Two different 
concentration levels of API. 
A  PCA algorithm was used to decompose the calibration spectra after SNV and mean-
centering treatment [81].  Figure 2-6A shows that the scores of the first two PCs, generated from 
the basic-calibration set, are uniformly distributed.  However, when the PCA algorithm was 
applied to the updated and risk-based calibration scenario data (preprocessed), two clusters formed 
in the PCA space (Figure 2-6B). This clustering indicates that variabilities were present across the 
calibration set, mostly in the PC2 direction. As most of the samples were prepared and scanned in 
the summer-season, the largest group contained summer-samples. Whereas, the smaller group 
contained samples added from the winter-season (low humidity condition). Also, a boundary was 
developed using a 95% confidence interval of PC1 and PC2 scores. It was observed that the 
developed confidence interval in the PC space of the updated calibration model mostly excluded 
samples from the smaller cluster (Figure 2-6B). Therefore, the samples that resided outside the 
boundary were primarily from the winter season. Nevertheless, increasing the confidence interval 






Figure 2-6: A) PCA of the basic calibration model with a 95% confidence interval, 
B) PCA of the updated calibration model with a 95% confidence interval, and C) 
PCA of the updated calibration model with a 99% confidence interval. Here the red 






Table 2-2: Performance of the different modeling approaches 
Different Models with  
predefined threshold 
Calibration scenarios 
Basic  Updated  Risk-based 
 Sensitivity Specificity Average  Sensitivity Specificity Average  Sensitivity Specificity Average 
SIMCA (𝑻𝟐 & Q=0.95) 0.5 1 0.75  0.67 1 0.83  0.85 1 0.925 
SIMCA (𝑻𝟐 & Q =0.99) 0.5 1 0.75  1 0.92 0.96  1 0.6 0.80 
PCA-SVDD (D=0.05) 0.5 1 0.75  1 1 1  0.93 0.98 0.955 
PCA-SVDD (D=0.01) 0.5 1 0.75  1 1 1  0.94 0.94 0.94 
Spectral SVDD (D=0.05) 0.5 1 0.75  1 1 1  0.93 1 0.965 




2.3.2 Model Performance of SIMCA and SVDD Methods 
2.3.2.1 SIMCA Method Performance 
While developing the SIMCA calibration model, several parameters were optimized. 
Spectra were preprocessed and PCs were determined using independent test sets (containing both 
target and non-target class samples) by maximizing the classification average performance of 
sensitivity and specificity. The baseline correction method was required as a preprocessing method 
to minimize batch-to-batch variabilities  due to particle size differences. Standard normal variate 
(SNV) helped to remove these variabilities.  The number of selected PCs has a major impact on 
the classification results.  Adding more PCs into the model increases the complexity of the model, 
which typically helps to reject non-target class samples.  However, a more complex model means 
that a higher amount of variation in the training set is considered; adding more PCs may result in 
an over fitted model and a potential risk of rejecting target samples during routine analyses. Hence, 
a model containing a minimum number of PCs to generate adequate specificity is preferable. This 
approach is often referred to as a parsimonious approach [163].  
After establishing a PCA model, an acceptance area is developed based on a threshold 
value. In this study, the decision threshold is set at √2 which creates a semi-circle in Hotelling’s-
𝑇2 and 𝑄 residual plot. This is based on a priori significance level of Hotelling’s 𝑇2 and 𝑄 residual. 
This significance limit for these two statistics are estimated based on the internally cross-validated 
values of 𝑇2 and 𝑄 residual associated with the calibration samples. In this study, two fixed 




In Table 2-2, the performance of SIMCA models is shown. Here, it was observed that, 
regardless of the significance level, the basic design scenario showed 100% specificity using 1 PC 
(rejected all the non-target class samples). According to Figure 2-7A, these non-target class 
samples have higher 𝑄 residual and Hotelling’s 𝑇2 and resided outside the boundary. Non-target 
class samples, containing a lower concentration of API, were separated from the target class. 
However, the other critical parameter, sensitivity of the model, is 50%. The rejected target samples 
have high 𝑄 residuals in the diagnostics plot (Figure 2-7A), which indicates that the target-class 
samples in the validation set had unmodeled variance. This performance is not unexpected, as 50% 
of validation target class samples were generated in the winter and had different moisture content. 
The model accepted target class samples which were manufactured during the summer seasons 
and had similar features of the basic calibration design set. 
The updated calibration scenario (which was developed by adding winter samples to the 
summer sample set) improved sensitivity compared to the basic set. This result indicated that to 
improve model performance, winter samples are required in the calibration set. Moreover, 
changing the threshold value from 0.95 to 0.99 further improved sensitivity.  The diagnostic plot 
in Figure 2-7B, showed that calibration samples prepared in the winter season had higher 𝑄  
residuals and Hotelling’s 𝑇2 relative to the samples prepared in the summer. While developing a 
decision boundary using 95% CI, most of these winter samples resided near the boundary or 
outside of the decision boundary. These samples are typically referred to as high-leverage samples. 
Similar patterns were observed for the risk-based calibration model (Figure 2-7C). Changing the 
significance level of Hotelling’s 𝑇2 and 𝑄 residual to 99% placed these high leverage samples into 
the decision boundary.  This change in the significance level improved the sensitivity of the model 




is also important to understand that the specificity of the model decreased due to the change of the 
significance level. Hence, with this higher significance level (99%), the model began to accept 
non-target class samples (Figure 2-7D).  
Figure 2-7: Diagnostics plots  of SIMCA using 95% threshold value of Hotelling's 𝑇2 and 
𝑄 residuals of A) Basic calibration set, B) Updated calibration set,  C) Risk-based 
calibration set,  and 99% threshold value of Hotelling's 𝑇2 and 𝑄 residual of D) Risk based 
calibration set. Here, red indicates the calibration samples from the target class, green 
indicates validation samples from the target class, and blue indicates validation samples 
from the non-target class. 
Similar results were observed for the risk-based scenario. By including samples stored in 
the low humidity condition, the sensitivity of the model improved. As the model also contained 




generated in the winter. This was an efficient approach of method development as it included 
moisture variabilities in the calibration set without considering samples generated during winter 
seasons.  Therefore, analysts were not required to wait to update the model until generating 
samples, which is often a tedious process. However, this model also had high leverage samples; 
changing the threshold value from 0.95 to 0.99 improved sensitivity but decreased the specificity 
of the model by accepting non-target class samples.   
2.3.2.2 SVDD Method Performance 
In this study, the SVDD algorithm was applied to the PCA decomposed data and 
preprocessed spectral data; these will be mentioned as PCA-SVDD and Spectral-SVDD 
subsequently. Both approaches were optimized individually using the test set to obtain the best 
possible results. During optimization, different factors such as the preprocessing method, the 
number of PCs, and the parameters of SVDD (i.e., D and σ) were considered. Previous literature 
suggested to fix the rejection fraction of the calibration model (D) according to a predefined value 
and then to optimize σ. In this study, two D values: 0.05 and 0.01 were considered. These two 
values represent the comparative performance of 95% CI and 99% CI of the method [166]. To 
optimize σ for three calibration scenarios, a search was performed based on the test set. While 





Figure 2-8: A boundary was developed using a support vector machine approach for 
updated calibration samples. Each row represents different D values whereas each 




While developing the PCA-SVDD method, the first two principal components’ scores were 
selected to develop the model for each calibration scenario. PCA-SVDD models were developed 
by optimizing σ. The impact of the σ parameter on the boundary development of the updated 
calibration scenario was visualized in Figure 2-8. Decreasing the σ value tightened the non-linear 
boundary of the updated calibration scenario by exploiting a higher number of support vectors 
(samples resided on the boundary) [21].  However, analysts should be cautious about the 
unnecessary tightening of the boundary, which may increase risk of overfitting of the model. Also, 
changing D values allowed more samples to reside outside the boundary, which is representing a 
similar approach to the confidence interval of PCA or SIMCA. One crucial difference between the 
decision boundary of SIMCA (based on the confidence interval) and PCA based SVDD analysis 
was identified. In the SVDD approach, samples from both summer and winter samples resided 
inside the boundary. However, while developing a SIMCA model based on the 95% CI, the model 
excluded most samples from the winter season. 
Performance of the different calibration scenarios is presented in Table 2-2. Basic 
calibration scenarios of PCA-SVDD did not contain moisture variation in the calibration model, 
and, therefore, failed to accept validation samples from different seasons. This performance is 
comparable to the SIMCA modeling approach. However, the performance of PCA-SVDD 
generated from updated and risk-based scenarios improved significantly relative to the SIMCA 
approach. The developed PCA-SVDD model successfully accepted more target class validation 
samples, compared to SIMCA, and demonstrated higher sensitivity. Additionally, the model 
successfully rejected non-target class samples by projecting them outside the boundary. Therefore, 




scenario also showed a similar trend to the updated approach. D values of both 0.01 and 0.05 
showed improved performance compared to SIMCA. 
Figure 2-9: Depiction of selected support vectors of updated  calibration set 
where the blue spectra are support vectors, red spectra are summer samples and 
green spectra are winter samples. Particular section is magnified to visualize the 
data clearly. 
The Spectral-SVDD approach also showed improved prediction results compared to 
SIMCA. Data is visualized in Figure 2-9. As the boundary was not possible to show for the 
multivariate spectral data, support vectors were depicted using the preprocessed spectra. 
According to Figure 2-9, the SVDD algorithm selected blue samples as support vectors from the 
calibration sample set. These support vectors were chosen from both summer (red) and winter 
(green) samples, indicating that the boundary was selected using both summer and winter sample 




2.4 Discussion and Summary 
Traditional development of decision boundaries for CM models is based on the assumption 
that there is a specific distribution that exists in the multivariate space (i.e., F- distribution or χ2 
distribution on the Hotelling’s 𝑇2 and 𝑄 residual space). Though these assumptions often vary in 
different versions of SIMCA, analysts develop decision boundaries at a specific significance level 
α (often set to 0.05) [17]. However, these assumptions are frequently violated as samples 
containing spectral variabilities may introduce bimodal, multimodal, non-symmetric statistical 
uncertainties, degrading model performance.  
This work proposes the use of SVDD as a class-modeling technique using NIRS. Due to 
distribution free boundary development, SVDD is a promising technique for use in both the 
laboratory and field for solving the calibration development challenges described above.  The most 
important advantage of SVDD is that boundary samples are determined without relying on 
distribution assumptions. Using a well-known example from NIRS (the effect of moisture on NIR 
spectra), this chapter demonstrates the advantage of SVDD.  
Though compared to the traditional SIMCA method, SVDD has not been widely used in 
pharmaceutical applications of chemometrics. However, it has been proven useful for class-
modeling applications. Moreover, the kernel feature allows the development of a non-linear 
boundary around calibration samples, offering a significant analytical advantage compared to 
traditional CM methods.   
One challenge of the SVDD approach is the visualization of data. While it is impossible to 




provide valuable insights about the developed method.  Another risk of using SVDD methods is 
overfitting. Here in this study, independent samples were used as test and validation sets, 
decreasing the risk of overfitting. However, analysts may not always have access to independent 
samples for optimization. In that case, separating the training set into two sets might be an option. 
To separate samples into two sets, randomization algorithms will ensure homogenous distribution 
of the available samples.  
Many studies have demonstrated the capabilities of different class-modeling techniques for 
pharmaceutical samples, but the development of methods for validating such models is still in its 
infancy. However, as regulatory bodies attempt to implement different spectroscopic techniques 
in the field for routine surveillance, analytical methods must be validated to ensure that these 
methods perform consistently during routine analyses. This work offers insight on 1) 
understanding the physical and chemical variability of typical pharmaceutical tablets, required 
knowledge for development of robust models, and 2) the advantages of SVDD methods for the 





3 Chapter 3: Application of Class-Modeling Techniques 
using Raman spectroscopy in the Presence of Moisture 
Variation 
3.1 Introduction 
Raman spectroscopy has emerged as a promising tool for detection of falsified drug 
products due to sharp peak features offering inherently good chemical specificity, the non-
destructive nature of the method, and the flexibility in sampling interfaces.  
One of the proposed uses of Raman spectroscopy is to detect active pharmaceutical 
ingredient (API) in the test sample. A pure component spectrum collected from API and a spectrum 
from the test sample may be utilized to determine correlation by a spectral matching algorithm. 
Because 50% of the falsified products detected in a recent study did not have the claimed API or 
contained the wrong API [27], this method was used to detect such falsified products.  
In another approach, instead of using pure component spectra, samples collected from an 
authentic manufacturer have been used to find the correlation between authentic and test spectra 
[14, 35, 78-80]. Utilizing authentic sample spectra allows the analyst to verify the correct 
formulation (including excipient composition) of the test sample. However, relying on the sample 
spectrum to calculate correlation has drawbacks. One limitation is that pharmaceutical excipients 
generally have less Raman signal compared to the API. Studies have showed that, since different 
generic samples of a specific therapeutic group contain similar formulations ( i.e., excipient 




products using correlation values because of the inadequate signal intensity from different 
excipients [14, 15]. This drawback of SM algorithms is also true when an analyst wants to detect 
highly similar falsified products (samples containing the same API, but unique excipient 
composition). Therefore, using class-modeling techniques can offer advantages of decreased false 
positives and false negatives. 
As an important step in development of any class-modeling technique, a calibration model 
development effort is required. While developing Raman calibration methods, it is necessary to 
ensure that models meet the required performance standards; in particular, the sensitivity and 
specificity must meet predetermined validation criteria. One of the widely used class-modeling 
algorithms, soft independent class modeling analogy (SIMCA), has been used to create models for 
detection of falsified medicines [109, 151, 155]. Though this method allows the analyst to extract 
relevant chemical and physical information about samples to get qualitative information, numerous 
sources of spectral variability that occur during the method life-cycle may confound Raman 
measurements and may ultimately decrease the sensitivity of the model (ability to accept target-
class samples). Therefore, to ensure long-term model performance, model sensitivity may be 
enhanced by including such sources of spectral variability in the target-class. These sources of 
variability may be identified during a risk assessment. Understanding the impact of such variability 
on the spectra and the effect of these spectral changes on model performance is a critical part of a 
sound model development process [151, 152].   
Many sources of Raman spectral variability arise during the pharmaceutical manufacturing 
process, including sampling error, analytical instrument instability, sample property variation and 




variability or as a result of sampling procedure: the time, location and method of sampling is often 
at fault. Typically, lot-to-lot differences of incoming raw materials introduce new physical and 
chemical variations [128, 129]. The consequence of these variations on Raman spectra may depend 
on the sampling configuration, spectral collection modalities, etc. [130-132] As an example, the 
effect of particle size variation in tablets has been compared for backscatter and transmission 
Raman spectroscopy [133]. Because backscatter Raman generates most of the signal from very 
near the tablet surface [167], particle size had a reduced impact relative to the transmission mode. 
In the case of transmission measurements, photon propagation characteristics were more 
influenced by particle size variation due to the effect of light scattering on the effective optical 
path length. When particle size variability was not included in the calibration set, quantitative 
model accuracy suffered. Spectral processing methods such as derivative, normalization, etc., were 
applied to remove the baseline effect of particle size variation, thereby improving model 
performance. Also, by matching particle size variability for both API and excipients in the 
calibration, adequate quantitative predictions were obtained for independent test sets [1, 133-135].  
A change of size, shape or density of tablets due to changes in the manufacturing process can also 
introduce spectral variability [136, 137]. By adjusting laser power and accumulation time, or 
enhancing density range in the calibration model, robustness can be enhanced against tablet size 
and density variations [134, 136].   
While the implementation of Raman in pharmaceutical applications has increased 
dramatically over the past decades due to the improvement of instrumentation [54, 168, 169], one 
continuing challenge, and a major source of spectral variability causing interference with the 
Raman spectral signal, is fluorescence. Produced by emission of photons from low-lying excited 




occurs in a sample whenever the frequency of the excitation laser coincides with transition energy 
from the ground to an electronically excited state. Different experimental strategies and instrument 
modifications have been developed to overcome this problem [170]. By using excitation sources 
in the near-infrared region coupled with multichannel detectors, modern dispersive Raman 
spectrometers decrease the fluorescence background and provide adequate Raman intensity [171]. 
Different spectral preprocessing methods have been used to reduce the impact of fluorescence 
signal on prediction results [172-175]. Moreover, model performance should be adequate as long 
as both calibration and validation sets contain similar fluorescence background without 
introducing other spectral disturbances [176].   
One of the challenging sources of variability that analysts often encounter during 
spectroscopic model development and deployment is environmental variability; for example, 
relative humidity will often vary from the warehouses where raw materials are stored to the 
facilities where products are manufactured.  This can cause significant variability in the amounts 
of water sorbed by pharmaceutical samples [177-179]. Additionally, falsified products are often 
seized after being exposed to unknown storage conditions. Therefore, the impact of relative 
humidity on model performance is critical and needs to be tested. Most often, Raman analytical 
methods ignore the effect of moisture because Raman presents relatively weak water scattering.  
However, because pharmaceutical samples exhibit fluorescence from active pharmaceutical 
ingredient (API) [146] , excipient [173, 174], dyes [175], capsule shells [180], etc., the effect of 
moisture as a fluorescence quencher needs to be considered [181]. This can introduce unwanted 
spectral inconsistency across calibration and test samples. Nevertheless, there is not enough 
literature evidence to show the moisture effect on Raman spectra. Therefore, influence of moisture 




The objectives of this chapter are to investigate the effect of moisture and fluorescence on 
Raman spectroscopic analysis for pharmaceutical solid oral dosage forms. The effect of these 
changes on Raman spectra and multivariate qualitative model performance was assessed. As 
SVDD is a potential class-modeling technique, performance of this method was compared with 
the SIMCA method during this investigation. Finally, strategies for the development of robust 
qualitative calibration models were discussed. 
3.2 Experimental Plans 
In this chapter, two datasets were used to provide adequate understanding of the effect of 
moisture on calibration model performance.  
1) Dataset 1: Lab-based acetaminophen tablets- Acetaminophen tablets were manufactured 
in the Duquesne University Center for Pharmaceutical Technology (DCPT). 
2) Dataset 2: Artemether- lumefantrine combinations tablets- Artemether-lumefantrine 
fixed dose combination tablets were collected from a generic manufacturer. 
3.3 Dataset 1: Lab-based acetaminophen Tablets 
Tablet were prepared at two scales of manufacturing for this data set, including:  
A) Lab-scale tablets, to study the effect of moisture on Raman spectra. 




3.3.1 Lab Scale Tablets to Understand the Effect of Moisture on Raman Spectra 
This experiment investigated the deleterious effects of water quenching on Raman spectra. 
To demonstrate this, a formulation composed of acetaminophen, lactose, microcrystalline 
cellulose (MCC), hydroxypropyl methylcellulose  (HPMC) and magnesium stearate was used.   
Granules of acetaminophen (APAP; Mallinckrodt Inc., Raleigh, NC, USA), HPMC 
(Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) and lactose (modified spray-dried; 
Foremost Farms USA, Rothschild, WI, USA) were manufactured using a fluid bed granulator 
(model WSG 5, Glatt, Binzen, Germany). The active containing granules were mixed with extra-
granular MCC (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA), lactose and 
magnesium stearate (Fisher Scientific, Waltham, MA, USA) in a bin blender. The mixture 
comprised of the aforementioned components were blended in a 3.5-quart V-blender (total mass 
of 1 kg) for 45 min. NIRS was used to demonstrate homogeneity at the target blending time. 
The tablets were generated on a Carver automatic tablet press (Model 3887. 1SD0A00, 
Wabash, IN, USA) using a 13 mm die and flat-faced punches. Target tablet weight was 700 mg. 
A five by three level, two factors [active content (19.11%, 23.21%, 27.30%, 31.40% and 35.49% 
w/w; and excipient ratio levels 2, 1, 0. 5)] full factorial design was created.  The use of a full-
factorial experimental design provided orthogonality between the active ingredient and the 
excipient ratios. While it would have been possible to have all other components vary 
independently from the active ingredient, the use of excipient ratio helped to reduce the number of 
design points, as summarized in the design (Table 3-1). After allowing the tablets to undergo 
viscoelastic relaxation (two weeks), they were placed in environmental chambers at room 




lithium chloride), 32% (saturated magnesium chloride), 52% (saturated magnesium nitrate) and 
75% (saturated sodium chloride). Tablets were left to equilibrate in each chamber, beginning with 
the lowest moisture level. Once the mass of tablets had equilibrated in the 11% RH chamber, they 
were analyzed and moved to the 32% RH chamber. The equilibration and analysis were repeated 
for each chamber. Tablets were moved from low to high relative humidity to simplify the 
experimental design and reduce the experimental period.  




















1 19. 11 2. 73 5. 46 51. 77 20. 43 0. 50 2. 0 
2 23. 21 3. 32 6. 63 48. 65 17. 70 0. 50 2. 0 
3 27. 30 3. 90 7. 80 45. 53 14. 97 0. 50 2. 0 
4 31. 40 4. 49 8. 97 42. 41 12. 24 0. 50 2. 0 
5 35. 49 5. 07 10. 14 39. 29 9. 51 0. 50 2. 0 
6 19. 11 2. 73 5. 46 38. 83 33. 37 0. 50 1. 0 
7 23. 21 3. 32 6. 63 36. 49 29. 86 0. 50 1. 0 
8 27. 30 3. 90 7. 80 34. 15 26. 35 0. 50 1. 0 
9 31. 40 4. 49 8. 97 31. 81 22. 84 0. 50 1. 0 
10 35. 49 5. 07 10. 14 29. 47 19. 33 0. 50 1. 0 
11 19. 11 2. 73 5. 46 25. 89 46. 31 0. 50 0. 5 
12 23. 21 3. 32 6. 63 24. 33 42. 02 0. 50 0. 5 
13 27. 30 3. 90 7. 80 22. 77 37. 73 0. 50 0. 5 
14 31. 40 4. 49 8. 97 21. 21 33. 44 0. 50 0. 5 







Fluorescence quenching effect 
To understand the nature of spectral change due to fluorescence quenching, spectra of pure 
components were collected in the presence of water and molecular gases, oxygen (O2) and nitrogen 
(N2).  To investigate the impact of water, pure component compacts were created by compressing 
approximately 700 mg of each material in the Carver press. Then, these pure component compacts 
were stored in the four aforementioned humidity conditions to observe the effect of moisture on 
Raman spectra. In addition, spectra were collected in the presence of O2 and N2 using custom gas 
chambers.  
3.3.2 Pilot scale Tablets to Understand the Effect of Moisture on Raman Model 
Performance  
In this experiment, the blends were compacted on a 38-station rotary tablet press 
(Elizabeth-Hata International, Inc., North Huntingdon, PA, USA). The stations were tooled using 
3/8 in. (9.5 mm) diameter, round biconvex punches and the corresponding dies. Only two stations 
were tooled to facilitate the collection of the tablets post ejection. Three tablets were collected 
every minute for 20 min. The turret speed was left constant at 30 rpm, and the target compression 
force was 8000 kp. The target tablet weight was 350 mg.  HPLC was performed on the tablets to 
ensure uniformity of blend and tablets. 
During the course of the study (from June 2014 - March 2015), a total of six granulations 
and fourteen tablet batches were manufactured using the target formulation. A large variability 
existed in the in the moisture content of the excipients and granules. These variabilities were 




not controlled; during the winter the air was dry (20–30% relative humidity (RH)), but during the 
summer months it was typical to observe a RH between 60% and 70%. Based on the seasonal 
differences, samples are categorized as summer, spring and winter samples. Both calibration and 
test sets included all these three seasonal samples.  
3.3.3 Raman Data Collection 
Raman spectra were collected on a TRS 100 (Cobalt Light Systems Ltd., Abington, 
Oxfordshire, UK) for analysis of compacts. The transmission spectrometer is equipped with a 
diode laser operating at 830 nm as the radiation source, a long pass spectral filter and a 
thermoelectrically cooled CCD camera for the detector. All compacts were scanned over the 
wavenumber range of 38-2400 𝑐𝑚−1. The measurements were conducted at room temperature 
(approximately 24ºC). Parameters were tuned according to the tablet scale: exposure time for pilot 
and lab scale tablets were 0.5 seconds and 1.3 seconds, respectively. Five accumulations were 
collected per spectrum with a laser power of 0. 6W.     
The effect of O2 and N2 gasses on the spectra of powdered samples was evaluated with a 
RamanRxn2TM backscattering spectrometer (Kaiser Optical Systems, Inc, Ann Arbor, MI, USA) 
and iCRaman software (version 4. 1, Mettler Toledo, Columbus, OH, USA). A fiber-coupled 
PhAT probe (HoloGRAMS version 4. 0, Kaiser Optical Systems Inc., Ann Arbor, MI, USA) was 
equipped with a 400-mW laser at 785 nm. The diameter of laser spot size was 6 mm. Accumulation 




3.3.4 Model Evaluation 
In order to evaluate class-model for authentication purpose and to determine the potential 
impact of moisture variation, both SVDD (see Section 2.2.1.2) and SIMCA  (see Section 2.2.1.1.) 
was applied [109]. The capability of a model developed at one moisture level to predict the target 
class of compacts stored at other relative humidity levels was tested. The sensitivity (see Section 
2.2.2) was used to evaluate the effect of moisture variability on model performance. Various 
diagnostic plots were employed to understand the underlying causes of model performance.  
3.3.5 Results and Discussions 
3.3.5.1 Effect of Moisture Variability on Raman Spectra using Lab-based Acetaminophen 
Tablets 
Figure 3-1: Raw spectra of calibration tablets at different moisture conditions: 




Figure 3-1 shows spectral baseline changes when tablets were exposed to four different 
moisture levels (11% (red), 32% (blue), 52% (green) and 75% (magenta) RH). It can be observed 
that increasing the water content in the tablet leads to a decrease in the fluorescent background.   
Figure 3-2: Raw spectra of a tablet (target formulation) exposed to repeat scans 
over eight weeks to test the photobleaching effect. 
Mechanistically, the decrease in fluorescence intensity was caused by the deactivation of 
the excited-state fluorophores in contact with certain molecules (e.g., water in this study) in the 
sample. These molecules are referred to as quenchers [39]. This spectral change, due to the 
presence of water, was much more significant than the effect of photobleaching (due to successive 
exposure of the sample to the laser). The effect of photobleaching is illustrated in Figure 3-2, where 
a tablet was stored at a relative humidity 52% and scanned repeatedly over eight weeks. With an 





Figure 3-3: Pure component raw spectra of A) acetaminopen, B) hypromellose, C) lactose, D) magnesium stearate, and 
E) microcrystalline cellulose stored in four different humidity conditions (11% RH, 32% RH, 52% RH and 75% RH in 




. To understand the source of spectral variation in the presence of moisture, a variety of 
compacts were prepared using pure components; the compacts were then exposed to different 
moisture levels. Figure 3-3 reveals that MCC and HPMC compacts demonstrated a significant 
decrease in the baseline with increasing water adsorption, which may be due to fluorescence 
quenching.  However, APAP, lactose and magnesium stearate spectra demonstrated very small 
changes in the different conditions. This is likely due to the absence of fluorescence with these 
three pure components. The results indicate that the primary source of spectral variation in the 
prepared samples was from MCC and HPMC, with water acting as a quencher. In Figure 3-4, 
fluorescence quenching for MCC and HPMC was demonstrated in the presence of oxygen, a 
known quenching agent in cellulosic materials [42]. Previous studies demonstrated that, due to the 
presence of lignin in the fiber component, a large number of pulp and paper samples exhibit laser 
induced fluorescence (LIF). However, in the presence of molecular oxygen, lignin caused LIF 
contributions to Raman spectra were significantly decreased [182]. Figure 3-4 shows that due to 
the presence of O2, the spectral baseline of MCC changed over time. But, when spectra were 
collected in the presence of N2 or air, quenching was reduced. This result suggests that 
fluorescence decreases dramatically in the presence of the quenching agent O2. A small spectral 
change was observed with MCC in the presence of air due to the continuous laser exposure. This 
provides another demonstration that the effect of photobleaching was less than that of quenching 
associated with moisture. Acetaminophen and lactose spectra demonstrated limited spectral 





Figure 3-4: Raman spectra collected in the presence of molecular gas A) 
MCC in presence of O2, B) MCC in presence of N2, C) MCC in presence 
of air, D) Acetaminophen in presence of O2. 
The effect of fluorescence quenching on spectral baseline has been shown to vary with the 
content of both fluorophores and moisture. To characterize the impact of these two factors, spectral 
slope and intensity was observed for raw spectra. The slope of the spectra was calculated from a 
simple least-squares regression between Raman shift and Raman intensity. Three Raman shifts 
(276, 750, 1404  cm−1) were chosen from the spectra to calculate this slope. The slope values are 
displayed in Table 3-2, where results from four moisture levels and three excipient ratios (2:1, 1:1 




First, the amount of fluorescent components affected the baseline intensity, as anticipated.  
Fluorescence intensity decreased with a decreasing amount of MCC (for a given moisture level).  
This change was reflected in the slope. Second, the moisture content had a significant impact on 
the baseline:  the Raman intensity decreased with increasing water content (for a given compact 
composition), causing a dramatically reduced slope with increasing moisture content (Table 3-2).  
These results emphasize the quenching effect of water on Raman spectra. 




%RH RS=276 cm-1 RS=750 cm-1 RS= 1404 cm-1 Slope (Calculated from least square) 
  Intensity count Intensity count Intensity count A. U. 
2 
11 85896 47659 14711 35593 
32 59688 33290 10039 24824 
52 34189 19205 5590 14300 
75 22719 12889 3585 9567 
1 
11 81946 45242 13930 34008 
32 56868 31702 9737 23565 
52 33534 18615 5531 14001 
75 24557 13951 3982 10287 
0. 5 
11 61985 34349 11061 25462 
32 42609 23625 7491 17559 
52 27139 15339 4803 11168 
75 22087 12424 3659 9214 





3.3.5.2 Effect of Sample Moisture Variability on Qualitative Model Performance using Pilot 
Scale Acetaminophen Tablets 
The observed spectral variations due to the presence of water had a significant impact on 
qualitative model performance using SIMCA and SVDD model. Performance was evaluated by 
developing three models, prepared in winter, summer and spring, where relative humidity was 
varied from 15%-75% RH. These models were then used to predict sensitivity of three test sets 
corresponding to the three seasons. 
A number of preprocessing methods such as baseline weighted least squares, 
normalization, mean centering, derivative, and detrending were evaluated to eliminate the baseline 
changes of the full spectral range described before. Random block cross-validation (five blocks) 
was used to determine the most suitable spectral pre-treatments and model complexity (number of 
principal components for SIMCA and C and σ for SVDD). An optimization was independently 
conducted based on the minimization of cross-validation error.  Savitzky-Golay first derivative 
(window size-31, polynomial order-2) followed by normalization to unit area and mean-centering 
was chosen for all models. Derivative methods were helpful to remove baseline variations and 
normalization decreased the intensity of variations introduced due to the fluorescence quenching 
or any physical differences between calibration and test sets.   
As shown in Table 3-3, both SIMCA and SVDD models offered good sensitivity for 
samples from the same moisture levels, where the preprocessing method was successful at 
removing fluorescent baseline variability. However, poor results were achieved for prediction of 




moisture levels of calibration and test sets. Figure 3-5 presents Hotelling’s 𝑇2 and 𝑄 residual plots 
for spring calibration model. The reconstruction error for summer and winter test sets was higher, 
indicating that the lack of robustness of the calibration model to moisture variability.   
Table 3-3: Effect of sample moisture variability on test set predictions: Lab Scale Tablet 
 
 
Global models include all of the expected variability in the calibration set. In this case, 
calibration sets from three seasons were combined to facilitate the creation of robust model:  
sensitivity for the test set at the different humidity levels are provided in Table 3-3. The global 
model demonstrated a lower prediction error compared to models created at unique humidity 
conditions  
3.4 Dataset 2: Artemether- Lumefantrine Combinations Tablets 
The World Health Organization (WHO) introduced artemisinin-based combination therapy 
(ACT) as first-line therapy to decrease the falciparum malaria, which was adapted by most 
countries [183]. Successful prevention and control of malaria can be achieved by ensuring the 
SIMCA 
  Summer Spring Winter Global 
Test Set Sensitivity  
Summer 0.95 0.75 0 1 
Spring 0 0.84 0.75 1 
Winter 0 0 1 1 
SVDD 
  Summer Spring Winter Global 
Test Set Sensitivity 
 
Summer 0.95 0.7 0 1 
Spring 0 0.93 0.8 1 




quality of ACTs and other antimalarials. However, one-third of anti-malaria medicines from 
malaria-endemic countries failed the quality test, which is alarming for the prevention of malaria 
[184]. Different fast screening processes have been proposed to test pharmaceutical tablets at 
different stages of the supply chain. Raman spectroscopy has been used to test the quality of 
artemether-lumefantrine fixed-dose combination products [146].  
Figure 3-5: Hotelling’s 𝑇2 vs. 𝑄 residual plot was generated from different 
seasonal conditions of test tablets (summer (red), spring (green), winter (blue)) , 
which were projected on the calibration set (spring (black)). 
However, as artemether has a high fluorescent background while using Raman 
spectroscopy, model performance may deteriorate due to the fluorescent quenching in the presence 
of moisture [146]. Therefore, it is hypothesized that, for artemether-lumefantrine samples, it is 
essential to consider moisture throughout the method development process. Artemether-
lumefantrine tablets produced by generic manufacturers were used as a model drug to evaluate the 




3.4.1 Sample Collection 
Anti-malarial drugs were obtained from a government registered pharmacy in Dhaka, 
Bangladesh. A total of 56 artemether-lumefantrine tablets, manufactured by Square 
pharmaceutical Ltd. (Lumetram®) were collected. Packaging was visually inspected to avoid any 
fraudulent activities, and the batch numbers were confirmed with the manufacturer for 
authenticity. Further, to independently verify the active ingredient in the manufacturers' standards, 
pure components of artemether (J&K Scientific San Jose, CA), and lumefantrine (Combi-block, 
San Diego, USA) were used. 
3.4.2 Samples Scan  
Raman data were collected using a RamanRXN2 spectrometer (Kaiser Optical Systems, 
Inc, Ann Arbor, MI, USA) and iC Raman software (version 4.1, Mettler Toledo, Columbus, OH, 
USA). The spectrometer was equipped with a 785 nm laser excitation and a fiber-coupled PhAT 
probe (HoloGRAMS version 4.0, Kaiser Optical Systems, Inc, Ann Arbor, MI, USA) with a 6 mm 
spot size. One accumulation with 5 s integration times were acquired over the range of 150–1,890 
cm−1 at 1 cm−1 increments. A dark scan was subtracted, and the cosmic ray filter and intensity 
calibration options were selected. Tablets were positioned at the end of the probe unit using an in-
house machined copper sample holder with a 10 mm diameter. The sample holder was threaded 
into the end of the PhAT probe tube so as to provide a fixed distance from the laser source to each 
sample. This reduces error related with repositioning and re-focusing. To decrease stray light 
effects while collecting samples spectra, a black cap was kept over the top of the sampling 
interface. The average of spectra from both sides of each tablet was used for calibration 




3.4.3 Samples Preparation to Investigate the Effect of Moisture 
Three chambers were used with target relative humidity (RH) of 15% (saturated solution 
of lithium chloride), 50% (magnesium nitrate) and 70% (sodium chloride). A total of 15 Tablets 
were left to equilibrate in each chamber. The equilibration of the mass over storage time at each 
RH condition was used as an indicator of stability. Tablets were moved from low to high relative 
humidity to simplify the experimental design and reduce the experimental period. Both sides of 
the tablets were scanned 5 times using the same parameters described above.  
3.4.4 Testing the Effect of Moisture on Model Performance  
Individual classification models were constructed from each sample set equilibrated at a 
single relative humidity. Test samples stored at the alternate relative humidity conditions were 
predicted. When the moisture level is different between calibration and test sets, method sensitivity 
should be challenged. Moreover, depending on the performance of sensitivity, the effect of 
moisture variance should be accounted for during method development.   
3.4.5 Results and Discussions 
3.4.5.1 Moisture Effect on Artemether-Lumefantrine Tablets  
Sample spectra of artemether-lumefantrine collected using Raman spectroscopy showed 
high fluorescence background (Figure 3-6). These spectral features were similar to the 
acetaminophen tablet dataset. Raw spectra of two pure components were collected. Here, 
artemether showed strong fluorescent background and peak features were suppressed. However, 






Figure 3-6: Raman spectra of artemther-lumefantrine combination. 
 
Figure 3-7: Pure component spectra of A) artemether and B) lumefantrine. 
Spectral variations were observed due to the presence of water in the tablet. As both 




quenching was observed due to the presence of water in the samples (Figure 3-8). It was also 
revealed that this quenching effect was prominent in the artemether (Figure 3-9). 
 
 
Figure 3-8: Spectra of tablets collected from three humidity conditions 
 





3.4.5.2 Model Performance in Presence of Moisture Variations 
Models developed at individual moisture levels accepted target class samples stored at 
similar moisture levels. However, the models failed to predict test sets collected at other moisture 
levels. This study resembled the previous acetaminophen studies described in this Chapter (using 
Raman) and Chapter 2 (using NIRS). The error statistics became higher in different humidity 
conditions, due to the increment of the difference of moisture level between calibration and test 
sets (Table 3-4). This was largely because of fluorescence quenching and resulted increase of 
baseline change. Therefore, Raman qualitative model performance decreased due to the lack of 
robustness. 






  11% 52% 70% Global 
Test Set Sensitivity  
11% 1 0.3 0 0.9 
52% 0 0.95 0.4 1 
75% 0 0 1 1 
SVDD 
  11% 52% 70% Global 
Test Set Sensitivity 
 
11% 1 0.4 0 1 
52% 0 0.925 0.2 1 




The effect of these spectral variabilities was observed in multivariate space described by 𝑄 
residual and Hotelling’s 𝑇2 (Figure 3-10). The 𝑄 residual values for the low moisture level of 
calibration set and high moisture level for the test set indicated that this test set has different 
spectral shape compared to the calibration set (Figure 3-10A). Global models including moisture 
variability showed improved performance by reducing 𝑄 residual (Figure 3-10B). This global 
model is often considered as a risk-based model. In this case, calibration sets from three relative 
humidity levels were combined to facilitate the creation of a global model. This global model 
demonstrated a lower prediction error compared to the models created at unique humidity 
conditions. Moisture variabilities can cause density changes of tablets which may also have effect 
on the spectra. Baseline correction and derivative methods were conducted to remove this 
interference.   
 
Figure 3-10: Hotelling’s 𝑇2 vs. 𝑄 residuals plots were generated from calibration 
plot (A) 11% RH samples (black), 52% RH samples (red) (B) global RH samples 




Changes of relative humidity often cause polymorphic changes in API or excipients.  
However, this formulation did not demonstrate such a risk.  Also, as the drug is stable over the 
proposed humidity range, stability was not an issue for the considered formulation. 
3.5 Summary and Conclusion 
It is difficult to preemptively identify all sources of variation that will be encountered 
during the pharmaceutical life-cycle. The experimental approach in this study provides an example 
of how a simple phenomenon like  moisture variability, arising from such phenomena as 
inconsistent environmental conditions, can, through fluorescence, significantly affect spectral 
baseline and model performance. Both SVDD and SIMCA methods were tested in this work using 
a global modeling approach to demonstrate opportunities for the creation of robust models for 
laboratory and production scale tablets.    
In this study, the presence of components containing 1) fluorophores and 2) moisture, 
negatively affected model performance.  Pharmaceutical raw materials, including excipients and 
APIs, often contain fluorescent components. In Dataset-1, lignin in the microcrystalline cellulose 
caused  laser induced fluorescence [182, 185]. In Dataset-2, artemether showed a strong 
fluorescence background. Moreover, variable moisture content also introduced spectral variance 
for these two datasets.  The water content of tablets will often vary between and within different 
tablet batches, depending on the relative humidity conditions during production, packaging, 
storage and analysis.  Water may be sorbed by samples very quickly depending on the relative 
humidity of the environment and material attributes [34]. While it is likely that the relative 
humidity of the laboratory may be controlled, it is very unlikely that the same environmental 




which have been exposed to a different humidity condition. This is particularly true in situations 
where spectroscopic method development takes place at one geographic and climatic location and 
routine use of the method occurs elsewhere [177].   
It is typically beyond the capacity of an analyst to eliminate sample components or strictly 
control the sources of variability. Understanding the effect of variabilities such as moisture and 
fluorescence during multivariate calibration model development will facilitate the generation of 
models which are robust against these variations. In the present study, the effect of fluorescence 
background was reduced by preprocessing the spectra. However, when calibration and test sets 
contained different moisture content, prediction performance was degraded. These findings 
regarding the effect of moisture on the Raman spectra should be useful information for method 
development. This is true for both SVDD and SIMCA algorithms.  
Though both SVDD and SIMCA algorithms performed satisfactorily after adding moisture 
variations in the calibration model, SVDD showed promising results. This study highlighted the 
usefulness of the SVDD algorithm for Raman spectroscopic techniques as a class model for 
pharmaceutical tablet authentication system. This was the first use of SVDD and Raman 





4 Chapter 4: Developing a SVDD Method with Non-Target 
Class Samples to Detect ‘Highly Similar’ Acetaminophen 
Tablets Collected from Global Sources  
4.1 Introduction 
The development and implementation of class modeling typically occurs in two stages, 
including 1) building a target class by generating a decision boundary around the target class 
samples, and 2) evaluating a test samples to determine method sensitivity and specificity, based 
on whether the sample resides inside or outside of the established multivariate decision boundary.  
Typically, development of a decision boundary for a SVDD model does not rely on samples 
from the non-target class. Method development using only target class samples is known as a ‘one-
class SVDD’ approach. In such a case, the model reaches an optimal condition by achieving the 
best sensitivity (ability to accept target class samples). 
However, samples from the non-target class can be used to optimize the model [21]. 
Including non-target class samples during modeling improves the description of the target class by 
defining a tighter boundary around the target class data in the areas where non-target objects are 
present. In contrast with the target class samples residing within the boundary, the non-target class 
samples should be outside of the multivariate boundary. This type of method development is 
feasible when several datasets from extraneous classes are available. These new non-target class 




objects from the non-target class). Understanding model specificity reduces the risk of accepting 
false samples. 
While developing a spectroscopic authentication method using a SVDD algorithm, the 
non-target class samples should be a true representation of falsified drugs. 
The pharmaceutical literature reports pharmaceutical products, including pure components 
and finished dosage forms, could be falsified in various ways. Primary methods of falsification 
involve altered composition of final dosage forms. This includes, but is not limited to, intentional 
adulteration of pharmaceutical ingredients, tablets prepared without active pharmaceutical 
ingredient (e.g., using only excipients), tablets manufactured using the wrong API, and tablets 
generated with the correct API, but unusual compositions of excipients. In practice, the most 
difficult samples to detect using spectroscopic methods could be the last category, which are often 
generated using similar manufacturing techniques. Therefore, during authentication model 
development, analysts should select non-target class samples which have similar compositions and 
have similar spectral features to the target class. Spectral matching algorithms would be one 
appropriate method to evaluate the spectral similarity between target and non-target class samples 
during development of a SVDD method. 
In this chapter, it is proposed that an appropriate non-target class of samples is essential for 
optimizing a SVDD method. To prove this, challenging samples (which are difficult to distinguish 
between non-target class and target class) from various producers containing identical API and 
similar excipient compositions were considered. Highly similar acetaminophen tablets collected 




4.2 Materials and methods 
4.2.1 Sample collection 
Tablet formulations containing acetaminophen were obtained from outlets readily 
available to tourists or visitors in Bangladesh, India, and China (Figure 4-1). The tablets were 
uncoated, intact and blister-packed. All tablets contained 500 mg of APAP according to the label. 
Samples which had similar size and shape were only considered in this study (Figure 4-2). Nine 
different manufacturers’ samples were collected from these three countries. The tablets were 
collected from different batches, 10 tablets per batch. Details are presented in Table 4-1.  
 







Figure 4-2: Image of the tablets from different manufacturers (M1-M9). 
 
















APAP Percentage in the 
tablet 
M1 558.3 500 89.55 
M2 599.7 500 83.37 
M3 582.7 500 85.81 
M4 577.7 500 86.55 
M5 557.3 500 89.71 
M6 582.3 500 85.86 
M7 554.0 500 90.25 
M8 590.7 500 84.65 




4.2.2 Confirming the Chemical Similarity of Samples using Raman Spectroscopy: 
Raman spectra were collected by following the protocol mentioned in section 3.3.3 . 
Figure 4-3: Raman spectra of different manufacturers’ samples and APAP. 
 
The presence of acetaminophen in each product was confirmed using Raman spectroscopy. 
The spectra are observed in Figure 4-3.  Here, the spectra were stacked to demonstrate the presence 
of API. Tablet spectra were compared in the fingerprint region (1850–400  cm−1), to verify the 
presence of API. The spectral correlation was calculated by comparing each of the sample spectra, 
with the acetaminophen spectrum. All products showed correlation coefficient values greater than 




4.2.3 NIR Measurement 
NIR spectra were acquired in the range of 1550–1950 nm with a 10 nm wavelength 
increment using a portable NIR ONE Sensor (Spectral Engine, VTT, Finland). Measurements were 
carried out in diffuse reflectance mode. For analysis, the entire spectral region (1550-1950 nm) is 
utilized because it is difficult to foresee at which wavelength alien objects will manifest deviations 
from the genuine sample. Each time, both sides of the tablets were scanned to increase the sample 
representation. Replicas were averaged before the analysis. 
4.3 Figures of Merit 
The following formula (Equation 1)  calculate sensitivity of the method (accepting genuine 
samples): 
Sensitivity=TP/(TP+FN)                                                                                    1                                  
where TP and FN are true positive and false negative, respectively.  If the model accepts 
falsified samples, the model needs further optimizations.   
The Specificity of the method (rejecting falsified samples) is used as validation parameter. 
The following formula (Equation 2) calculates this parameter: 
Specificity=TN/(TN+FP)                                                                                 2                       




4.4 Theory  
4.4.1 Unsupervised analysis (PCA) 
The Principal Component Analysis (PCA) method projects multivariate spectra into low-
dimensional space, which emphasizes the variabilities present in the collected spectral data 
although they do not precisely aim to identify them [81, 82]. PCA decomposes the multivariate 
response arranged in an 𝑋 matrix into a product of two new matrices as indicated in the following 
equation 3: 
𝑋 = 𝑇𝑘𝑃𝑘
𝑇 + 𝐸 3 
  
 
Where 𝑇𝑘 is the matrix of scores which represent how samples relate to each other, 𝑃𝑘  is 
the matrix of loadings which contain information about how variables relate to each other, k is the 
number of factors included in the model and E is the matrix of residuals, which contains the 
information not retained by the model. The reader is referred to the works of Wold et al. [81] and 
Martens & Naes [82] for a more detailed discussion of PCA. 
4.4.2 SVDD 
See Section 2.2.1.2. 
4.4.3 Spectral correlation method 
The spectral correlation method compares two spectra under study. This algorithm 




(Equation 4) [67]. This spectral correlation (𝑆𝐶) method is often mentioned as a similarity and is 
the equivalent of measuring the cosine of the angle between two spectra.   
𝑆𝐶 = 100 ∗ √[(𝑆𝑎𝑚𝑙𝑒1𝑚 ∙ 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚)2]/[(𝑆𝑎𝑚𝑝𝑙𝑒1𝑚 ∙ 1)(𝑆𝑎𝑚𝑝𝑙𝑒2𝑚 ∙ 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚)]  4 
Here 𝑆𝑎𝑚𝑝𝑙𝑒1𝑚 and 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚  is the 𝑚
𝑡ℎ absorption value in the spectra.  𝑆𝐶 measures the 





4.5 Experimental Strategy 
Acetaminophen tablets manufactured by nine generic manufacturers produced in three 
countries were used to demonstrate the proposed model development approach. In this study, the 
calibration model was first developed using M1. After that, the model was optimized and validated 
with both target and non-target classes (using M2-M9). Figure 4-4 displays a flow diagram of the 
protocol. 
Figure 4-4: Method development flow path. Relative to the contemporary process 
analytical method development cycle which typically includes target class samples, 






4.6.1 Spectral Investigations and PCA Analysis 
Raw spectra failed to reveal significantly unique features of different sample sets. Baseline 
shifting in the raw spectra was caused due to sample positioning variability. A standard normal 
variate (SNV) method removed the baseline shifting associated with sample positioning 
variability. Figure 4-5 shows the preliminary differences where primary variations were observed 
in 1650-1850 nm and 1900-1950 nm.   
Figure 4-5: SNV treated spectra from nine different manufacturers. 
While using the PCA algorithm, different preprocessing methods and their combinations 
were tested. To distinguish product from different manufacturers, the most efficient preprocessing 
methods were SNV following the second order Savitzky Golay derivative, using a second-order 




preprocessing methods further removed baseline shifts and sharpened the spectral peaks. Principal 
component analysis (PCA) was applied to different manufacturers’ samples (M1-M9). The results 
show that 4 PCs describe 97.46% of data variation. The score plots presented in Figure 4-6 
demonstrated that M9, M2, M4, and M5 were well separated from M1 (target class). However, 
other groups showed substantial overlapping, in the plot of PC1 vs. PC2 scores. When considering 
the plots generated using subsequent PCs, it is possible to separate other classes from the target 
class. However, the close location of different groups indicated the high similarity of samples from 
different manufacturers. In this case, PCA alone would not be adequate to consistently discriminate 
all tablets from the target class.
Figure 4-6: A combined PCA model including all the calibration 




4.6.2 SVDD Model Performance: 
The spectra of 30 samples from M1 manufacturer were used for the calibration model 
development.  Then, 20 more samples from M1 were used for sensitivity calculation. Additionally, 
20 samples from each of the other eight manufacturers (M2-M9) were considered as non-target 
class samples for optimization and for use as the validation sets. These non-target class samples 
were used for the assessment of specificity. Among these eight manufacturers (M2-M9), one was 
used to optimize the model and the other seven  were used for validation purposes. Therefore, a 
total of eight models were developed using optimization sets to calculate specificity. For each non-
target class, a total specificity is computed along with seven partial specificities, one for each non-
target class. The total specificity is the average of the seven partial specificities (Table 4-2). 
Column one contains the non-target class names used for optimization. The second and third 
columns show the number of support vectors and selected σ, respectively. The other eight columns 
present the partial specificities, calculated separately for each non-target class. Mismatches (total 
specificity less than 90%) are bold marked in column 9.  
Table 4-2: Performance of SVDD using NIR spectroscopy 
  
 Validation specificity  






σ  M2 M3 M4 M5 M6 M7 M8 M9 
Total  
specificity 
M2 2 0.3  0.65 0.15 0.45 0.91 0 1 1 0.59 
M3 2 0.23 1  1 1 1 0.63 1 1 0.95 
M4 2 0.23 1 1  1 1 0.63 1 1 0.95 
M5 2 0.245 1 0.9 0.55  1 0.54 1 1 0.86 
M6 2 0.27 1 0.7 0.25 0.8  0.5 1 1 0.75 
M7 3 0.21 1 1 1 1 1  1 1 1.00 
M8 2 0.3 1 0.65 0.15 0.45 0.91 0 1 1 0.74 




It can be seen that values of total specificity obtained for the models which used M2, M5, 
M6, M8 and M9 as optimization sets are unsatisfactory. This result means that if these samples are 
used as the non-target class to optimize the SVDD, the model could run the risk of having higher 
false positives. This was observed in the Table 4-2. Such models failed to reject the rest of the 
classes (M3, M4, M7). However, three models which used  M3, M4 and M7 to optimize the model 
reliably distinguished between target and the non-target class samples. Among these, M7 worked 
best as that model rejected all non-target class samples. Figure 4-7 shows that M2 is spectrally 
different than the calibration spectra, whereas M7 is highly similar. 
 
Figure 4-7: Spectral comparison of calibration set (M1), and non-target classes 
(M2 and M7) 
Therefore, it can be concluded that the selection of a pertinent non-target class set for the 




reject “highly similar” samples using the SVDD method, it is essential to use highly similar non-
target class samples for model optimization. This creates a model that is sensitive to non-target 
class test samples that are “highly similar” to target class samples. 
4.7 Non-Target Class Sample Selection: 
A correlation coefficient was calculated to automatically select a suitable non-target class 
set for model optimization of falsified drug detection. This effort defined a method for setting 
quantitative criteria for selection of ideal non-target class samples which would help to optimize 
the model. Figure 4-8 showed the correlation coefficient values between the calibration set and 
different non-target class sets. All of the samples exhibited a correlation of more than 0.95. 
However, among these, non-target class, M7, showed the highest correlation with the target class, 
M1. This correlation value between M1 and M7 was similar to the correlation values of different 
batches of  M1 (as different batches of M1 were used as calibration  and test sets). Because of this, 
it was difficult to separate M7 from M1, when other sample sets (M2-M6, M8 and M9) were used 
to optimize the model. Therefore, M7 was the ideal non-target class candidate to be used for 





Figure 4-8: Spectral correlation coefficient values between the calibration set 
and different manufacturers’ samples sets (M2-M9) including a unique batch of 
a calibration set (M1). 
 






The final workflow for falsified detection is proposed in Figure 4-9. To obtain better 
performance, a SVDD model will be optimized using a non-target class sample. Before applying 
the SVDD algorithm, these non-target class samples can be selected using a simple mathematical 
treatment, such as correlation coefficient, for testing similarity between the target class and non-
target class. 
4.8 Discussion and Conclusion: 
It is understood that a spectroscopic system for authentication of pharmaceutical products 
will require modern chemometric tools. The SVDD method was used with both target and non-
target class samples to demonstrate an approach for development of an authentication method. The 
proposed SVDD method differs from a conventional two-class classification method because the 
SVDD defines a closed boundary around target-class samples, whereas traditional two-class 
support vector machine methods develop a boundary between these two classes. Furthermore, the 
method does not require a strict representative sample of the target distribution; a calibration set 
with extreme objects is acceptable, even desirable. However, it is also important to understand that 
an effort to reduce false positives (accepting falsified samples) can result in an increase in false 
negatives (rejecting authentic samples). With the presence of non-target class samples used for 
model optimization, the boundary is developed rationally.  
In this chapter, it was observed that exploiting non-target class samples during model 
development is useful for optimization of SVDD models. Adding non-target class samples in the 




model based on both sensitivity and specificity parameters. Selecting appropriate non-target class 
samples to optimize the model requires a quantitative approach such as spectral correlation 
calculation.   
 Figure 4-10 demonstrates the importance of careful non-target class sample selection. In 
Figure 4-10A, when green samples are used as the non-target class, the spherical boundary around 
the banana shaped target class data (blue) is appropriate to reject these green samples. However, 
if yellow samples (which are closer to the target class blue samples than the non-target class green 
samples) are used as non-target class samples, the spherical boundary is inadequate to reject these 
non-target class yellow samples (Figure 4-10B). Therefore, model optimization using ideal non-
target class samples is required. After model optimization, an appropriate non-linear boundary 
could be developed.  This tighter boundary is seen in Fig 4-10C, around the target-class data, which 
allows the model to distinguish non-target class (yellow objects), seen outside the boundary.  
The finding from this study emphasized that to develop a spectroscopic method with the 
help of chemometric methods, analysts should consider a pertinent test set and validation. Without 
utilization of appropriate samples to optimize the model, the method will not perform adequately. 
This proved the hypothesis mentioned in section 1.2.  
Figure 4-10: Modeling of a banana-shaped data set (blue) using non-target 




5 Chapter 5: Application of Experimental Design to 
Generate Synthetic Non-Target Class Samples and the 
Effect of Raw Material Variability of the Target Class on 
the Class- Model Performance 
5.1 Introduction 
Development of class-modeling methods typically involves two stages. Initially, the model 
should be developed using a calibration data set containing representative variations of target-class 
samples; ideally, these samples should contain all possible sources of product variation. In 
Chapters 2 and 3, the effect of moisture variation on NIR and Raman spectroscopy was discussed. 
After an initial calibration model development, the model is then optimized using various complex 
test sets, an approach that is highlighted in Chapter 4. Therefore, for proper model performance, 
the optimization set (or test set) should include both authentic target class and non-target class 
samples originating from alternative classes (see Figure 4-4).  
One of the challenges of model development that has not been adequately addressed in the 
literature is to find appropriate falsified samples to consider as an alternate class. Notably, it is 
crucial to test the ability of the model to recognize samples which have a highly similar 
composition to the target class. These falsified samples are often referred to as “high quality” 
falsified products [15]. It is often difficult to find these alternate classes to be used in model 




Researchers have proposed several strategies to collect alternate classes of samples. 
Products manufactured by competitors can be a potential source of the non-target class sample. 
Rodionova et al. used competitors’ products as a non-target class to optimize the decision boundary 
for the SIMCA-DD method and successfully improved model performance by adjusting the 
boundary area [186]. In the previous chapter of this dissertation, the SVDD method was optimized 
using legitimate analogs of the target class; this approach demonstrated good performance. 
However, samples from different manufacturers may not always be available, especially for brand 
products (which have a high risk of falsification). Another group of researchers proposed the use 
of samples stored in higher humidity conditions [13]. However, a high-water content may change 
physico-chemical structures of the samples significantly, which may not be appropriate to be 
considered as “high quality” falsified products. 
One potential strategy to overcome this challenge is to generate synthetic samples in the 
lab using statistical experimental design, or design of experiments (DOE), which can be a useful 
statistical tool to explore the capability of spectroscopic identification of falsified products 
containing unique chemical compositions. DOE is useful to gain understanding about which non-
target class samples are spectrally similar to the target class samples. 
Synthetic samples, generated in the lab, can provide progress in resolving another 
challenge of method development; namely to collect a fully representative calibration set 
accounting for possible future variations in the target class. Using a material sparing approach, 
potential sources of product variation such as moisture deviations, variabilities from raw material 




samples with significant moisture variation were used to improve model performance. Likewise, 
the effect of raw material variabilities can be addressed. 
It is understood that the change in chemical composition or physical variations due to raw 
material variability may exhibit a unique inherent response with different analytical techniques. 
For example, NIR spectra involve a combination of absorbance and scattering properties of light 
and exhibit response to both chemical and physical changes in pharmaceutical products. Raman 
spectroscopy, on the other hand, is very sensitive to fluorescence; this is a major source of spectral 
variability causing interference with the Raman spectra. Fluorescence is produced by the emission 
of photons from low-lying excited electronic states, and often masks the vibrational shift of Raman 
spectra [59]. Different pharmaceutical samples exhibit fluorescence arising from various active 
pharmaceutical ingredients [146] , excipients [173, 174], dyes [175], capsule shells [180], etc. As 
anticipated, samples generated using different excipient compositions should have a different 
response for Raman and NIR spectroscopy. Therefore, non-target class samples will be different 
based on the anticipated chemical response of the analytical method used to detect falsified 
samples. Likewise, the impact of physical variability will also typically be different for NIR and 
Raman spectroscopy. This chapter will evaluate such phenomena. 
The objectives of this chapter include: 
1. To demonstrate the usefulness of DOE during spectroscopic model development with 
class-modeling techniques such as SIMCA and SVDD.  
2. To use raw material variability to demonstrate the importance of creating representative 




3. To explore the effect of DOE and raw material variability on NIR and Raman models 
for false-sample identification. 
5.2 Materials and Methods 
5.2.1 Target Class Samples 
The model drug product is a 350 mg tablet containing Acetaminophen (APAP; 
Mallinckrodt Inc.,Raleigh, NC, USA) at 50% w/w active pharmaceutical ingredient (API), 
microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA) 
at 15% w/w lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA),  Starch 
at 15% w/w (Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan), cross carmellose 
sodium (Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) at 4% w/w and magnesium 
stearate (Fisher Scientific, Waltham, MA, USA) at 0.50% w/w as excipients. Colloidal silicon 
dioxide, at 0.50% w/w, is used to improve APAP flow before combining with the excipients.  
Materials were dispensed by weight (Data Range, model no AX504DR, Mettler Toledo, 
Columbus, OH) and were transferred to a bin blender. In total, 1kg of material was weighed and 
the nominal weights for all constituents were adjusted to the observed mass data to calculate actual 
concentration. Blending was performed at the Duquesne University Center for Pharmaceutical 
Technology with a 5.5-L bin blender (L.B. Bohle LLC, Warminster, PA, USA) with DeltaV 
(Emerson Process Management, Equipment & Controls, Inc., Lawrence, PA, USA) controls.  
Blend Monitoring: Lab scale blends with a total mass of approximately 1 kg were created 




The top sensor was set to collect spectra when inverted to assure that each scan had powder directly 
in front of the sensor. At 15 rpm, the scans were collected at 4 s intervals. Pure component and 
granule scans were collected by filling the blender for 45 mins.  Diffuse reflectance NIR spectral 
data was collected using the MicroNIR-W spectrometer (Viavi Inc., USA). It uses a linear variable 
filter (LVF) technology, with an InGaAs detector (900–1,700 nm), a pair of integrated vacuum 
tungsten lamps, and provides wireless capability. This spectrometer was attached to the lid of the 
blender and rotated with the blender while running the process. Spectra were collected with 16 co-
additions averaged for a single scan with an integration time of 0.033 s. The dark and light 
reference scans are internal for the top sensor and were collected once daily. Different blend end 
point criteria were tested using moving block standard deviations. Mixtures were assumed to be 
homogeneous when standard deviation reached a minimum value.  
5.2.2 Sample Considerations for Non-Target Class using Design of Experiment (DOE): 
The goal of this effort was to create non-target class products containing identical API 
concentration but different excipient composition to the target class. As three diluents (lactose, 
starch and MCC) are the primary excipient compositions, the ratio of these three components was 
varied. A fully balanced, three-constituent mixture design composed of MCC, lactose and starch 
were used to generate the appropriate formulation (excipient ratio) for tablets (Figure 5-1). Total 
composition of these three excipients were kept at 45% w/w of the target formulation because the 
target tablet contains 45% w/w diluent. Simplex centroid design was used to change the 
composition of these three excipients in the formulation. Table 5-1 summarizes the design. Figure 




Presster (Model 5869, Norwood, MA) by a 10 mm die and flat-faced punches. The target tablet 
weight was 350 mg. Thirty replicate tablets per level were created to test the performance. 
 
Figure 5-1: Samples generated using different excipients compositions. 
 
Table 5-1: Seven different formulations were generated using a mixture experimental 
design  










 Formulation 1 50 0 0 45 4 0.5 0.5 
Formulation 2 50 0 22.5 22.5 4 0.5 0.5 
Formulation 3 50 22.5 0 22.5 4 0.5 0.5 
Formulation 4 50 0 45 0 4 0.5 0.5 
Formulation 5 50 15 15 15 4 0.5 0.5 
Formulation 6 50 22.5 22.5 0 4 0.5 0.5 
Formulation 7 50 45 0 0 4 0.5 0.5 
Grey color row: Target class formulation which was used for calibration model development and 
unique batches of Formulation 5 was used as test set. 
5.2.3 Target Class Samples Containing Raw Material Variabilities  
Raw material variations were simulated by changing the vendors of starch (Table 5-2).  The 










components of the target formulation remained unchanged.  In total, two batches were prepared.  
These batches will be further referred as R1 and R2.   





5.2.4 NIR Spectral Collections 
NIR reflectance measurements for both sides of each tablet were acquired over the 
wavelength range of 925 to 1700 nm at a 6.38 nm increment averaging 5000 scans (JDSU 
MicroNIR). Prior to scanning, the tablets were precisely centered using the positioning iris 
standard on this instrument.  
All spectral data were analyzed in the Matlab environment (version 8.6, MathWorks, 
Natick, MA) using the PLS_Toolbox (version 8.8, Eigenvector Research, Inc, Manson, WA) and 
software developed by the Duquesne University Center for Pharmaceutical Technology. 
5.2.5 Raman Spectral Collection  
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5.2.7 Spectral Investigations 
Spectral investigations were conducted using below mentioned methods: 
1. Spectral matching: See Section 4.4.3 
2. Principal component analysis: See Section 4.4.1 
5.2.8 Class-Model 
The chemometric model for this study was developed using SIMCA and SVDD. Details  
of the methods are reported in earlier section of this document. 
1. SIMCA: See section 2.2.1.1 




5.2.9 Experimental Strategy 
 
Figure 5-2: Flow chart of experimental plan. 
The goal of authentication is to reject non-target class samples and accept target class 
samples. This study generated sample formulations using DOE to identify suitable compositions 
for meeting the goals of the experiment. Raw materials from two different vendors were used to 
generate variations in the target class samples. Both NIR and Raman spectroscopy data were 

























5.3.1 Near-Infrared Spectroscopy 
Figure 5-3: Preprocessed NIR spectra of A) samples of different formulation 
generated using DOE, B) pure component spectra of different components of 






5.3.1.1  Spectral investigations 
NIR spectra from the unique formulation design points are shown in Figure 5-3A.  To 
understand the source of variation, the spectra of pure components are shown in Figure 5-3B. As 
lactose, MCC, and starch are cellulosic excipients, spectral similarity is expected for these 
components; dissimilarity from APAP is noticeable in Figure 5-3B. Moreover, the excipients’ 
peaks dominate the longer wavelength regions. Therefore, spectral variation for the various DOE 
samples are observed primarily in the excipient dominated regions. Figure 5-3C shows the raw 
spectra of two different sample sets (R1 and R2, correlating with the formulations created from 
two unique sources of starch). 
Figure 5-4: Spectral correlation of target class (F-5) with samples containing 
different chemical and physical variations.  
Spectral correlation: Spectral correlations between the calibration set (target class (F5)) 




for test sets of F5 (different batch), R1, and R2; because there were no chemical differences of 
these formulations with the target class. However, different chemical design points showed lesser 
correlations. Other design points, F3 and F4 showed the highest correlation values with the target 
class, F5.   
As described in Chapter 2, spectral correlation is useful for distinguishing different classes 
of samples. If the spectral correlation value from testing meets a specific threshold value, then the 
sample is declared as the target class to verify the product empirically. Several studies have 
suggested using 0.95 as a threshold value to distinguish different classes of samples (see Section 
1.3.3.1.2). That means if the matching threshold value is 0.95 between two sample sets, these 
samples are considered equivalent. However, it is obvious that the threshold may change if samples 
are highly similar. For example, in this study, the threshold should be higher than 99.98, as the 
closest non-target class samples have this correlation value. 





Principal component analysis (PCA): Preliminary PCA was performed on the entire data 
set. It reveals both similarities and differences in tablets produced by various formulations of DOE 
and raw material variations. The PCA model with two PCs explains 95.54% of the total variance. 
The PCA model showed minimal variation for sample spectra derived from R1 and R2 
formulations (containing different sources of starch). The preprocessing method removed the 
spectral deviation arising from variation in physical factors. In the scores plot (Figure 5-5), it was 
observed that F3 and F5 samples sets were overlapped despite the chemical variations being 
significantly different between these two sets. 
5.3.1.2 Class-Model Performance of NIRS: 
SIMCA model performance: As noted, Formulation 5 was considered to be the target 
class. A total of three batches of this formulation were included into the calibration model to 
incorporate the batch to batch variabilities. Model performance was observed using DOE and 
samples having raw material variations.  
At first, SIMCA was developed using one PC and a 95% confidence interval threshold of 
Hotelling’s 𝑇2 and 𝑄 residual (Figure 5-6A). The model successfully rejected F1, F2, F4, F6, and 
F7, but failed to reject F3. Hotelling’s 𝑇2 and 𝑄 residual plots explained the failure of rejecting 
F3. Low 𝑄 residual values showed that this formulation overlapped with the calibration sample 
set, whereas other formulation design points were located far from the calibration set. The model 
developed using PC1 successfully accepted test sets R1 and R2, except for two samples from R1. 
Hotelling’s 𝑇2 and 𝑄 residual plots showed that genuine samples manufactured using different 




confidence interval to 99%, the model accepted only one of these samples (Figure 5-6 (C-D)). 
However, with the new boundary, the model also started to accept the F4 design point, as F4 is the 
second nearest design point after F3. 
To reject all non-target class design points, a SIMCA model with one PC was not sufficient, 
even though it accepted samples containing raw material variability. Next, two PCs (explaining 
95.54% of total variance) were used to develop a SIMCA model. After adding PC2, the model 
became more specific and rejected all formulations. Figure 5-7(A-B) revealed that F3 now had 
higher Hotelling’s 𝑇2 and 𝑄 residuals compared to the previous PCA model. However, after 
adding two PCs, the model started to reject samples with raw material variabilities, which were 
four R1 and seven R2 samples. Nevertheless, increasing the confidence interval from 95% to 99% 
improved the sensitivity of the model (Figure 5-7 (C-D)). The SIMCA model with 99% CI 
accepted all samples with raw material variability.  
Using cross-validation to select the number of PCs can be another option.  Here, cross-
validation suggested three PCs for the SIMCA model. However, a SIMCA model developed using 
three PCs is unnecessary, as the model already rejected all formulations using fewer PCs. 




Figure 5-6: Model diagnostics plots of SIMCA model, which was developed using the first PC, (A) Threshold was 
developed using 95% CI. B) Magnified version of plot A, C) Threshold was developed using 99% CI, D) Magnified 




Figure 5-7: Model diagnostics plots of SIMCA model, which was developed using first two PCs, (A) Threshold was 
developed using 95% CI, (B) Magnified version of plot A, (C)Threshold was developed using 99% CI, D) Magnified 




Table 5-3: Performance of SIMCA model using NIRS 
Different Models with 
predefined threshold 
Calibration approaches 
1 PC 2 PCs 
 Sensitivity Specificity Average Sensitivity Specificity Average 
SIMCA (𝑻𝟐& Q=0.95) 0.96 0.84 0.9 0.81 1 0.905 
SIMCA (𝑻𝟐 & Q =0.99) 0.98 0.78 0.88 0.97 1 0.985 
SVDD model performance: In this study, the SVDD algorithm was applied to the 
preprocessed spectral data, including Savitzkay-Golay derivative and normalization. Here, two D 
values, 0.05 and 0.01, were considered. A series of σ values were applied with incremental steps 
of 0.1. The best performance was obtained from a σ value of 0.9. The performance of the different 
approaches is summarized in Table 5-4. Both threshold values of D rejected all of the non-target 
class samples. Support vectors were visualized in Figure 5-8. Formulation 4 was plotted to show 
the similarity with target class samples.  
Table 5-4: Performance of SVDD model using NIRS. 
 
 
 σ =0.9 
Different models with 
predefined threshold 
Sensitivity Specificity Average No. of SVs 
Spectral SVDD (D=0.01) 0.89 1 0.945 6 






Figure 5-8: A) Depiction of selected support vectors of the calibration set where the blue spectra are support vectors 
and red spectra are calibration samples B) Calibration set (red), R1 and R2 sample sets (cyan). C) Calibration set 






5.4 Raman Spectroscopic Methods 
5.4.1 Spectral Investigations 
Figure 5-9: A) Spectra of different design points of pharmaceutical formulations, 
B) Raman spectra of pure components, (C) Spectra of two batches of samples. 
In this experiment, the API showed a Raman signature in tested samples. Figure 5-9 shows 
that Raman spectra of different formulation design points were dominated by the API 
(acetaminophen or APAP) because the aromatic ring of APAP is a strong Raman scatterer 





since it exhibits several characteristic bands that are directly correlated with the molecular structure 
of the substance of interest.  
The other dominating spectral source is the fluorescence background of MCC. While this 
formulation has a high drug load, the APAP is detectable. For products with a low drug load, the 
Raman spectra of the API may be masked by the fluorescence of the excipients.   
Spectral correlation: The spectral correlation value of F5 is displayed in Figure 5-10. It 
was observed that F2 and F6 showed the highest correlation with the target F5 formulation. Due 
to the strong fluorescence signal, MCC was the main reason for this similarity. In Figure 5-10, F6 
showed the nearest correlation value. The second nearest formulation was F2. 






Figure 5-11: The scores plot of a PCA model which was developed combining 
all formulations.  
Principal component analysis (PCA): The total spectral range was used to analyze the 
data. Data were preprocessed using SNV and mean-centering. The PCA plot (Figure 5-11) shows 
that the first two PCs explained 89.4% of the total variance. Similar to the spectral correlation 
value, F2 and F6 resided near the target formulation, F5. From Figure 5-9, it is observed that F2 
and F6 have similar spectral features to F5 (target class, F5) due to the presence of fluorescence 
background. Samples containing raw material variabilities (R1 and R2) overlapped with F5. This 
indicates that Raman was insensitive to the raw material variability in the present study.  
5.4.2 Class-Model Performance 
SIMCA: Similar to the NIR model, Formulation 5 was used as the target class. Two batches 




observed using samples containing raw material variabilities (R1 and R2) and DOE samples (F1, 
F2, F3, F4, F6 and F7).  
Using Raman spectra, the first SIMCA model was generated from one PC and a 95% 
confidence interval threshold of Hotelling’s 𝑇2 and 𝑄 residual. In this case, the model 
appropriately rejected all non-target class formulation design points, except 7 samples from F6.  
Hotelling’s 𝑇2 and  𝑄 residual plots explained the failure of rejecting these samples. As 
Formulation 6 had low 𝑄 residual values, these samples resided inside the boundary (Figure 5-12 
(A-B)).  
While F6 contained MCC which had similar fluorescence background compared to F5 
(target class samples), it was observed that the model developed using PC1 successfully accepted 
the test sets R1 and R2, except 11 samples. After increasing the confidence interval to 99%, the 
model accepted nine of these eleven samples, improving the sensitivity of the model (Figure 5-12 
(C-D)). However, increasing this boundary also influenced the model to begin accepting more 
samples from the F6 design point, meaning specificity was decreased.   
Next, a SIMCA model using two PCs (which explains 89.4% of total variances) was used 
to develop the SIMCA model. After adding PC2, the model became more specific and rejected all 
formulations (Figure 5-13 (A-B)). However, after adding two PCs, the model rejected more 
samples of R1 and R2; as a result, sensitivity decreased significantly. Increasing the confidence 
interval from 95% to 99% improved the sensitivity of the model. However, the SIMCA model 





Figure 5-12: Diagnostics plots of SIMCA model, developed using the first PC, (A) Threshold was developed 
using a 95% CI, (B) Magnified version of plot A,  C) Threshold was developed using 99% CI, D) Magnified 




Figure 5-13: Model diagnostics plots of SIMCA model which was developed using first two PCs, (A) Threshold 
was developed using 95% CI, (B) Magnified version of plot A, C) Threshold was developed using 99% CI, D) 




Raman showed satisfactory performance with the use of  one PC. This indicates that Raman 
spectroscopy does not rely on an extra direction of variations to identify non-target class samples 
compared to the NIRS. Therefore, Raman model was less complex, and sharp spectral features of 
Raman may help to identify different non-target class samples. But, this observation may vary 
depending on the API and excipient signals of different formulations.   
Table 5-5: Performance of SIMCA model using Raman spectroscopy. 
SVDD: In this study, the SVDD algorithm was applied to the preprocessed spectral data. 
A Savitzky-Golay derivative and normalization was applied to the data. Here, two D values, 0.05 
and 0.01, were considered. A series of σ values were applied with incremental steps of 0.1.   
Performance of the different approaches is described in Table 5-6. Both threshold values 
of D rejected all non-target class samples. Support vectors were visualized in Figure 5-14A. Raw 
material did not show variations with the target class samples (Figure 5-14B). Therefore, model 
was successfully accepted these samples. Formulation 6 was plotted to show the similarity with 
target class samples (Figure 5-14C). There are slight variations observed between target class and 
F6 in the lower wavelength regions (around 200  cm−1), which enabled the rejection of this 





1 PC 2 PC 
  Sensitivity Specificity Average Sensitivity Specificity Average 
SIMCA 
(𝑻𝟐 & Q=0.95) 
0.972 0.84 0.906 0.4 1 0.7 
SIMCA 
(𝑻𝟐 & Q =0.99) 






Figure 5-14: A) Depiction of selected support vectors of the calibration set where the blue spectra are support vectors 
and red spectra are calibration samples, B) Calibration set (red), R1 and R2 samples (cyan), C) Calibration set (red) 







Table 5-6: Performance of SVDD model using Raman spectroscopy. 
 σ =0.25 
Different Models with 
predefined threshold 
Sensitivity Specificity Average SV 
Spectral SVDD (D=0.01) 0.9333 0.9167 0.925 3 
Spectral SVDD (D=0.05) 0.8667 0.9778 0.922 4 
5.5 Discussion and Conclusion 
The proposed DOE approach allows an analyst to test the developed method against 
various non-target class samples. Given the flexibility of designing samples, analysts should be 
able to create samples containing the identical API but different excipient composition, as this may 
be the most challenging condition to detect. Rationally designed samples, defined by DOE, are 
helpful for identifying which non-target class samples are spectrally similar to the target class 
samples, and which samples pose a risk in terms of potential method failure. 
In this study, CM model using NIRS struggled to separate F3 as non-target class samples, 
whereas CM model using Raman failed to separate F6 as non-target class samples. NIR 
spectroscopy is sensitive to the C-OH bond, causing starch, lactose, and MCC to have similar 
spectral features. F3 showed the highest similarity to F5, and therefore, F3 has a higher risk of 
increasing the false positives (reduced model specificity).  However, for Raman spectroscopy, F6 
was a challenging formulation. Both F2 and F6 contained a higher amount of MCC, similar to the 
target class, F5. Because F6 had lactose in its formulation, it had a more significant peak intensity 
than the starch. This caused F6 to be the closest non-target class sample. Therefore, using F6 




Moreover, these lab generated non-target class samples have similar solid fraction, size, 
shape, etc., compared to the target class.  Therefore, physical factors demonstrated minimum effect 
on the spectra in this case. 
Although the implementation of DOE requires more samples, this approach offers 
significant benefit in that it will help to minimize the risk of model failure.  Using small scale lab-
based samples reduces the burden of sample preparation and makes the model development more 
efficient.   
In this study, changing excipient vendors did not have a significant impact on model 
performance. However, in general, switching to a different vendor can result in several physico-
chemical changes, including moisture variation, particle size variability, etc.   
Another source of variation, lot-to-lot variability of excipients,  can also be a factor to be 
modeled.  It is expected that the inter-manufacturer variabilities will be more significant than the 
batch to batch variability of an individual manufacturer (intra-manufacturer variability). However, 
it is difficult to preemptively identify all sources of variability that might be introduced by different 
manufacturers during the pharmaceutical life-cycle. The experimental approach of this study 
provided an example of the effect of manufacturer and lot-to-lot variabilities on sample spectra 
and model performance. 
Having appropriate non-target class samples is critical for model development. These non-
target class samples challenged both SIMCA and SVDD. Typically, a model developed using more 
PCs in the SIMCA model can separate challenging samples which resided near to the target class. 




material variability  from different vendors. Nevertheless, the model that is developed using a 
fewer number of PCs may appropriately accept the samples with variability in raw material 
supplier. Careful model development will prevent unnecessary rejection of target class samples 
(false negatives) or incorrect authentication of falsified products (false positives). This model 
optimization becomes logical in the presence of statistically representative non-target class 





6 Chapter 6: Onsite Implementation of Portable 
Spectrometers to Analyze Commercially Available 
Pharmaceutical Products  
6.1 Introduction 
This chapter discusses the use of portable spectrometers to analyze pharmaceutical 
products in health care settings. Researchers have been using two portable spectrometers to collect 
data in two different pharmacies over a span of a few months. Theses pharmacies are located in 
the city of Pittsburgh. Various brand and generic products were selected based on a previous 
history of falsification. Results from the testing of two products are reported here.  
To accomplish this project, a comprehensive data collection protocol was developed. This 
protocol was used during the feasibility studies to verify the spectral collection methodology and 
for the collection of data to improve the understanding of  factors that influence the product spectra. 
The effect of sample positioning, lot-to-lot variability, variations from manufacturing site change, 
and the impact of wavelength range on the performance of two different spectrometers are reported 
in this chapter.  
Different multivariate methods, including, principal component analysis (PCA), 
Hotelling’s 𝑇2 and 𝑄 residual statistics were used to develop understanding of the source of 
spectral variations.  Finally, the collected data were used to develop and validate qualitative 




data management system to implement a real-time authentication technique. This study will 
provide direction for the detection of falsified medicines in different locations worldwide. 
The objectives of this chapter include: 
(1) Evaluate the effect of sample positioning.  
(2) Evaluate the possible sources of spectral variation while collecting data from 
commercial samples. 
(3) Compare the effect of spectral wavelength ranges on method performance using two 
different spectrometers.  
(4) Develop NIRS models for the analysis of tablet authenticity. 
6.2 Materials and Methods  
6.2.1 NIR Instrumentation 
Currently, a variety of portable NIR spectrometers are available from different 
manufacturers. Whereas each technology has its own strengths and weaknesses, micro electro- 
mechanical systems (MEMS) technology was chosen for this work because of the advantages of 
fast data acquisition rate, affordability, and lack of moving parts. 
The NIR ONE Sensor (Spectral Engine, VTT, Finland) uses the patented Micro Electro 




filter with a single-element InGaAs detector. This compact spectrometer has a window made by 
quartz for a sample surface system.  
Two spectral ranges were utilized with two different devices (Figure 6-1).  
1) Diffuse reflection spectra were recorded in the wavelength range of 1550–1950 nm. This 
will be mentioned as SWL-NIR (Short Wavelength NIR) in the rest of the chapter. 
2) Diffuse reflection spectra were recorded in the wavelength range of 2000–2450 nm. This 
will be mentioned as LWL-NIR (Long Wavelength NIR) in the rest of the chapter.   
The spectrometers were connected to a laptop through a USB communication cable and 
controlled using  sensor control software  developed by Spectral Engines Oy.  
Figure 6-1: Two NIR spectrometers were used to analyze two products, 
















6.2.2 Sample Positioning Study 
Sample orientation is critical; the instrument has a detector (red circles in Figure 6-2) at 
the center of the sampling window and two lamps, one located on each side of the detector (yellow 
circles in Figure 6-2). The spectrometers were marked using a straight line to facilitate sample 
positioning.  The marking is simulated in Figure 6-2. This line was drawn two ways:  
A) Passes through the detector but perpendicular to the lamps ( Figure 6-2A) and  
B) Passes through the detector and lamps (Figure 6-2B).  
 
Figure 6-2: Two orientations of the sample based on the drawn line which is, A) 
Passes through the detector but perpendicular to the lamps,  B) Passes through 
the detector and lamps. 
An oval shaped tablet was scanned six times with repositioning. Standard deviation was 








6.2.3 Sample Collection in Pharmacy 
Two commercial tablets: apixaban (Eliquis, by Bristol-Myers Squibb) and atorvastatin 
(Atorvastatin, by Apotex) were scanned at the pharmacies in Pittsburgh. A transportable station 
was set up containing portable spectrometers and reference standards (Figure 6-3A-B)). Tablets 
were collected from bottles stored in the pharmacy. From each bottle, 30 tablets were collected 
and both sides of each tablet were scanned. All tablets were replaced in the bottle after completing 
the analysis.  
All of the calculations were performed using Matlab 8.6  (The Mathworks Inc, Natick, 
MA), along with the PLS_Toolbox 8.8 (Eigenvector Research Inc, Wenatchee, WA) and other 
analysis tools written at the Duquesne University Center for Pharmaceutical Technology for this 
study.  
 
Figure 6-3: Portable stations, A) A briefcase sized transportable system to carry spectrometers 







6.2.3.1 Apixaban: Considered Samples 
The label claim of apixaban was 5 mg. A total of nine lots of product were analyzed. 
Among these lots, seven were manufactured in Switzerland and two were manufactured in the 
USA.  Table 6-1 summarizes the lot number, manufacturing site and expected dose of the analyzed 
tablets. 
Table 6-1: Detail of apixaban tablets 
Molecule Product Name and Dose Lot No 
Manufactured 
Location* 
Apixaban ELIQUIS 5MG AAY3155 Switzerland 
Apixaban ELIQUIS 5MG AAY4017 Switzerland 
Apixaban ELIQUIS 5MG AAK9028 USA 
Apixaban ELIQUIS 5MG AAT0949 USA 
Apixaban ELIQUIS 5MG AA22725 Switzerland 
Apixaban ELIQUIS 5MG AA28472 Switzerland 
Apixaban ELIQUIS 5MG AA28448 Switzerland 
Apixaban ELIQUIS 5MG KK2981 Switzerland 
Apixaban ELIQUIS 5MG KL2418 Switzerland 
*It was mentioned in the label that the respective products were from USA and Switzerland. 
 
 
6.2.3.2 Atorvastatin: Considered Samples 
The label claim for atorvastatin tablets tested in the project was 40 mg. A total of fourteen 
lots of products were scanned. All of these lots were manufactured in Canada. Table 6-2  






Table 6-2: Details of the atorvastatin tablet 
Molecule Product Name and Dose Lot No Manufactured Location 
Atorvastatin ATORVASTATIN 40MG NW6364 Canada 
Atorvastatin ATORVASTATIN 40MG PJ2815 Canada 
Atorvastatin ATORVASTATIN 40MG PJ9375 Canada 
Atorvastatin ATORVASTATIN 40MG NK2915 Canada 
Atorvastatin ATORVASTATIN 40MG NT7727 Canada 
Atorvastatin ATORVASTATIN 40MG NT7700 Canada 
Atorvastatin ATORVASTATIN 40MG 3088695 Canada 
Atorvastatin ATORVASTATIN 40MG 3070915 Canada 
Atorvastatin ATORVASTATIN 40MG PC4481 Canada 
Atorvastatin ATORVASTATIN 40MG C805309 Canada 
Atorvastatin ATORVASTATIN 40MG 18230211 Canada 
Atorvastatin ATORVASTATIN 40MG PK0500 Canada 
Atorvastatin ATORVASTATIN 40MG PT5469 Canada 
Atorvastatin ATORVASTATIN 40MG PK1767 Canada 
 
6.3 Results and Discussion 
6.3.1 Sample Repositioning Study 
Spectral variation was observed among different rescans of oval-shaped tablets in both “A” 
and “B” orientations, whereas round-shaped tablets showed minimum variation, with repositioning 
as expected. Therefore, the spectral behavior of oval shaped tablets is reported. The bulk of the 
spectral variations, due to repositioning, took the form of a change in spectral baseline.  
For the oval-shaped tablet, the average standard deviation of SWL-NIR absorbance intensity for 
the orientation “B” was 0.15, whereas for the orientation “A”, it was 0.05. For the LWL-NIR 
spectrometer, average standard deviations were 0.07 and 0.02 for “B” and “A” orientations 




compared to the orientation “B” for oval-shaped tablets. This was true for both SWL-NIR and 
LWL-NIR spectrometers.  Therefore, orientation B was used to analyze all oval shaped tablets in 
the further research. However, from the data, it was also observed that the SWL-NIR spectrometer 
was more sensitive for repositioning of tablets relative to the LWL-NIR spectrometer. A number 
of data preprocessing techniques such as the standard normal variate (SNV) transformation, 
multiplicative scatter correction (MSC), Savitzky–Golay (SG), etc., can be applied to mitigate this 
variation.  
Exploratory sample analysis 
6.3.1.1 Apixaban 
Spectral behavior of various batches of apixaban tablets were observed for SWL-NIR and 
LWL-NIR spectrometers in Figure 6-4A and Figure 6-5A respectively. These spectra were SNV 
and second derivative Savitzky–Golay treated. From preprocessed spectra, significant spectral 
variances was observed among different batches. Primarily, the two batches prepared in the USA 
(blue and green spectra) were different from the batches prepared in Switzerland. Spectral 
differences were pronounced in SWL-NIR spectra compared to the LWL-NIR spectra. These 
variations may evolve from different factors such as raw material variabilities, manufacturing 
variabilities, moisture variabilities, etc. However, a detailed history of sample preparation or 
manufacturing conditions was not available.  
Based on the spectral features of the pure component spectra, it is assumed that the site-to-
site variation is likely due to some difference in the excipients (Figure 6-4B, Figure 6-5B).  The 




anhydrous, microcrystalline cellulose and sodium lauryl sulfate (SLS) all exhibit peaks in that 
same region. It is assumed that the contribution from these three components may change between 
the manufacturing sites. Further analysis might reveal the true source(s) of variation. 
  
Figure 6-4: A) Preprocessed SWL-NIR spectra of different batches of apixaban, 







Figure 6-5: A) Preprocessed LWL-NIR spectra of apixaban, B) LWL-NIR 






Figure 6-6: A) Scores plot of different batches of apixaban, B) Loadings plot of 
PCA analysis of apixaban using SWL-NIR spectrometer. 
A two component PCA model captured nearly 95.99% of the spectral variation (Figure 6-
6).  The first PC explained nearly 74.87% of the variance. For SWL-NIR, the PCA analysis 
revealed cluster formation of PC 1 and PC 2 plot (Figure 6-6A). Though subtle differences were 




variation, as displayed in Figure 6-6.  As different batches were produced in the USA and 
Switzerland, the clusters were primarily due to the manufacturing site variations. 
Further analysis was conducted by developing a PCA calibration model using only samples 
manufactured in Switzerland (Figure 6-7). When the USA samples were projected on the PCA 
model, the nature of the clusters in the manufacture sites were apparent (Figure 6-7B). Also, the 
diagnostics plots showed the high Hotelling’s 𝑇2 and 𝑄 residuals.  (Figure 6-7C).  The 𝑄 
contribution plot emphasizes the important variables generated by the unmodeled variation in the 
model.  It was apparent from the 𝑄 contribution plot that  high 𝑄 residual was observed around 






Figure 6-7: SNV treated spectra of product from two manufacturing sites. Using 
these data, a PCA model was developed where Switzerland lots were used for 
calibration, and USA manufactured samples were projected. B) Scores plot of 
PC1-PC2,  C) Plots of Hotelling’s 𝑇2and 𝑄 residuals, D) Plots of  Q contribution. 
Data were collected using the SWL-NIR instrument. 
A two component PCA model explained 81.48% of the LWL-NIR spectral variance. The 
first PC explained 57.89% of the spectral variance (Figure 6-8). Unlike the SWL-NIR PCA model, 
the PC scores of the LWL-NIR model appeared to be less related to site differences as the data 
from two sites were overlapped (Figure 6-8A). However, when the PCA model was developed 
using samples generated in the Switzerland site, projected USA samples resided outside the 
calibration space (Figure 6-9). This difference between the two manufacturing sites was also 




Both the SWL-NIR and LWL-NIR PCA models demonstrated the potential effect of 
manufacturing site on the prediction model.  Samples from two different manufacturing sites 
should be included in future calibration models as controlled variation. This strategy would cause 
little effect on the sensitivity (ability to accept target class samples) of the model performance.  
In summary, both repositioning studies using the standard deviation data and the 
exploratory analysis using PCA models suggested that LWL-NIR measurements are less sensitive 
to sample positioning error and manufacturing site change relative to the SWL-NIR measurements. 






Figure 6-8: A) Scores plot of different lots of apixaban,  B) Loadings plot of 






Figure 6-9: A) SNV treated spectra of products from two manufacturing sites. 
Using these data, a PCA model was developed where Switzerland lots were used 
for calibration, and USA manufactured samples were projected on PCA model,  
B) Scores plot of PC1-PC2, C) Plot of Hotelling’s 𝑇2 and 𝑄 residuals, D) Q 














6.3.1.2 Atorvastatin  
Different lots of atorvastatin tablets (SNV transformed and second derivative SavGol 
treated) are shown in Figure 6-10 and 6-11. Unlike apixaban, minimum spectral variations of 
Figure 6-10: A) Preprocessed SWL-NIR spectra of atorvastatin, B) SWL-NIR 




different wavelength regions were observed. Major components of these tablets were plotted, as 
seen in Figure 6-10B and 6-11B. 
 
 
Figure 6-11: A) Preprocessed LWL-NIR spectra of atorvastatin B) LWL-NIR spectra 




The PCA scores (Figure 6-12A) and loadings (Figure 6-12B) of the SWL-NIR spectra 
confirmed the minimum variations among different batches, as different groups overlapped. Two 
PCs explained 92.6% of the spectral variation.  
Figure 6-12: A) Scores plot of different lots of atorvastatin, B) Loadings plot of 




 The PCA loadings and scores for the LWL-NIR spectra are shown in Figure 6-13 . The 
first PC explained nearly 66.85% of the spectral variance, and the second PC explained an 
additional 19.04% of the spectral variance.  
 Figure 6-13: A) Scores plot of different lots of atorvastatin, B) Loadings plot of 
PCA analysis of atorvastatin using LWL spectrometer. 
The two-axis plot of the PC scores does not show any significant clustering in the data. 




6.3.2 Multivariate Model Development: Calibration Set Considerations 
Including appropriate samples into the calibration set is an essential element of a 
multivariate method development process. Section 6.3.3. in this chapter evaluated several 
important elements of method development while collecting spectra of commercial products. It 
was observed that spectral variation due to manufacturing site change was prominent. Lot-to-lot 
variability within sites was less than the spectral variability associated with site differences. 
Spectral range was also important to consider, as the degree of variation changed based on the 
wavelength regions. Regardless of the spectrometers used in this study, samples collected from 
multiple batches and multiple manufacturing sites (if available) were used in the calibration set to 
provide a sufficiently broad range of variation to develop a robust target class. Also, tablets were 
scanned with a consistent orientation, as discussed in Section 6.3.2.  
The next section focuses on the model performance of the NIRS authentication method. 
 
6.3.3 Method Development and Performance 
6.3.3.1 Apixaban   
Sample considerations and model development:  The calibration model developed for the 
authentication of apixaban tablets used 150 samples drawn from five production batches including 

















To optimize the model, independent target (samples from unique batches) and non-target 
class samples were used to test the model. One new lot of 5 mg apixaban product was used as 
target class test samples. These tablets were used to ensure the highest specificity of the model. A 
new batch of samples containing a lower concentration of API (2.5 mg) was used as non-target 
class samples to ensure the highest sensitivity of the model.  The SVDD model parameters, both D 
and  were optimized accordingly (Table 6-3 and Table 6-4).  
SWL-NIR  
Calibration Test Val-1 Val-2 Val-3 
Samples (n) 150  60 90 30 30 
Batches (n) 5 2 3 1 1 
Model Type SVDD, SIMCA on Spectra 
Preprocessing SNV + Second derivative + Normalize 
Spectral range (nm) 1550-1950 
D 0.01 
 0.2 
SV numbers 3 
LWL-NIR  
Calibration Test Val-1 Val-2 Val-3 
Samples (n) 150 60 90 30 30 
Batches (n) 5 2 3 1 1 
Model Type SVDD, SIMCA on Spectra 
Preprocessing SNV + Second derivative + Normalize 
Spectral range (nm) 2000-2450 
D 0.2 
 0.2 




A combination of SNV, second derivative and normalization was chosen based on 
maximum average performance of sensitivity and specificity.  The preprocessed calibration spectra 
are shown in Figure 6-14A. The calibration model used three samples as support vectors (depicted 
in Figure 6-14A as blue spectra). 
The validation data consisted of three sets of samples.  
The first validation set was target-class samples. This validation set (Val-1) consisted of 
90 samples of target class samples from three batches containing apixaban (5mg). These batches 
were manufactured at two different facilities (one in the USA and two in Switzerland).  
The second and third validation sets were non-target class samples.  The second validation 
set (Val-2) consisted of 30 commercial samples containing a low dose of apixaban (2.5 mg). The 
third validation (Val-3) set consisted of 30 laboratory scale samples manufactured at the Duquesne 
University Center for Pharmaceutical Technology (DCPT) using MCC and apixaban. The purpose 
of the third validation set is to provide an additional test of the specificity using samples including 
a similar amount of apixaban (5mg) but different excipient composition.  
Validation Method Performance: Method validation (with a validation set) was 
conducted after the optimization of the model (using a test set). The validation performance was 
evaluated based on the following two key performance criteria: sensitivity and specificity. The 
specificity was tested using different batches of target class samples (Val-1), and the sensitivity 
(ability to reject non-target class samples) was tested using two sets of samples: 1) low dose 
















SWL- Apixaban 0.9111 0.8667 1 
LWL- Apixaban 0.8667 0.7812 1 
SIMCA 
SWL- Apixaban 0.76 0.81 1 





During validation, it was observed that this method successfully rejected all samples from 
Val-3 set, while rejection of Val-2 was less obvious. The reason for the difference in performance 
was explained in Figure 6-14 (C and D). It was observed that the Val-3 set (Figure 6-14C) was 
spectrally significantly different from the target class samples. However, Val-2 is highly similar 
to the target class which means that the model failed to reject all samples (Figure 6-14D). It is 
Figure 6-14: SWL-NIR spectra of calibration set with A) support vectors, B) validation set 




important to mention that while the Val-2 set was from the same manufacturer, and contained 
similar compositions, it was challenging for the model to reject all samples from Val-2. This result 
was confirmed using a diagnostic plot of Hotelling’s 𝑇2 and 𝑄 residuals. All of the Val-3 (cyan 
dots) have high 𝑄 residuals and Hotelling’s 𝑇2 compared to the Val-2 (blue dots) (Figure 6-15). 
The higher values of these two statistical parameters indicated the successful rejection of Val-3 
compared to Val-2. 
 
It was observed that SVDD performed better than SIMCA for authentication of 
pharmaceutical samples. As, adding different manufacturing sites into the calibration set generated 
clusters in the calibration space, SIMCA model suffered to provide optimum performance. 
However, SVDD showed better sensitivity by accepting Val-1 samples, though they were 
generated in two manufacturing sites. Appropriate preprocessing methods helped to improve 
Figure 6-15: A PCA diagnostics plot of validation sets with the 





performance. It was observed that combination of SNV, second derivative and normalization 
showed the best performance compared to other combination of routines. This preprocessing 
decreased the impact of sources of variability such as sampling variability and correcting for 
pathlength variation. These overall improved model performances.   
Similar performance was observed for LWL-NIR. The results showed comparable patterns 










Figure 6-16: LWL spectra of calibration set with A) Support vectors, B) 










Sample considerations and model development: For atorvastatin, SNV, 2nd Derivative 
and normalization preprocessing methods were chosen based on the performance. An independent 
test set (defined below) was used to optimize the model performance. Spectra of the preprocessed 
calibration set are shown in Figure 6-18A, along with samples which were selected as support 
vectors (blue spectra). 
Model development for authentication of atorvastatin used 150 target class samples drawn 
from production batches (40 mg). The test set was samples from different batches of product to 
provide independence. Samples manufactured by three other generic manufacturers were used as 
the non-target class product to optimize the model. The calibration datasets are summarized in 
Figure 6-17: A PCA diagnostics plot of validation sets with the calibration 




Table 6-6 and Table 6-7. The validation samples consisted of three subsets of samples selected 
from production scale and lab scale samples.  
Table 6-6: Summary of atorvastatin calibration and validation sets.  
SWL-NIR 
 Calibration Test Val-1 Val-2 Val-3 
Samples (n) 150 30 90 90 30 
Manufacturers (n) 1 2 1 3 1 
Batches (n) 5 1 3 3 1 
Model Type SVDD, SIMCA on Spectra 
Preprocessing SNV + Second  derivative + Normalization 
Spectral range (nm) 1550-1950 
D 0.01 
 0.15 




Table 6-7: Summary of atorvastatin calibration and validation sets.  
LWL-NIR 
 Calibration Test Val-1 Val-2 Val-3 
Samples (n) 150 30 90 90 30 
Manufacturers (n) 1 2 1 3 1 
Batches (n) 5 1 3 3 1 
Model Type SVDD, SIMCA on Spectra 
Preprocessing SNV+ Second derivative + Normalize 
Spectral range (nm) 2000-2450 nm 
D 0.01 
 0.2 






The first validation set (Val-1) consisted of 30 samples, including one batch of target class 
samples.  As atorvastatin is a generic product, samples available from other manufacturers were 
used as the validation set. Three different manufacturers products (M1-Atorvastatin 40 mg from 
Mylan Pharmaceutical, M2-Atorvastatin 40 mg from Lannett Company Inc., M3- Atorvastatin 40 
mg from Dr Reddy’s Laboratories) were included in the second validation sets (Val-2). The third 
validation (Val-3) set consisted of one batch of laboratory scale samples manufactured using MCC 
with atorvastatin. Validation datasets are summarized in Table 6-6 and Table 6-7. 
Validation Method Performance: Performance of the atorvastatin model was observed 
using three validation sets. The SVDD model successfully accepted all samples in the target class 
Figure 6-18: SWL-NIR spectra of calibration set with A) support vectors, B) validation set 1, C) 




validation set (Val-1). Although Val-3 was significantly different than the Val-2 samples (Figure 
18C-D) the model successfully rejected other non-target class validation sets (Val-2 and Val-3). 
Among the three manufacturers of Val-2, Man-2 was close to the target class samples whereas 
other alternative class samples (M1 and M3) were demonstrated to reside far from the target class 
samples (Figure 19). Similar spectral behavior (LWL-NIR) of these samples was observed in 
Figure 6-20 and Figure 6-21. Samples collected using different spectrometer  showed good 
performance.  









SWL- Atorvastatin 1 1 1 
LWL- Atorvastatin 1 1 1 
SIMCA 
SWL- Atorvastatin 1 1 1 
LWL- Atorvastatin 1 1 1 
 
Figure 6-19: SWL-NIR spectra of calibration sets with three 








Figure 6-20: LWL-NIR spectra of calibration set with A) support vectors, B) validation set 1, 
C) validation set 2, and D) validation set 3. 
 
Figure 6-21: LWL-NIR spectra of calibration sets with 





The goal of an authentication technique is to predict target class samples accurately and to 
reject non-target class samples. However, many challenges exist in the development of an NIR 
based classification technique, including the broad spectral features of NIR spectrometers in 
general, and the unwanted sensitivity to physical variability. In Chapters 2 and 3, it was observed 
that moisture is a critical factor to consider during multivariate method development. In the current 
chapter, it was observed that sample manufacturing site change created spectral variation. Spectra 
acquired from multiple manufacturing sites were pooled for qualitative model development. 
Including samples from unique manufacturing sites in the calibration sample set created bimodal/ 
multimodal distribution in the calibration space, violating the assumptions of the traditional 
parametric distribution-based SIMCA method. Hence, these studies used a non-parametric 
distribution-based method, the support vector data description (SVDD) algorithm, provided a more 
robust class. The SVDD method proved to be a useful class-modeling technique for portable NIRS 
to monitor tablet quality in pharmacies. Additionally, including non-target class samples was 
critical to the development of robust multivariate models.  
This study also explored the impact of positioning error. This was effectively mitigated 
using a specific sample orientation system and spectral preprocessing techniques. It was also 
observed that a longer wavelength range spectrum was less sensitive to sample positioning and 
manufacturing site than a shorter wavelength range spectrum. 
This chapter reemphasized the value of using a pertinent calibration model and the SVDD 




7 Chapter 7: Summary 
As the spread of falsified drugs is increasing worldwide, it is often difficult for regulatory 
authorities to surveil falsified products at various locations in the pharmaceutical supply chain. 
Using portable spectrometers (i.e., Near-Infrared (NIR) and Raman spectrometers) may help to 
remove this barrier.  Rapid screening of pharmaceutical products by these analytical tools is an 
effective way to enhance consumer safety. However, the use of such techniques is not 
straightforward due to the multivariate nature of the collected data and the significant variety of 
potential factors influencing the analytical measurements. To overcome the challenge of current 
multivariate methods using spectroscopic data, this dissertation compiled three critical elements 




Figure 7-1: Different elements of this dissertation involved with development of a 
spectroscopic authentication system and accomplished steps (✓). Combination of these three 














ü Different NIR and Raman 
spectrometers.
ü Wavelength range.
ü Sensitivity to external factors.
ü Sample composition sensitivity
ü Limitations of current method.
ü Advanced algorithm.
ü Careful optimization.
ü Understanding variabilities (FN).
ü Highly similar samples (FP).




Three elements regarding the project include: 
1) While developing a spectroscopic authentication method, the specific advantages and 
disadvantages of each spectroscopic techniques should be considered by the analyst.  
A variety of NIR and Raman spectroscopic equipment was explored to understand the 
sensitivity of these spectrometers to different physico-chemical variations such as 
moisture and chemical composition.  
2) To achieve consistent performance during routine analysis of pharmaceutical samples, 
calibration and validation sets should include the spectral variation which may arise 
during routine analysis. Moreover, during model development, the analyst should use 
highly similar samples to reduce false positives. If these highly similar falsified samples 
are not readily available, using DOE to generate simulated falsified samples should 
serve the purpose.  
3) Using a support vector machine based calibration method avoids the typical 
assumptions required with more traditional methods regarding data distributions. 
Moreover, the SVDD method was demonstrated to offer improved capability for 
detecting highly similar non-target class samples.  
These elements combinedly explored in different experiments of this dissertation.  
In Chapter 2, a NIR spectroscopic-based class-modeling calibration technique was 
described. While developing a spectroscopic method for detecting false-samples, several 
challenges associated with the method development were addressed.  One of those challenges is 
the sensitivity of spectrometers toward unwanted variabilities such as moisture, manufacturing 




magnesium stearate were generated using a pilot-scale manufacturing system over different 
seasons of the year. Since the lab did not have controlled humidity conditions, samples generated 
during different seasons were exposed to different humidity levels. Initially, the calibration model 
was developed in the winter season; the model used to predict validation sets was developed in the 
summer season. As the season was different between calibration and validation sets, the model 
failed to accept the target-class samples, indicating a degradation of the model performance when 
moisture variance was unaccounted for. To resolve this, the model was updated to include summer 
samples in the calibration set. However, moisture variance in the newly added samples led to 
significant extrapolation compared to the original experimental domain, defined by the previously 
collected samples (during the winter). Therefore, adding summer samples to the calibration set 
created a binomial/multimodal distribution, violating the assumptions of traditional parametric 
distribution-based SIMCA modeling techniques.  Hence, this chapter suggested using a non-
parametric distribution-based method, support vector data description (SVDD), to develop a robust 
NIR class-modeling technique for the detection of falsified samples. Performance of SVDD was 
evaluated and compared with the traditional SIMCA approach. The SVDD method demonstrated 
superior performance relative to the SIMCA method for detection of falsified samples. Hence, 
when a binomial/multimodal distribution exists in the calibration model, SVDD is a useful class-
modeling technique for monitoring tablet quality. 
In Chapter 3, the influence of moisture variation on the performance of Raman 
spectroscopy for class modeling was evaluated. Although water is a weak Raman scatterer, 
moisture variability has an indirect effect on analytical model performance because many 
pharmaceutical components have artifacts in the form of baseline variation associated with 




the prediction accuracy of a multivariate calibration algorithm developed using Raman 
spectroscopy. To demonstrate this phenomenon two sets of tablets were used, 1) lab based 
acetaminophen tablets containing lactose, MCC, HPMC, and magnesium stearate, and 2) 
commercially produced artesunate tablets, which is an anti-malarial agent often falsified by 
fraudulent manufacturers. Tablet moisture variation was introduced by placing samples in a variety 
of humidity chambers. Significant spectral effects arising from fluorescence were identified in the 
Raman spectra due to moisture variation and fluorescence related spectral variability. This caused 
substantial degradation of the prediction performance for target class samples. Thus, the work 
demonstrated that accounting for moisture variation during method development reduced the 
prediction error of the SVDD and SIMCA based class-models.    
Requirement of appropriate non-target class samples during multivariate authentication 
system development was highlighted in Chapters 4 and 5. In Chapter 4, it was shown that to 
enhance spectroscopic performance using the SVDD algorithm, non-target class spectral data are 
critical for model optimization. This is important for the model which is developed to identify 
challenging falsified drugs. It was demonstrated that using non-target class data can further tighten 
the decision boundary around the target class samples, thereby improving model performance. 
Moreover, if the non-target class samples are highly similar to the target class, the model exhibited 
the desired performance. For this study, acetaminophen tablets were collected from different parts 
of the world, which were manufactured by various producers. Tablet size, shape, and weight were 
analogous, and the products demonstrated similar spectral features. Among the nine 
manufacturers’ tablets, samples from one manufacturer were used to develop a target class, and 
the eight other data sets were used for model optimization and validation. The model was 




other non-target class samples. Furthermore, optimization of the decision boundary minimizes the 
false positives.  
In Chapter 5, predictions models for highly similar non-target class products were 
developed using DOE.  Both NIR and Raman spectrometers were used to scan the samples. It was 
demonstrated that the critical non-target class samples were unique for the two different analytical 
techniques. These DOE based samples were useful to improve the model performance, and they 
resolved the critical issue of limited accessibility to actual falsified drug products. 
The insight gained from Chapters 2 through 5 was used to develop a spectroscopic 
authentication method for use in the health care setting or other remote testing sites.  In Chapter 6, 
portable spectrometers were used to scan different commercial products in two local pharmacies. 
A protocol was developed to collect data from available products. This study also highlighted the 
requirement of careful considerations of calibration samples and the use of  an advanced algorithm 
for the actual modeling. The developed model performed successfully by accepting target class 
samples and rejecting non-target class samples at the local pharmacies in Pittsburgh. 
This dissertation emphasizes the importance of 1) applying critical prior knowledge 
regarding pharmaceutical products, pharmaceutical manufacturing/processing, analytical 
methodology, and chemometric techniques, and 2) the application of a specific modern approach 
to develop a successful spectroscopic authentication system. Combining all these pieces gives a 




Future applications of this project will include developing a cloud-based platform. The 
developed model will be stored in a cloud-based server, facilitating effective management of 
models and data for the analyst in the field.  It will enable a global product tracking system, from 
manufacturers to the rural clinics which will address the scourge of falsified drugs. Moreover, a 
combination of an enhanced modeling approach, utilizing critical prior knowledge, will provide 
the prescription for the solution to the current crisis of falsified drugs in the developing countries. 
Also, this can be a potential application for IoT based testing of pharmaceutical products and 
enhanced supply chain integrity in developed countries.  
  
Figure 7-2: A schematic diagram of a possible cloud-based 
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